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ABSTRACT 
 
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterised by 
uncontrolled proliferation of haematopoietic cells driven by the fusion gene Bcr-Abl.  
The advent of a mechanism specific kinase inhibitor, Imatinib, targeting the 
constitutively active Bcr-Abl kinase has paved the way for new treatment strategies. 
However, resistance emerges, particularly in those in more advanced disease stages.  
One factor in this resistance is the presence of a quiescent subset of CML cells that are 
insensitive to Imatinib.  CML resistance to Imatinib is linked with over-expression and 
activation of Lyn, a member of the Src family kinases (SFK).  The main aim of the 
project was to investigate whether transforming growth factor-β (TGF ) might influence 
drug-resistance through direct affects on Lyn kinase levels and its activation.  
This research builds on previous findings of Bcr-Abl-dependent up-regulation of TGFβ 
signalling, implicating this cytokine in CML.  Human MYL cell lines derived from a 
CML patient were used to show TGFβ plays a role in imatinib-resistance through direct 
effects on Lyn protein turnover.  Stimulation of MYL cells with TGFβ produced cyclic 
changes in high molecular weight bands in the presence of proteasomal inhibitors. These 
high molecular weight bands are due to TGF  inducing Lyn ubiquitination, and that this 
is mediated via TGF -dependent expression of the c-cbl E3 ubiquitin ligase. Cell cycle 
analysis in combination with poly ADP ribose polymerase (PARP) cleavage assays 
show TGFβ causes cell quiescence, and that the inhibition of the signalling pathway 
releases cells from growth arrest and enhances Imatinib-induced cell death.  
Collectively, data highlights a potential new dual-treatment approach using a 
combination of Imatinib and SB431542 to enhance imatinib-mediated cell death in 
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CML. Furthermore, it is speculated that hyper-activation of the TGF  pathway in the 
presence of Bcr-Abl drives CML drug  resistance by a co-operative mechanism 
involving Lyn kinase ubiquitination and activation, which is linked to the c-cbl proto-
oncogene.   
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1.1 Background 
 
 
Chronic myeloid leukaemia (CML) is a devastating blood cancer typified by the 
occurrence of the Philadelphia chromosome translocation that leads to the combining of 
two genes Bcr and Abl which generates the constitutively active Bcr-Abl tyrosine 
kinase.  The discovery of Imatinib mesylate paved the way for targeted disease 
treatment in the 1990’s.  Unfortunately, Imatinib rarely acts as a complete cure, 
particularly in late stage disease, and the detection of residual CML contributing to 
resistance has made it necessary to search for alternative treatments, and ways to 
overcome Imatinib resistant forms of CML.    
The signalling network driving CML is complex and multifaceted. One example is the 
TGFβ signalling pathway which plays a role in differentiation, cell growth, apoptosis, 
haematopoiesis, and is well established as playing a prominent role in cancer 
(Meulmeester and ten Dijke, 2011). TGFβ has an inhibitory effect on haematopoietic 
cells, and research has suggested that de-regulation of this pathway can lead to 
carcinogenesis (Kim and Letterio, 2003). 
This thesis has aimed to look at the involvement of TGFβ during later stages of disease 
progression, with the aim of establishing and validating a novel dual therapy approach 
that may be used to combat drug  resistance.  Alongside this, a more mechanistic study 
looked to determine the molecular mechanisms responsible for TGFβ’s involvement in 
drug  resistance in addition to highlighting novel interconnections between TGFβ and 
Lyn kinase activation through ubiquitination. 
19 
 
The remainder of this introduction reviews the current research on CML, 
including current treatments and proposed resistance mechanisms, together with the 
TGFβ signalling pathway, its involvement and connections with Lyn kinase and their 
association with CML drug resistance. 
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1.2 Leukaemia 
 
 
Cancer is a consequence of uncontrolled abnormal cell growth.  Under normal 
conditions, cells will form, mature, undertake their intended function and die, to be 
replaced by new cells.  It is when these homeostatic cell processes are disturbed that 
cancer can occur.   
Leukaemia is cancer of the blood, and is characterised by abnormal proliferation of the 
haematopoietic cells in the bone marrow. These cancer cells are immature and build up 
in circulating blood and organs of the body.  
Leukaemia can vary depending on cell type and the mechanisms responsible for its 
progression, and it can fall into two main types, either an acute or chronic form.  Acute 
forms of the disease are typified by the rapid accumulation of immature blood cells 
within the bone marrow preventing healthy cell production.  This rapid increase in blood 
cells leads to spillage into the bloodstream and subsequent spread to other organs 
throughout the body.  Of the two forms, this is the more aggressive, is often seen in 
childhood leukaemia and, if left untreated can lead to death within a few weeks or 
months. The chronic form is typified by a slow but excessive increase in blood cells, and 
disease progression is much slower compared to acute forms, often taking several years. 
Chronic leukaemia occurs more frequently in the elderly, and is often a consequence of 
abnormal maturation of the blood cells.  If left untreated, the disease may persist for 
many months or even years.  
Based on these classifications, there are four main disease categories for leukaemia; 
acute lymphoid, acute myeloid, chronic lymphoid and chronic myeloid leukaemia.  
21 
 
Table 1 summarises the annual incidence of leukaemia among adults in the UK (LRF 
2010).  
 
 
Acute Lymphoblastic Leukaemia  400 
Chronic Lymphocytic Leukaemia 3300 
Acute Myeloid Leukaemia 2200 
Acute promyelocytic Leukaemia 200 
Chronic Myeloid Leukaemia 550 
Hairy Cell Leukaemia 200 
T-Cell Actute Leukaemia 200 
 
Chronic Myelomonocytic Leukaemia 300 
 
Table 1: Annual adult incidence of Leukaemia in the UK (Adapted from Leukaemia  
 and Lymphocytic Research Fund 2010) 
 
 
 
 
 
 
 
 
22 
 
1.3 Haematopoiesis 
 
 
Leukaemia by definition is a disorder of the haematopoietic system.  Haematopoiesis is 
a complex process of differentiation leading to the formation of mature blood cells from 
a rare population of primitive haematopoietic stem cells (HSCs).  These HSCs are 
predominately found in the adult bone marrow where they serve to repopulate the 
mature cell lineages, in addition to maintaining the stem cell pool.  The mature cells are 
short lived and a constant high turnover ensures adaptation to the surroundings.  This 
makes the homeostatic control of this process critical to prevent haematological diseases 
such as leukaemia.  These HSCs are identified through the expression of cell surface 
proteins CD34, and as such are known as CD34+ (Collins, 1994). 
There are three major cell types contained within the blood; white blood cells, red blood 
cells and platelets, all of which are formed from a single immature bone marrow stem 
cell during the process of haematopoiesis.   These cells go on to develop into still 
immature precursor cells and subsequently into mature blood cells within the bone 
marrow.  The first step of this maturation process is into one of two subgroups, myeloid 
or lymphoid.  The myeloid lineage develops into the red blood cells, platelets and 
certain types of white blood cells.  The lymphoid lineage develops into the lymphocytes. 
Figure 1 shows the various lineages of the blood cells and their differentiation fates.  
The classification of leukaemia can be divided into categories within the affected cell 
type from either lymphocytic or myeloid lineages, resulting in lymphoid or myeloid 
leukaemia.   
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It is now well established that the regulation of haematopoiesis is through an intricate 
network of extracellular and intracellular regulatory factors (reviewed by Akala and 
Clarke, 2006; Blank et al 2008). For many years the TGFβ family has been thought to 
play an important role in this network. Its roles in haematopoiesis will be discussed later 
in this chapter.   
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1.4 Chronic Myeloid Leukaemia 
 
 
Chronic myeloid leukaemia (CML) was the first malignant disease to be associated with 
an acquired non-random chromosomal abnormality.  According to the World Health 
Organisation (WHO) classification, the term “myeloid” refers to all cells belonging to 
the granulocytic (neutrophil, eosinophil, basophil), monocyte/macrophage, erythroid, 
megakaryocytes and mast cell grouping.  Nowell and Hungerford reported the 
association in 1960, along with the detection of a minute chromosome they termed the 
Philadelphia chromosome after the city of its discovery.  This led to the finding of the 
reciprocal chromosomal translocation, t(9:22)(q34;q11).  The consequence of which is 
the fusion of a number of sequences from the BCR gene at 22q11 with sequences of the 
c-Abl oncogene from 9q34.  The resulting Bcr-Abl product is a hybrid gene found on 
chromosome 22.  Incidence of the disease occurs at approximately 1.0 to 1.5 in every 
100,000 people, and are rarely seen among children, with the average age of onset 
between 50-60 years.  The identification of Bcr-Abl as the causative agent of CML was 
confirmed using a murine model in which bone marrow was transformed with Bcr-Abl 
and transplanted into mice that then went on to develop CML-like symptoms (Daley GQ 
et al., 1990). 
The Bcr-Abl product is believed to occur initially in a single HSC giving it a 
proliferative advantage over the common population, leading to the increase in cell 
number (Bruns et al., 2009).  Disease development follows a tri-phasic pattern, 
consisting of an initial chronic phase, which progresses to an accelerated phase and 
finally on to blast crisis.  The chronic phase can have many years of disease evolution, 
26 
 
and often it is not until the presentation of worsening physical symptoms such as weight 
loss and sweats, along with increased blood cell production that it is diagnosed.  During 
the accelerated stage, increased mutations occur, such as those within the kinase domain 
of Abl, and generation of reactive oxygen species are more commonly seen, which aid 
progression of the Bcr-Abl driven disease (Branford et al., 2003).  This second disease 
stage is believed to be triggered through a set of mutations which reach a “threshold” of 
genetic abnormalities which go on to promote disease development.  In some cases the 
accelerated phase can be by-passed, with direct development from chronic to blast 
phase.   
Blast crisis occurs when haematopoietic differentiation becomes arrested and immature 
blasts accumulate in the bone marrow and enter into the circulation (Melo and Barnes, 
2007).  This is driven by deleterious genetic events which occur within stem and 
progenitor cells of the leukaemic clone. Despite classifications, the precise definition of 
the three stages has been widely debated.  
The progression from chronic to accelerated and blast phase has been shown to be 
accompanied by non-random chromosomal aberrations (Calabretta and Perrotti, 2004), 
the most common of which are duplication of the Philadelphia chromosome, trisomy 8, 
19 (Kantarjian et al., 1987).  More specifically, during blast crisis, mutations in p53, Ras 
(Baum and Ren, 2008), and amplification of Myc have been reported.  
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1.5 Bcr-Abl in CML 
 
 
Chronic myeloid leukaemia results from a reciprocal translocation between 
chromosomes 9 and 22 giving rise to a fusion gene product Bcr-Abl.  This chromosomal 
recombination which creates a longer chromosome 9 and a shorter chromosome 22 is 
termed the Philadelphia chromosome. The exact location of chromosome breakage can 
vary.  Within chromosome 22, the breakage occurs in the breakpoint cluster region 
(BCR) gene, for chromosome 9, it is within the c-Abl gene. 
 The c-Abl oncoprotein is a 145kDa non-receptor protein tyrosine kinase localised both 
in the cytoplasm, where it weakly associates with actin filaments, and the nucleus where 
it is associated with chromatin (Kipreos and Wang, 1992).  It exists as an inactive 
monomer as a result of its tyrosine kinase domain being inhibited by its SH3 domain.  
The protein exists in 2 iso-forms a1 and b1, both of which are ubiquitously expressed in 
mammalian cells.  There are differences in the N-termini of the iso-forms termed the 
variable domains,  which are caused by alternative splicing of the first 2 exons called 1a 
and 1b in human genes (Ben-Neriah et al., 1986). There are 3 Src homology domains 
(SH1-SH3) located towards the N-terminus. The SH1 domain contains the tyrosine 
kinase function, while the SH2 and SH3 domains allow for interaction with other 
proteins (Cohen et al., 1995).  Normal Abl function is involved in the cell cycle 
(Kipreos and Wang, 1992), in the response to genotoxic stress (Yuan et al., 1999), and 
in integrin signalling (Lewis and Schwartz, 1998).  However, it is important to note that 
the majority of this data has been obtained using ectopic expression studies in fibroblasts 
rather than studies of endogenously expressed proteins in hematopoietic cells. 
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Break-point cluster region (Bcr) is a 160kDa ubiquitously expressed protein (Laneuville, 
1995). The centre of the molecule contains a dbl-like and pleckstrin-homology (PH) 
domain shown to stimulate GTP-GDP exchange (Denhardt, 1996).  The C-terminus 
contains GTPase activity for Rac (a small GTPase of the Ras superfamily) (Diekmann et 
al., 1991).    
At the molecular level there are at least 4 different Bcr-Abl fusion genes due to the 
potential breakpoints in Bcr (Figure 1.1). Breakpoints within the Abl gene can occur 
anywhere over a large area at the 5’ end upstream of the first exon b1, downstream of 
the second exon a1, or more frequently, between the two (Melo, 1996).  This leads to the 
formation of 1 of 3 abnormal proteins of different molecular weight known as p210 (M-
bcr). Due to alternative splicing, fusion transcripts with either b2a2 or b3a2 can be 
formed. Further upstream breakpoints result in p190 (m-bcr) with e1a2 mRNA, and 
finally the break-point downstream of exon 19 result in p230 (μ-bcr), associated with a 
rare Philadelphia positive chronic neutrophilia leukaemia (Pane et al., 1996).  Of these 
variants, p210 is most common among CML patients. 
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The activation of the tyrosine kinase and transforming functions of Bcr-Abl are 
dependent on the fused Bcr sequences.  These sequences are also responsible for altering 
the subcellular localisation of Abl.  The Bcr-Abl proteins block nuclear translocation 
and activate the F-actin binding function, which is required for efficient transformation 
of cells (McWhirter and Wang, 1993).  The cytoplasmic location of Bcr-Abl (Wetzler et 
al., 1993) allows access to a wider range of cellular substrates than those available to the 
predominately nuclear Abl protein (Van Etten et al., 1989).  With rare exceptions, such 
as secondary mutations which cause constitutive activation of the STAT5 pathway 
resulting in maintenance of the transformed phenotype with Bcr-Abl silenced (Horita M 
et al., 2000), Bcr-Abl expression is retained throughout the course of the disease, 
suggesting a selection pressure favouring continuous expression (Melo and Barnes, 
2007).  In support of evidence showing that epigenetic changes are reliant on 
constitutive Bcr-Abl activity, research shows an increase in Bcr-Abl expression levels 
prior to progression to advanced stage disease (Gaiger et al., 1995), together with results 
showing altered expression of genes such as PRAME and JUN-B which may play a role 
in blast phase (Oehler et al., 2009; Radich et al., 2006).   
Bcr-Abl has a wide variety of downstream substrates (Figure 1.2) which it activates 
through phosphorylation, and this is aided through its autophosphorylation which allow 
interaction with SH2 domain containing substrates such as Grb2.  CrkL is a key 
substrate in neutrophils which is involved in the  phosphoinositide 3-kinase (PI3K) 
pathway which is subsequently involved in processes such as protein synthesis and cell 
survival (Oda et al., 1994). 
 
31 
 
B
cr
-A
b
l
P
I3
K
/A
K
T
F
O
X
O
s
B
C
L
2
S
T
A
T
5
, 
M
Y
C
B
C
R
-
A
B
L
B
A
D
M
D
M
2
p
5
3
S
H
P
-1
S
E
T
P
P
2
A
W
n
t/
β
-C
a
te
n
in
N
o
tc
h
S
h
h
R
O
S
D
o
u
b
le
 
S
tr
a
n
d
 
B
re
a
k
s
M
is
m
a
tc
h
C
h
ro
m
o
so
m
a
l 
a
b
er
ra
ti
o
n
s 
a
n
d
 p
o
in
t 
m
u
ta
ti
o
n
s
E
n
h
a
n
ce
d
 
S
el
f-
R
en
ew
a
l
In
h
ib
it
io
n
 o
f 
T
u
m
o
u
r 
S
u
p
p
re
ss
o
rs
G
en
o
m
ic
 
In
st
a
b
il
it
y
E
n
h
a
n
ce
d
 P
ro
li
fe
ra
ti
o
n
/S
u
rv
iv
a
l
F
ig
u
r
e
 1
.2
: 
P
a
th
w
a
y
s 
a
ff
e
c
te
d
 b
y
 B
c
r-
A
b
l 
d
u
r
in
g
 C
M
L
 (
A
d
a
p
te
d
 f
r
o
m
 P
e
r
r
o
tt
i 
e
t 
a
l 
2
0
1
0
)
 
 
32 
 
1.6 CML Treatment and Resistance Mechanisms 
 
 
There are a range of options available to treat CML sufferers including stem cell 
transplantation, and a variety of chemotherapeutic drugs.  To date, therapies have 
involved hydroxy-urea and interferon-α only as a means of prolonging life, working to 
slow down disease progression rather than actually offering a cure.  Bone marrow 
transplantation is effective but is rarely an option due to donor shortages and 
complications with overall post-operative patient health.   
During the 1990’s, Imatinib mesylate (Gleevec) was specifically designed to act on the 
ATP binding site of the kinase domain within Bcr-Abl.  Since its introduction, 5-year 
survival rates from CML patients have risen from 40-60% to 90% for patients with 
chronic phase disease (Bixby and Talpaz, 2009).  Recent karyotype results show that 60-
70% of patients undergo a complete cytogenetic response (CCyR), defined by the 
complete absence of any Philadelphia positive (Ph+)  marrow cells, and remain so 5 
years after initiating Imatinib therapy (Hochhaus et al., 2009). Results have also shown 
a decrease in the number of patients progressing to accelerated and blast phase after 
Imatinib therapy (Hochhaus et al., 2009).  The drug has since been the frontline therapy 
due to its effectiveness and low toxicity.  Unfortunately, Imatinib resistance is a growing 
problem, with the detection of minimal residual disease at the molecular level through 
PCR (Druker et al., 2006).  It is currently estimated that 20-30% of patients will go on to 
develop resistance to Imatinib, with treatment responses seen in advanced stage CML 
often being slow and short-lived (Druker et al., 2001). 
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Imatinib resistance can be either primary (known as refractory), where initial treatment 
is unresponsive, or secondary (known as acquired resistance) where an initial treatment 
response is lost (Druker et al., 2006). Acquired resistance can be characterised by a loss 
of a major cytogenetic response and complete haematological response.   Resistance can 
be further divided into haematological (lack of normalisation of peripheral blood 
counts), molecular (persistence of Bcr-Abl transcripts) and cytogenetic (persistence of 
the Philadelphia chromosome).   
The realisation that Imatinib therapy was not the complete cure for CML in all patients 
prompted further investigation into the development of resistance.  It is currently 
thought that resistance occurs through a range of factors with multiple interactions 
necessary for its emergence, the mechanisms can be divided in to Bcr-Abl dependent 
and independent.  
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1.6.1 Bcr-Abl Independent Mechanisms 
 
 
Drug pharmacokinetics plays an important role in determining the efficacy of any 
treatment.  Several studies have highlighted variability in Imatinib plasma levels among 
patients receiving 400mg orally (le Coutre et al., 2004; Peng et al., 2004).  Imatinib is 
metabolised by the cytochrome p450 isoenzymes and therefore differences in 
concentration of these enzymes can influence Imatinib levels in the plasma.  This is an 
important consideration as basal Imatinib plasma levels are associated with both 
cytogenetic and molecular responses (Picard et al., 2007).  In addition, the success of 
Imatinib as a targeted therapy has allowed its structural manipulation to develop 
potential treatments for other kinase related diseases such as gastrointestinal stromal 
tumours (Skobridis et al., 2010) which often have mutations in the PDFGR or KIT 
receptor (Ma et al., 2002).  
The amount of drug that enters the target cell will depend on the balance of influx and 
efflux proteins.  MDR-1 is a multi-drug resistance gene which encodes the p-
glycoprotein involved in efflux of chemotherapeutic drugs.  This gene is over-expressed 
in blast phase CML and implicated in Imatinib resistance (Mahon et al., 2000).   The 
mechanism of MDR-1 mediated resistance is still unclear, as over-expression in K562 
cells did not confer Imatinib resistance (Ferrao et al., 2003).  In contrast, over-
expression of MDR-1 has been observed in patients failing to induce a major 
cytogenetic response (Galimberti et al., 2005).  The adenosine triphosphate-binding 
cassette (ABC) transporter ABCB1 also known as MDR-1 is expressed in normal 
haematopoietic stem cells (Zhou et al., 2001), and this may explain the apparent 
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inherent Imatinib insensitivity reported in CML stem cells (Chu et al., 2005; Lepper et 
al., 2005). 
During Imatinib treatment, variation in cell susceptibility causes a biphasic decline in 
Bcr-Abl transcript levels (Komarova and Wodarz, 2007).  Differentiated cells are more 
readily cleared than stem cells which are not affected due to their quiescence and 
increased ABCB1 levels.  Generally, the quiescent population make up approximately 
0.5% of the CD34+ population and have intrinsic resistance to Imatinib (Roeder et al., 
2006).  These cells have been shown to over-express the Bcr-Abl transcript at 
significantly higher levels than more mature CML cells (Copland et al., 2006).   
 
1.6.2 Bcr-Abl Dependent Mechanisms 
 
 
Amplification of the Bcr-Abl gene in addition to up-regulation of the Bcr-Abl kinase in 
the absence of Bcr-Abl mutations has been reported in patients with blast phase CML 
who developed Imatinib resistance (Gorre et al., 2001).  Additionally, this resistance 
was in the absence of mutations within the kinase domain of Bcr-Abl (Mahon et al., 
2000).  Further patient analysis has suggested that point mutations are a more common 
mechanism of drug  resistance as only 2 of 66 patients showed gene amplification 
(Hochhaus et al., 2002).  
The development of point mutations leading to treatment resistance has long been 
known in CML.  The occurrence of these mutations ranges from 40-90% depending on 
various factors such as disease phase, resistance definition, and detection method.  The 
first discovery of Bcr-Abl mutations were found in patients who had developed Imatinib 
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resistance, and a significant number had the T315I mutation (Gorre et al., 2001).  
Normally threonine 315, also known as the gatekeeper residue, will form a hydrogen 
bond between Abl kinase and Imatinb, inhibiting kinase activity.  However, if this is 
replaced by an isoleucine residue, as occurs in this mutated form, the hydrogen bond 
interaction is disrupted, Imatinib cannot bind to the Abl kinase and the drug is 
ineffective (Gorre et al., 2001).  
Abl kinase contains an activation loop which can adopt either an open (active) or closed 
(inactive) conformation. Crystallographic evidence shows Imatinib can bind the closed 
DFG (aspartate-phenylalanine-glycine) conformation and ‘locks’ it closed (Schindler et 
al., 2000), but is unable to bind the open conformation.  Some mutations favour this 
open conformation, and include those at residues 253 and 255. They are located at the 
end of the P-loop of Abl kinase which is within the ATP binding domain.    
Some mutations occurring at the activation loop prevent the formation of the inactive 
kinase, the form which Imatinib can bind.  Imatinib itself has been implicated in 
promoting drug resistance through up-regulating the chemokine CXC receptor 4 
(CXCR4) protein which increases cells movement to the bone marrow 
microenvironment (Jin et al., 2008).  This environment, which enhances survival of 
quiescent populations, is typically hypoxic.  Strategies to overcome cell quiescence have 
been investigated and growth factors such as granulocyte macrophage colony-
stimulating factor (GM-CSF) have been used.  These enhanced leukaemia initiating cell 
(LIC) proliferation and subsequently reduced cell number after exposure to Imatinib 
(Holtz et al., 2007). Interestingly, LICs have been shown to have higher levels of Bcr-
Abl than mature progenitor cells, which is also true in patient samples with Imatinib 
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resistance (Jamieson et al., 2004).  This suggests that these LICs may have inherent 
resistance to Imatinib.  
Not all mutations lead to resistance, and there is variation among transforming 
capabilities.  Analysis of the phosphotyrosine proteome has highlighted different 
phosphorylation signatures among the different mutants suggesting a variation in 
substrate specificity, leading to activation of various signalling pathways, such as in the 
case of the M351T kinase domain mutation which exhibits an increase in SHIP1 and 
consequently reduced Akt levels compared to native Bcr-Abl expressing cells (Griswold 
et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
1.7 Treating Imatinib Resistance 
 
 
In the event of Imatinib resistance, increases in Imatinib dosage have been used with 
positive results.  However this strategy is potentially limited as further development of 
disease and increased dosages will ultimately become intolerable for the patient.  To 
combat this problem, more potent Abl tyrosine kinase inhibitors have been developed.  
They are divided into two main groups; ATP-competitive and ATP non-competitive 
inhibitors.  From these, the ATP-competitive inhibitors contain two subclasses, the Src 
family kinase (SFK)/Abl inhibitors and 2-phenylaminopyrimidine-based compounds.   
Dasatinib and SKI-606 are SFK/Abl inhibitors, while Nilotinib is of the latter subclass 
of inhibitor (Kantarjian et al., 2006). Nilotinib is structurally similar to Imatinib and has 
an improved topographical fit into the kinase pocket (O’Hare et al., 2005; Redaelli et 
al., 2009).   Dasatinib has a completely different structure to Imatinib and Nilotinib, and 
is able to bind Bcr-Abl in the active conformation (Tokarski et al., 2006; Vajpai et al., 
2008).  The use of molecular modelling SKI-606 also known as Bosutinib was shown to 
be effective against a broad range of Bcr-Abl mutations, and to have fewer side effects, 
which may be due to not inhibiting KIT or PDGFR (Puttini et al., 2006).  Currently, the 
clinical trials for these next generation tyrosine kinase inhibitors are still ongoing, but 
initial results have shown both Dasatinib and Nilotinib to have greater efficacy in 
comparison to Imatinib as a front line therapy (DASSION trial 2010).  
Even the advent of these new ATP-competitive inhibitors however, cannot inhibit the 
phosphorylation of Bcr-Abl T315I, since this mutation crucially blocks the Imatinib-
binding site preventing access for the drugs.  Interestingly, identical amino acid 
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substitutions were found at homologous positions in the kinase domain of c-Kit (T670I) 
and PDGFRα (T674I) kinases in Imatinib-resistant gastrointestinal stromal tumours and 
hypereosinophilic syndromes, respectively (Cools et al., 2003).  These results highlight 
a crucial role for this conserved amino acid in controlling the accessibility of the ATP-
pocket to inhibitors.  The FMS receptor has been identified as a potential therapeutic 
target, and research has identified predicted similarities between Dasatinib hydrogen 
interactions with Abl and FMS, the receptor for CSF-1 (Brownlow et al., 2009). 
Research into mutations of Bcr-Abl have shown there to be graded forms of resistance. 
Those that occur within the P-loop confer a highly resistant phenotype and poor 
prognosis; mutations outside of the P-Loop are associated with a less potent resistance to 
Imatinib.  Results have shown that second generation inhibitors such as Dasatinib are 
able to induce or restore a complete cytogenetic response (CCyR) in 40-50% of patients 
who have failed initial Imatinib therapy.  However there are still 20% of patients who 
fail to respond to either Imatinib or Dasatinib treatments (Hochhaus et al., 2009). 
The International Randomised Study of Interferon and Imatinib (STI571) (IRIS) results 
have shown that 98% of CML sufferers treated with Imatinib in early chronic phase 
achieve complete haematological response after 60 months, indicating that primary 
resistance is rare. This highlights the importance of disease treatment during early stage 
disease but does not address those in accelerated or blast crisis stages where resistance is 
a much more common occurrence.   
The next step therefore was the development of the non-competitive inhibitors, where 
the status of the ATP-binding pocket is not relevant in their mode of inhibition.  
ON012380 is claimed to be the first agent capable of inhibiting both wild-type and all 
Imatinib-resistant kinase mutations, including T315I in vitro and in vivo (Gumireddy et 
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al., 2005).  At present, ON012380 is still to undergo clinical trials to prove its safety in 
CML patients.  Another recent approach is to target downstream proteins in the Bcr-Abl 
signalling pathway.   Histone deactylase inhibitors LBH in combination with Vorinostat 
and Dasatinib have been able to lead to polyubiquitination of Bcr-Abl and downstream 
effectors AKT and c-Raf.  In leukaemia cells, they cause apoptosis due to an increase in 
pro-apoptotic proteins Bax and Bim together with a reduction in anti-apoptotic Bcl-2, 
Bcl-XL and Survivin (Nimmanapalli et al., 2003). Another novel approach being 
investigated is whether kinase inhibitors directed at other proteins already in clinical 
trials have an off target effect on the Bcr-Abl/T315I.  Results indicate that the p38 MAP 
kinase inhibitor BIRB-796 and the aurora kinase inhibitor VX-680 are both capable of 
binding Bcr-Abl/T315I (Carter et al., 2005; Harrington et al., 2004).  Alternative 
secondary combination treatments to prevent disease progression currently being 
investigated are anti-oxidants (Skorski, 2008) which would protect against cancer-
causing DNA damage; farnesyl transferase inhibitors (Copland et al., 2008), which 
prevent Ras signalling, a known substrate of Bcr-Abl;  sonic hedgehog antagonists 
(Zhao C et al., 2009) which prevent self-renewal and repair when combined with 
tyrosine kinase inhibitors, and protein phosphatase 2A (PP2A) (Perrotti and Neviani, 
2008) activators which target Bcr-Abl and subsequent downstream substrates by remove 
activating phosphate groups.   
Currently, none of the available treatments have significant impact on control or reversal 
of advanced stage disease.  This makes detection and treatment paramount during 
chronic phase.  The need for other methods of disease control could further help combat 
resistance. As well as targeting Bcr-Abl, it is necessary for alternative methods to be 
investigated, involving proteins potentially affecting disease development or resistance.  
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The previously mentioned compounds are effective against the majority of Bcr-Abl 
mutations, but not all, which paves the way for further investigation.  These novel 
inhibitors offer targeting of Src Family kinases (SFK’s) such as Lyn, and Dasatinib has 
been shown to reduce phosphorylated STAT5 levels in CML cell lines ((Nam et al., 
2007), which is a known downstream target of Lyn.  Lyn kinase is a protein which has 
become the subject of much research interest since its association with CML drug  
resistance (Donato et al., 2003; Wu et al., 2008a; Wu et al., 2008b). 
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1.8 Lyn Kinase 
 
 
Lyn kinase is a member of the Src family of non-receptor protein tyrosine kinases of 
which there are eight members currently known; Lyn, Hck, Fyn, Lck, Blk, Yes, Fgr and 
Src.  Lyn is expressed in all blood cells apart from T cells.  All members of this family 
share similar structures (Boggon and Eck, 2004 ).  All members have a unique N-
terminal region which varies among the members, and this region contains either a 
myristoylation or palmitoylation site (Koegl et al., 1994; Resh, 1999). This type of 
modification has been found to regulate protein trafficking.  Lyn mono-palmitoylation 
causes transport from the golgi to the plasma membrane, whereas Fyn is a dually 
palmitoylated protein targeted directly to the plasma membrane (Izumi Sato et al., 
2008).  The N-terminal region is adjacent to a  Src homology 3 (SH3) domain which 
interacts with proline rich sequences via the PXXP consensus sequence (Koch et al., 
1991).  This is followed by the Src homology 2 (SH2) domain which is involved in the 
interaction with phosphotyrosine motifs with the highest affinity shown to the pYEEI 
consensus (Koch et al., 1991).  The final domain is the kinase domain responsible for 
enzymatic activity. The proteins themselves are highly regulated through interactions 
between the SH2 and SH3 domains as well as other regulatory proteins.  
Lyn kinase is present in B lymphocytes and myeloid cells.  Lyn is expressed in two 
protein forms, derived from alternative splicing, and both are expressed in myeloid cells.  
Studies have found equal protein levels of the two isoforms in haematopoietic cells with 
the splicing variation resulting in a 63bp difference within the amino-terminal coding 
region of the gene, giving rise to 53kDa and 56kDa proteins.  Kinase activity of the two 
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forms has been studied and they both display comparable activities (Yi et al 1991).  Lyn 
kinase contains a Src homology 3 (SH3) domain which has two main functions; 
regulation of its kinase activity and directing binding to specific substrates, allowing 
association with proline rich motifs (Koch et al., 1991).  
 
  
 1.8.1 SH2 and SH3 Domain 
 
 
In addition to interacting with various proline-rich subsrates, the SH3 domain acts as a 
negative regulator of Lyn functional activity.   Binding of the SH3 domain to the back of 
the kinase domain, via a proline rich linker, between the SH2 and kinase domains 
maintains the inactive form of the enzyme, through formation of a left-handed poly-
proline type II helix (Xu et al., 1999).  This formation prevents closure between the N 
and C terminals of the kinase domain favouring the inactive form of the activation loop.  
A hallmark of this protein family is the possession of two tyrosine motifs with opposing 
regulatory functions.  The C terminal tyrosine motif which is phosphorylated in the 
inactive state (Y508) by C-terminal kinase (Csk), while the activation loop which is 
located within the cleft between the N and C lobes of the kinase domain is 
phosphorylated to promote the active conformation (Y397).  The association of the SH2 
and SH3 with the kinase domain promotes an overall stable inactive protein structure, 
while the SH2 and SH3 interactions alone provide a low affinity interaction, not strong 
enough to cause a fully inactive protein.  A summary of the structure is shown in Figure 
1.3.  
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 1.8.2 Phosphorylation-mediated Activation 
 
 
Lyn activation occurs through phosphorylation of the activation loop at residue 397.  
This site has also been shown to be phosphorylated through other Src family members in 
addition to tyrosine kinases (Sun et al., 2002).  Research has shown that there are graded 
levels of activation of Lyn protein; i) Fully inactive, which has the SH2/SH3 interactions 
with a phosphorylated 508 residue within the SH2 domain and an unphosphorylated 
activation-loop, ii)   a partially active form where SH2/SH3 interactions are interrupted 
with the activation loop remaining unphosphorylated, or iii) a fully active form in which 
the 397 residue within the activation loop is phosphorylated (Chong et al., 2005). 
 
 
 1.8.3 Extrinsic Regulation 
 
 
Currently, not a great deal is known about the regulation of dephosphorylation of the 
two tyrosine sites via phosphatases. While not family member specific, a number of 
phosphatases have been implicated.  Proline-enriched tyrosine phosphatase (PEP), T-cell 
protein tyrosine phosphatase (TCPTP), tandem SH2 domain-containing protein tyrosine 
phosphatase (SHP1) as well as CD45, have all been shown to dephosphorylate the 508 
phosphorylated tyrosine residue (Baker et al., 2000; Cloutier and Veillette, 1996; Van 
Vliet et al., 2005).  Of these, CD45 has emerged as playing a more prominent role in 
haematopoietic cells (Wang et al., 2002).  In addition to removal of the negatively 
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associated phospho-tyrosine, the phosphatases have also been shown to remove 
phosphate from the activation loop, so they are involved in activation as well 
inactivation of the proteins (Baker et al., 2000; Van Vliet et al., 2005).   
 
The phosphorylation of the Src family kinase (SFK) proteins appears to be a multi -
factorial process involving kinases in addition to adaptor/scaffold proteins.  C-terminal 
Src kinase (Csk) and CSK-homologous kinase (CHK) are able to phosphorylate the c-
terminal tyrosine residue (Chong et al., 2005).  Csk is usually found in the cytoplasm 
and relies on Csk-binding protein (Cbp) to facilitate its recruitment to the plasma 
membrane.  This then enables Csk to interact with the SFK member. Lyn kinase has 
been shown to directly associate with Cbp (Ingley et al., 2006).   Once in its active form 
the SFK can bind Cbp through its SH3 domain which stabilises the active conformation 
(Ingley et al., 2006).   
Interestingly, Lyn has been shown to form a negative feedback loop with Suppressor of 
Cytokine Signalling 1 (SOCS1) protein which is involved in the ubiquitination of Lyn 
(Kyo et al., 2003).  SOCS1 is recruited to Lyn by the adaptor protein Cbp in the same 
manner as Csk (Zhang et al., 1999).  Increased SOCS1 showed increased levels of 
ubiquitinated Lyn which was significantly decreased in SOCS deficient cells (Zhang et 
al., 1999).   
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 1.8.4 Lyn involvement in Disease 
 
 
Lyn plays an important role in B cell development and is activated through B cell 
receptor signalling where it acts as a negative regulator.  Interestingly however, in B cell 
chronic lymphocytic leukaemia (B-CLL), increased levels of Lyn result in defective 
apoptosis (Contri et al., 2005).  Recently, over-expression of Lyn has been implicated in 
drug  resistance of chronic myeloid leukaemia and shown to be activated independently 
of Bcr-Abl (Wu et al., 2008a).  Wu et al go on to suggest that Lyn kinase is responsible 
for regulating the Imatinib sensitivity in CML cells.   
Recently, Lyn has been shown to act as both a negative and positive regulator in 
signalling responses (Lowell, 2004; Xu et al., 2005).  Evidence of  Lyn involvement in 
down-regulating signalling responses came from the lyn-/- mice which develop auto-
immune disease (Chan et al., 1997; Hibbs et al., 1995).  In B cells, Lyn is crucial in 
down-regulating B cell receptor ligation-mediated activation where it is responsible for 
phosphorylating inhibitory receptors in the B cell signalling cascade, such as CD22 and 
Fc gamma IIb resulting in suppression of the active B cell responses (Lowell, 2004). as 
well as recruiting tyrosine phosphatase SHP-1 which turns off the activating response 
(DeFranco et al., 1998). 
Interestingly, in myeloid cells Lyn has been shown to play a positive role.  In 
haematopoiesis Lyn is needed for stem cell factor-induced proliferation and chemotaxis 
(O'Laughlin-Bunner et al., 2001). 
Lyn is able to inhibit neutrophil apoptosis through association with the granulocyte 
macrophage colony-stimulating factor (GM-SCF) receptor (Wei S et al., 1996). 
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In haematopoietic progenitor cells, Lyn -/- mice showed enhanced sensitivity to myeloid 
specific growth factors such as interleukin 3 (IL-3) and stem cell factor (SCF) (Harder et 
al., 2001).  The knockout mouse also developed significant increases in myeloid cells in 
the spleen, lymph nodes and bone marrow.  These results suggest that Lyn plays a 
negative role in the modulation of myelopoiesis.    It is noted however that these Lyn 
deficient mice do not develop leukaemia in terms of uncontrolled blast proliferation.  In 
CML, knockdown of elevated Lyn expression by siRNA resulted in increased apoptosis 
and an increase in Imatinib susceptibility (Ptasznik et al., 2004).   Interestingly, in some 
studies, the development of Lyn dependent signalling has been linked to the appearance 
of new phosphorylation sites (Lee et al., 2008). 
Lyn has also been the target of the more recently developed CML drug Dasatinib which 
targets the Src family kinases and is aimed at patients unresponsive to Imatinib.  
Recently, Lyn hyper-activation has been highlighted in CML resistant populations.  
Acute myeloid leukaemia (AML) is also reported to have increased levels of 
phosphorylated Lyn kinase which could be decreased with protein phosphatase 2 
(PP2A) or Lyn siRNA (Dos Santos et al., 2008). 
The ability of Lyn to switch from positive to negative regulator for the same agonist in 
different cell types suggests a much wider signalling network.  With Lyn playing such a 
varied role among cell systems it is not surprising that tight regulation is required, and as 
such, deregulation causing an imbalance can lead directly to disease promotion. 
Overall, it appears that in normal haematopoiesis Lyn has a role in the inhibition of 
myeloid cell development, yet in the context of disease it is able to act as a positive 
regulator of growth and survival.  One study has implicated TGFβ in the regulation of 
Src family members suggesting it can down-regulate Lyn (Atfi et al., 1994). 
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1.9 TGFβ Signalling 
 
 
The TGFβ family play a dual role in cell signalling, influencing both normal and disease 
states.  TGFβ is able to elicit a huge number of signalling responses through targeting a 
wide range of genes, giving rise to diverse cellular responses such as proliferation, 
apoptosis, differentiation, and epithelial-mesenchymal transition (EMT).  
Effects are dependent on cell type and stimulation context (Siegel and Massague, 2003).  
TGFβ was initially reported to cause fibroblasts to undergo transformation (Roberts et 
al., 1980).   Often the TGFβ signalling cascade is reported to be mutated in cancers. An 
example of the different responses to TGFβ  can be seen among epithelial cells where 
TGFβ stimulation causes growth arrest and apoptosis, processes associated with tumour 
suppression, and the induction of the epithelial to mesenchymal transition (EMT) and 
fibroblast activation, responses involved in the promotion of cancer metastasis and 
fibrotic disease (Siegel and Massague, 2003).  There is growing evidence suggesting 
TGFβ is secreted by tumour cells which actively contributes to cancer processes such as 
cell growth, invasion and metastasis (Franco et al., 2011; Komatsu et al., 1989). 
The overall ability of TGFβ to be involved in such a wide range of cellular processes 
would suggest a complex signalling pathway mechanism, yet the mediation of the TGFβ 
signal is relatively simple.  
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1.9.1 TGFβ Ligand and Receptors 
 
 
The TGFβ superfamily can be subdivided into the TGFβ/activin/nodal family and the 
bone morphogenetic protein (BMP)/growth and differentiation factor (GDF)/Muellerian 
inhibiting substance (MIS) family, these classifications are based on their structural 
similarities and functional roles.  TGFβ is the founding member of the superfamily and 
exists in three mammalian isoforms; TGFβ-1, TGFβ-2, and TGFβ-3.  They share around 
80% homology and signal through the same receptors.  Research carried out in this 
thesis looks exclusively at TGFβ-1.   
TGFβ is initially synthesised as a precursor protein, and then proteolytically processed 
to an inactive form bound to the amino-terminal precursor called the  latency-associated 
peptide (LAP) (Munger et al., 1997). The secreted growth factor and pro-peptide 
complex prevents a response being elicited prematurely.  Initially synthesised as 55kDa 
polypeptides, TGFβ then forms dimers after production.  This is then cleaved to form 
small latent TGFβ in the golgi apparatus (Dubois et al., 1995).  This complex contains 
the mature 25kDa protein with LAP, this usually associates with latent TGFβ binding 
protein (LTBP).  TGFβ is activated by several mechanisms including plasmin digestion 
through cleavage of LAP (Grainger et al., 1995),  and activation of small or large latent 
complexes through thrombospondin (Ribeiro et al., 1999).  The activation of TGFβ is a 
multi-step process demonstrating the regulation used in the control of active TGFβ 
production.  
There are a range of type I and II receptors which are utilised by TGFβ family members.  
There are seven mammalian type I receptors known as ALK 1-7 (Activin receptor-like 
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kinase), and five type II receptors.  In the vast majority of cell types TGFβ uses ALK5 
and TGFβRII.  In addition, a type III receptor (TGFβRIII), also known as betaglycan, 
serves as a co-receptor by presenting the ligand to TGFβRII. The cytoplasmic domains 
of TGFβRIII and TGFβRII interact.  TGFβRIII preferentially binds autophosphorylated 
TGFβRII, promoting the formation of a TGFβRII/TGFβRI complex (Blobe et al., 2001). 
TGFβ family members elicit signalling through interactions with 2 receptor 
serine/threonine kinases known as the type I (TGFβRI) and type II (TGFβRII) receptors.  
Ligand binding mediates formation of a heterotetrameric complex allowing the 
constitutively active TGFβRII to phosphorylate the glycine-serine rich domain of 
TGFβRI, activating its kinase domain, causing the assembly of two type I and two type 
II receptors (Figure 1.4).  The TGFβ family transduce their signals via the 
phosphorylation, and subsequent activation of receptor activated Smad proteins via the 
TGFβRI.  Activated Smads translocate into the nucleus where they associate with other 
transcription factors to regulate gene expression (Massague et al., 2005).   
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1.9.2 SMADS 
 
 
Smads are the intracellular messengers of the TGFβ signalling pathway.  They were first 
identified in Drosophila and named MAD proteins (Sekelsky et al., 1995). In mammals, 
there are 8 known Smad proteins which are grouped according to function: receptor 
activated Smads (R-Smads: 1,2,3,5 and 8), the common mediator Smad (co-Smad: 
Smad4), and the inhibitory Smads (I-Smads: 6 and 7).  TGFβ is known to signal through 
Smads 2 and 3, while Smads 1, 5 and 8 are activated through BMP signalling.  Both R- 
and Co-Smads contain an N-terminal MH1 (MAD homology 1) and C-terminal MH2 
domain which are connected via a non-conserved linker region.  
Upon ligand binding, phosphorylation of R-SMADs by TGFβRI occurs on the C-
terminal Ser-Ser-X-Ser-Ser (SSXSS) motif, also known as the MH2 domain which is 
highly conserved among all Smad proteins. R-Smad phosphorylation is facilitated by 
other proteins such as SARA (Smad anchor for receptor activation) (Tsukazaki et al., 
1998).  SARA was originally identified as a Smad2 interacting protein which can also 
associate with the TGFβ receptor complex and present Smad2 to the complexes for 
phosphorylation and activation (Tsukazaki et al., 1998).   SARA contains the FYVE 
domain, a phospholipid binding domain, which functions as an adaptor to recruit Smads 
2 and 3 to the TGFβ receptor complex.  Recently, SARA has been found to bind to 
phosphatidylinositol 3-phoshphate (PtdIns3P) in the membrane and promote TGFβ 
receptor trafficking to the early endosome leading to Smad2 phosphorylation (Itoh F et 
al., 2002).  Additionally,  R-SMAD phosphorylation is coupled with the internalisation 
of the TGFβR (Hayes et al., 2002).  After phosphorylation, dissociation occurs between 
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the SARA/receptor complex and the R-SMAD, a hetero-oligomeric complex is then 
formed between the R-Smad and co-Smad 4.  This complex then translocates into the 
nucleus and interacts with Smad binding elements (SBEs) or GC rich sequences present 
in certain promoters (Shi et al., 1998). The SBEs are often located near binding sites for 
various other transcription factors, consequently Smads are able to influence a wide 
range of gene expression mechanisms (Massague et al., 2005).  The complexity of 
signalling is regulated in part through accessory proteins in the nucleus which facilitate a 
specific transcriptional response.  Smads have a low affinity for DNA binding, so co-
activator proteins such as p300, and CREB-binding protein (CBP) and co-repressors 
such as Ski and SnoN aid in regulating the response. 
I-Smads lack the C-terminal sites for phosphorylation by TGFβRI found in both R- and 
co- Smads.  Smad7 inhibits the TGFβ/activin and BMP pathways whereas Smad6 
exclusively inhibits the BMP pathway (Hayashi et al., 1997).  These two Smads are able 
to inhibit signalling via different mechanisms. Smad6 competes with Smad4 for binding 
to phosphorylated Smad1, creating a Smad1/6 complex, which is unable to regulate 
transcription (Hata et al., 1998).  Smad7 however competes with R-Smad for the 
interaction with TGFβRI by forming stable interactions with the receptor (Hayashi et al., 
1997).  In addition, Smad7 is able to mediate TGFβ receptor ubiquitination and 
degradation by recruiting Smurf1/2 ubiquitin ligases (Kavsak et al., 2000).  Caveolin-1 
is known to interact with TGFβRI and its overexpression leads to the promotion of 
receptor degradation.  Smad7 and Smurf2 are located within caveolin-1 vesicles, and are 
thought to be involved in this receptor complex and promote proteasomal-dependent 
degradation (Le Roy and Wrana, 2005). 
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Despite the Smads being widely known as the intracellular mediators of TGFβ 
signalling, other pathways can be activated through TGFβ, independently of them.  In 
primary epithelial cells and some breast cancer cell lines, activation of Ras, c-Jun N-
terminal kinase (JNK) and extracellular signal-regulated kinase 1/2 (ERK) by TGFβ has 
been reported (Mulder, 2000).  TGFβ activated kinase-1 (TAK1) a member of the 
MEKK family and activator of JNK and p38 MAPK pathways (Yamaguchi et al., 1995) 
was activated by TGFβ.  Recently, the TGFβ receptor has been found to be modified 
through sumoylation which is a small ubiquitin-like modifier (SUMO) which enhances 
the TGFβ response through recruitment and activation of Smad3 (Kang et al., 2008).  
This evidence goes some way towards detailing the complexity surrounding the TGFβ 
signalling pathway and how multiple signalling transducers can have a huge range of 
effects within a cell. 
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1.10 TGFβ in Haematopoiesis 
 
 
A number of studies have suggested TGFβ is directly involved in the inhibition of 
murine and human haematopoietic stem and primitive progenitor cells in vitro (Batard et 
al., 2000; Keller et al., 1988; Sitnicka et al., 1996), whereas more differentiated cells are 
more resistant to these affects.  In more mature cells the presence of other growth factors 
makes the effect on these cells more complex.  Transient blockage of autocrine 
signalling through expression of a dominant negative TGFβRII enhances proliferation 
and survival of human HSCs in vitro (Fan et al., 2002).  An in vivo study also showed 
the inhibitory affects of TGFβ-1 by directly injecting it into femoral arteries of mice, 
demonstrating inhibition of multi-potent haematopoietic progenitors in bone marrow 
(Goey et al., 1989).  These results suggest that both autocrine TGFβ production from 
HSCs, and TGFβ from surrounding stromal cells are involved in the maintenance of the 
HSC population.  
Interestingly, TGFβ-2 has been shown to have a positive affect on HSCs while TGFβ-3 
only functions as an inhibitor on early haematopoietic progenitors (Jacobsen et al., 
1991).  Another study showed that TGFβ-2 demonstrated opposing effects and this was 
dose dependent. In low concentrations it had a stimulatory affect, while at higher 
concentrations proliferation was inhibited (Langer et al., 2004). 
It has been observed that early progenitor CD34+CD38- cells show a strong response to 
TGFβ inhibition whereas more mature CD34+CD38+ are less sensitive (Van Ranst et al., 
1996).  In addition, research has shown a branching of the TGFβ pathway where Smad4-
Smad2/3 associations promotes growth inhibition in haematopoietic cells, whereas 
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Smad2/3 interacting with Transcriptional Intermediary Factor 1γ (TIF1γ) mediates 
differentiation (Wei et al., 2006). 
TGFβ is believed to exert the anti-proliferative affects through two mechanisms 
resulting in the inhibition of cell-cycle responses. Firstly, it down-regulates c-Myc 
which is involved in antagonizing the TGFβ pathway through cyclin dependent kinase 
inhibitor (CDKI) repression, and secondly it upregulates CDKIs such as p15, p21 and 
p27 (Massagué et al., 2000).  Interestingly, p21-/- and p27-/- mice were inhibited by 
TGFβ, demonstrating that the anti-proliferative affect is independent of these two 
proteins (Cheng et al., 2001).  A number of studies have shown that the only CDKI to be 
significantly up-regulated by TGFβ is p57, and targeted siRNA has shown it to be 
crucial for TGFβ-mediated cell cycle arrest in haematopoietic cells (Scandura et al., 
2004; Yamazaki et al., 2009).   In addition to cell cycle proteins, TGFβ has also been 
shown to down-regulate haematopoietic cytokine receptors such as IL-1 and stem cell 
factor (SCF) (Dubois et al., 1990; Jacobsen et al., 1995).  Smad5 has been shown to play 
a role in mediating the inhibitory effects of TGFβ in haematopoietic progenitor cells by 
using antisense oligonucleotides to knock it down, which reversed the inhibitory effects 
(Bruno et al., 1998).  
Another study looked at completely knocking out the TGFβ signalling pathway through 
over-expression of Smad7 in HSCs resulting in a greater ability of cells to self-renew 
(Blank et al., 2006). 
Despite the large amount of evidence presenting TGFβ as an inhibitor of haematopoietic 
cell growth in vitro, the in vivo studies suggest a different outcome. It is also a 
consideration that the high TGFβ doses used may not reflect physiological conditions.  
To overcome this, one study used a TGFβ receptor knockout model and concluded that 
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TGFβ is dispensable for regulation of HSC quiescence or self-renewal in vivo (Larsson 
et al., 2003; Larsson et al., 2005)  It is thought that these differences may be due to the 
more complex in vivo setting, and highlights the importance the surrounding 
environment can have on the TGFβ-mediated effects. 
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1.11 TGFβ and Leukaemia 
 
 
In addition to its role in cell growth inhibition and acting as a tumour suppressor, TGFβ 
can also promote tumour metastasis in late stage disease highlighting its involvement in 
both disease suppression and progression (Derynck et al., 2001).  The disruption of 
TGFβ signalling through mutations causing either inactivation or a down-regulation of 
expression is known to play an important role in carcinogenesis (Derynck et al., 2001; 
Massagué et al., 2000). 
In acute myeloid leukaemia (AML) two mutations involving Smad4 are known, which 
disrupt the propagation of TGFβ transcriptional activity (Imai et al., 2001).  Further 
evidence goes on to suggest that TGFβ alone is not able to cause the onset of leukaemia 
but is a factor in disease progression.  This is supported further by evidence that  both 
Smad3-null and TGFβRI knockout mice independently did not go on to develop 
leukaemia (Datto et al., 1999; Yang et al., 1999), but patient data suggests loss of 
TGFβRI/II can lead to myeloid or lymphocytic leukaemia (Le Bousse-Kerdilès et al., 
1996).   
A number of studies have tried to uncover the effect TGFβ has on leukaemia cell 
proliferation.  For example, Kadin et al (1994) found resistance to TGFβ-mediated 
inhibition was associated with loss of TGFβRII expression in T-cell lymphomas.  
Alternatively, Cashman et al (1998) showed that CML cells were responsive to TGFβ 
growth inhibition.  Alongside this, Atfi et al (2005) suggests Bcr-Abl positive cells 
inhibit the TGFβ response without adversely affecting Smad activity but by activating 
Akt which blocks the TGFβ effect through retention of FoxO3 in the cytoplasm.  Møller 
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et al (2007) demonstrated that Bcr-Abl expression in TF-1 cells rendered them more 
sensitive to the growth inhibitory effects of TGFβ than the parental cell line.  In addition 
to the growth inhibitory effects, TGF  plays a vital role in maintaining the growth and 
differentiation balance in haematopoietic cells (Fortunel et al., 2003; Kim and Letterio, 
2003).   More recently, growing evidence for a mixed population of tumour cells, which 
are able to self-renew and propagate tumour formation, has been suggested. These 
findings have been discovered in many organs and tissues including blood (Lapidot et 
al., 1994), breast (Al-Hajj et al., 2003) and brain (Singh et al., 2004).   Aberrant TGF  
signalling in adult T-cell leukaemia/lymphoma suggests that down regulation of the 
tumour suppressor zinc finger E-binding homeobox 1 (ZEB1) which is normally an 
enhancer of TGF  signalling through Smad2/3 binding, combined with enhanced 
Smad7,  leads to TGF  anti-growth resistance (Nakahata et al., 2010).  Members of the 
TGF  receptor family ALK1 and ALK5 have been studied and ALK5 has been found to 
be overexpressed in acute myeloid leukaemia. This correlates with a negative impact on 
complete remission in patients, and highlights the potential for small molecule inhibitors 
to target the receptor (Otten et al., 2011).   
A further recent development in the study of CML is the role of the stem cell niche. As 
mentioned previously, HSC’s are thought to play a role in disease persistence and be 
refractory to therapy, and recently the environment harbouring these cell populations has 
been investigated.  Matrix-metalloproteinase-9 (MMP-9), involved in matrix protein 
regulation,   , has been reported to be up-regulated in CML (Yoon et al., 2006).  MMP-9 
is regulated by TGFβ and this activation leads to MMP-9 induced cell migration and 
subsequent spread of cells away from the niche and into the circulation, promoting 
metastasis.  It has also been shown using HSc025 (Smad inhibitor) that MMP-9 up-
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regulation is Smad independent and occurs via the PI3K/Akt pathway.  The PI3K/Akt 
pathway has previously been implicated in CML and work by Naka et al (2010) has 
shown that TGF  critically regulates the leukaemia initiating cell (LIC) population.  
Inhibition of the pathway resulted in an increase in phosphorylated Akt leading to export 
of nuclear Foxo3a resulting in a reduction in the potency of LIC driven disease.  In non-
LICs, Bcr-Abl activates Akt, leading to repression of Foxo3a effects, such as apoptosis 
and cell cycle arrest, allowing these cells to proliferate.   
One study which has tried to establish a mechanism through which leukemic cells are 
resistant to the effects of TGF  looked at childhood leukaemia resulting from a TEL-
AML1 fusion gene, the most common in paediatric cancer.  The study shows that TEL-
AML1 is able to bind Smad3 and suggests that this leads to a sequestering away from the 
nuclear target sites compromising the ability to activate negative cell cycle regulators 
such as p27Kip1 in early B cell progenitors (Ford et al., 2010).  The cell cycle inhibitor 
p15 also involved in mediating TGFβ induced cytostatic effects is often silenced due to 
promoter hyper-methylation in AML (Krug et al., 2002). 
TGFβ regulation via the gene Pml has been found in promyelocytic leukaemia, Pml-/- 
primary cells showed impaired TGFβ induced growth inhibition.  Interestingly, this was 
rescued by adding a cytoplasmic isoform (cPML), suggesting it is critical for TGFβ 
functions.  This research also showed that Smad2/3 phosphorylation and nuclear 
translocation was reduced in PML-/- cells (Lin et al., 2004).  This followed on from work 
which identified retinoic acid (RA) as being able to reverse the TGFβ insensitivity in 
acute promyelocytic (APL) leukaemia caused by PML-RARα over-expression through 
degradation of the over-expressed protein (Lin et al., 2004). The involvement of Smad3 
in leukemogenesis has also been found in T-cell ALL where it is identified as a tumour 
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suppressor, with protein levels undetectable in children suffering from the disease. 
Finally, TGF  can be negatively regulated, leading to leukaemia.  The oncoproteins c-
Ski which are overexpressed in leukaemia patients (Kronenwett et al., 2005) are known 
to effect TGF  signalling through interference with the R-smad/Smad4 complex in 
addition to the recruitment of co-repressors such as N-CoR and histone deacetylases 
(HDACs) (Liu et al., 2001).   From these examples it is clear to see that TGFβ appears 
to have a changing or transient role in leukaemia pathogenesis, and can act in conflicting 
fashion dependent on cell type.   
In general, TGF  is considered a strong inhibitor of committed progenitor cell function, 
and autocrine production of TGF  maintains haematopoietic stem cells in a non-
dividing quiescent state.  During carcinogenesis the role of TGF  as a tumour 
suppressor appears to change, emerging as an oncogenic factor. The ability of TGF  to 
be involved in a range of signalling pathways, which may elicit cross-talk mechanisms, 
and can be either Smad dependent or independent, only highlights the vast complexity 
of its role in disease development.  Evidence suggests that while TGF  is important, it is 
not involved in leukaemia initiation, but plays a role in leukaemia progression. 
Combined with the observation that it is often up-regulated in leukaemia (Mori et al., 
2000) it can be suggested that it plays a role in disease invasion.  Clearly, understanding 
TGF  regulation and its downstream targets is of paramount importance in the context 
of CML.  Protein levels within a cell can be controlled through a range of post-
translational modifications, TGF RI levels are known to be regulated  through Smad7-
mediated Smurf2 ubiquitination (Kavsak et al., 2000), and evidence has also highlighted 
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TGF  to downregulate Src kinases including Lyn (Atfi et al., 1994) which may be via 
ubiquitination. 
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1.12 The Ubiquitin Proteosome System 
 
 
Ubiquitination  is a post-translational modification involved in the majority of cellular 
events, where  a 76-residue ubiquitin (Ub) protein  can be attached to target proteins and 
affect their localization, activity, structure and interaction partners through lysine 
residues.  Proteins can become mono or polyubiquitinated.  Ub is activated through an 
enzymatic cascade, by a ubiquitin activating enzyme the E1 enzyme, and then 
transferred to a ubiquitin conjugating enzyme E2.  The E2 enzyme   transfers the 
ubiquitin to an E3 ubiquitin ligase which consequently catalyzes the transfer of the 
ubiquitin to a lysine residue of the target protein (Figure 1.5).  Substrate specificity is 
mainly determined by the E3 ligase (Pickart and Fushman, 2004).  Ubiquitination is 
reversible through deubiquitinating enzymes (DUBs) which remove the Ub modification 
from the substrate (Komander et al., 2009).  In addition, proteins contain Ub binding 
domains (UBDs), which increase the ability for this modification to influence cellular 
protein activities.  
 
 
1.12.1 Roles of Ubiquitination  
 
 
The ubiquitin modification of a protein causes a specific functional change.  Ubiquitin is 
able to affect its target protein based on the particular modification.  The ubiquitination 
reaction generates an iso-peptide bond between the carboxyl terminus of Ub and the 
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amino group of lysine on the target substrate (Weissman, 2001), and in certain instances 
the terminal amine or Cysteine group can also be modified (Cadwell and Coscoy, 2006; 
Ciechanover and Ben-Saadon, 2004). 
The substrate modification can be via different mechanisms.  Monoubiquitination occurs 
when a single ubiquitin molecule binds a substrate, and is involved in non-proteolytic 
processes such as gene expression and nuclear export.  Poly-monoubiquitination can 
occur where several lysine residues on a target protein have a single ubiquitin attached 
(Figure 1.6).  Ub contains 7-internal lysine residues, making it possible to form chains, 
and therefore can be targeted for ubiquitination on these seven lysine residues serving as 
ubiquitin substrates.  This allows a target protein to be polyubiquitinated through the 
addition of Ub chains (Xu et al., 2009).  The structural diversity of these chains, gained 
through the additional ubiquitination of specific lysine residues on ubiquitin, allows 
functionally distinct signals to be generated.  Polyubiquitination through lysine 48 is 
known to target the substrate for proteasomal degradation, whereas ubiquitin chains 
linked through lysine 63 are believed to signal in a similar way to monoubiquitination 
(Sorrentino et al., 2008). 
Proteins targeted for ubiquitination are complexed with specific ubiquitin-conjugating 
enzymes known as E3 ligases which attach the 76-residue protein to the target substrate.  
Phosphorylation has been highlighted as an important factor in ubiquitination.  Many 
parallels have been drawn between the two modifications.  Phosphorylation of substrates 
is a well characterised way of creating binding sites for E3 ligase binding.  An example 
of this is Cbl, a monomeric Ring E3 ligase, involved in ubiquitination of the EGFR, 
which binds its substrate through a phosphotyrosine binding domain, only after receptor 
phosphorylation (Levkowitz et al., 1998). 
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1.12.2 Ubiquitination in TGFβ Signalling 
 
 
E3 ubiquitin ligases are essential in targeting substrate specificity, and are divided into 
Homologous to the E6-AP Carboxyl Terminus (HECT) domain and Really Interesting 
New Gene (RING)-type ligases. The RING E3s can be single-chain proteins or multi-
subunit complexes and they act as scaffolds using an associated E2 ligase to transfer Ub 
onto target substrates. In contrast, the HECT E3s have intrinsic ubiquitin ligase activity 
used for direct substrate ubiquitination. Arkadia is an example of a RING finger E3 
ligase, and recent data suggests it plays an important role in modulating levels of nuclear 
phospho-smads together with the Smad transcriptional co-repressor SnoN (Levy et al, 
2007; Nagano et al, 2007). In addition, the RING E3 ligase Ectodermin/TIF1  has been 
implicated in Smad4 degradation (Dupont et al, 2005). Within the HECT-domain E3 
ligases are a small sub-group known as the Neural precursor cell expressed 
developmentally down-regulated 4 (NEDD4) family. There are nine NEDD4 family E3 
ligases in human and mouse, including NEDD4-2/NEDD4L, WWP1/Tiul1, WWP2, 
AIP4/Itch, Smurf1, Smurf2, HecW1/NEDL1, and HecW2/NEDL2. Smurf1 (Smad-
ubiquitin regulatory factor 1) is a NEDD4 family E3 ligase, and this was the first E3 
ligase to be implicated in the TGF  signalling pathway.  Smurf1 binds and regulates 
levels of un-stimulated BMP-regulated Smad 1 and 5 (Zhu et al, 1999). Smurf2 binds 
and ubiquitinates primarily phospho-Smad 1 and 2 (Lin et al, 2000; Zhang et al, 2001; 
Bonni et al, 2001), but is also recruited to the type 1 TGF  receptor via Smad7 (Kavsak 
et al., 2000; Ebisawa et al., 2001; Suzuki et al, 2002). Other NEDD4 family E3 ubiquitin 
ligases that regulate the TGF  pathway at different levels include NEDD4-2 (Kuratomi 
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et al, 2005), WWP1/Tiul (Komuro et al, 2004; Morén et al, 2005; Seo et al, 2004), and 
AIP4/Itch (Bai et al, 2004; Lallemand et al, 2005), and WWP2 (Soond and Chantry, 
2011). 
Recently, TRAF6, a two ring domain ubiquitin ligase, was shown to be responsible for 
the activation of the TGFβ-activated kinase 1 (TAK1) through lysine-63 
polyubiquitination, allowing the downstream activation of Smad independent JNK and 
p38 pathways (Sorrentino et al., 2008; Yamashita et al., 2008).  
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1.13 Connections between TGFβ, Lyn and E3 ubiquitin ligases 
 
 
There are a number of potential E3 Ubiquitin ligases that might connect TGF  to Lyn, 
and literature searches have highlighted the Ring finger E3 Ubiquitin ligase, c-cbl, as a 
very promising candidate (Shao et al 2004). C-cbl is an SH2-domain-containing E3 
ubiquitin ligase that is known to interact with Lyn. In addition, other published studies 
highlight de-regulated TGF  signalling in cbl -/- cells suggesting possible interactions 
between TGF  and c-cbl (Wohlfert et al 2006).  
TGFβ is known to inhibit cell growth, and this response is often lost in cancerous cells. 
Studies have implicated a role for TGFβ in Lyn activation.  Atfi et al (1994) suggest 
TGFβ causes a decrease in cellular levels of Lyn together with a decrease in pro tein 
activity. In 1995 Pazdrak et al reported a TGFβ-mediated inhibition of Lyn through IL-
5, suggesting an inhibitory role for TGFβ in eosinophils. 
The E3 ligase Cbl has previously been linked to Lyn kinase ubiquitination (Kyo et al., 
2003).  Importantly, they are also substrates of the SFKs (Hunter et al., 1999).  The Cbl 
proteins have largely been studied in relation to the epidermal growth factor receptor 
and its role in receptor recycling and degradation (Katzmann et al., 2002).   
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1.14 Aims and Hypothesis 
 
 
TGFβ has long been studied and its deregulation is well documented in many cancers.  
This research aims to further investigate the role of TGFβ in CML disease progression 
and resistance. My initial hypothesis is that up-regulation of TGF  activity by Bcr-Abl 
is responsible for maintaining the small population of Imatinib-resistant stem cells in 
CML causing the residual persistent disease, leading to relapse. The theory was that 
CML could be completely eradicated only by a combination therapy; where it is 
necessary to administer both a Bcr-Abl inhibitor together with a TGF  receptor inhibitor 
to allow the quiescent cell population to enter back into the cell cycle where Imatinib 
would induce apoptosis, summarised in Figure 1.7. While this was being investigated 
research emerged unveiling Lyn kinase as a contributor to imatinib resistance through 
over-expression.  Futhermore, a paper by Atfi et al (1994) described TGFβ down-
regulating Src family kinases including Lyn in prostate carcinoma cells.  This provided a 
link between the two, so it was speculated that TGFβ may also be having an effect on 
Lyn kinase in CML, and indeed, on drug  resistance.  
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Overall, the underlying hypothesis is that Bcr-Abl up-regulates TGF -signalling and 
that imatinib resistance through Lyn kinase expression is mediated by TGF .  The aims 
of the project were: 
1. To confirm Bcr-Abl up-regulation of TGF  Smad-dependent signalling through 
luciferase reporter analysis in well established TGF -responsive cell lines 
2. To characterise MYL and MYL-R CML derived cell lines in terms of TGF  
responsiveness, through cell proliferation and protein analysis studies. 
3. Assess a dual-therapy approach to overcoming drug  resistance using a TGF  
signalling inhibitor alongside Imatinib. 
4. Investigate a link between TGF  and Lyn kinase in drug  resistance through 
over-expression and endogenous analysis in CML cells. 
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2. MATERIALS AND METHODS 
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2.1 Materials 
 
 
Recombinant human TGFβ was bought from R&D Systems.  SB431542 compound was 
bought from Sigma Aldrich.  Imatinib Mesylate (STI571) was donated by Novartis. 
Lyn-Flag expression vector was obtained from Hiroshi Murakami (Okayama 
University), and CAGA12 from Caroline Hill (CRUK Laboratories), TRAF6 constructs 
were a gift from Justin McCarthy (University College Cork), Cbl constructs from Stan 
Lipkowitz (National Institutes of Health, Maryland), Bcr-Abl-p210 from Helen James 
(University of East Anglia). 
Competent DH5α cells were purchased from Invitrogen. 
 
2.2 DNA Preparation 
 
2.2.1 LB Agar Plates/ LB Media 
 
E. Coli DH5α cells were grown in Luria-Bertani medium (LB) which was sterilised by 
autoclaving.  After cooling, ampicillin (100μg/ml) was added if required.  If bacterial 
cultures were grown on solid media, agar was added to the LB prior to autoclaving.  LB 
agar was cooled before the addition of ampicillin (100μg/ml), and then poured into 
10cm dishes, left to solidify at room temperature and then stored at 4°C. The 
components for both are shown in Table 2.1.  
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 LB Media LB Agar 
Bacto-Tryptone 10g 10g 
Bacto-Yeast Extract 5g 5g 
Sodium Chloride 5g 5g 
5M Sodium Hydroxide 200μl 200μl 
Bacto-Agar - 30g 
Distilled Water 1000ml 1000ml 
Table 2.1: Compositon of LB media and LB agar 
 
2.2.2 Heat Shock Transformations 
 
A vial containing 50μl of competent DH5α cells was thawed on ice and, 1μg of plasmid 
DNA was added.  The same volume of water was added to a separate sample of cells to 
serve as a negative control.  Cells were mixed gently and then incubated on ice for 30 
minutes before heat-shock treatment at 42°C in a water bath for 20 seconds, before 
being incubated on ice for 2 minutes. 950μl of pre-warmed LB was added and incubated 
for 1 hour at 37°C, shaking at 225rpm. The mixture was then spun down at 6,000 rpm 
for 5 minutes and the supernatant was removed. The DH5α cells were re-suspended in 
the remaining supernatant and pipetted onto an antibiotic selective LB agar plate, and 
incubated at 37°C overnight. 
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2.2.3 DNA Purification 
 
Competent cells were transformed as described previously.  Colonies were isolated from 
agar plates grown up overnight using a pipette tip, and transferred to 15ml Falcon tubes 
each containing 2mls of LB plus a selected antibiotic. These were incubated at 37°C, 
250rpm with shaking for 12-16 hours. Cells were centrifuged at 4300rpm for 5 minutes, 
and the supernatant was aspirated.  DNA was purified from the remaining pellet using a 
Plasmid Spin Miniprep kit (Qiagen), and carried out in accordance with the 
manufacturer’s guidlines.  DNA concentration was analysed using Nanodrop 
spectrophotometer (Thermo Scientific). Samples were stored at -20°C. 
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2.3 RNA Techniques 
 
2.3.1 RNA Extraction 
 
Total RNA was extracted from cells using the Promega SV Total isolation kit (Promega) 
following the manufacturers guidelines.  RNA was eluted in a final volume of 100μl, the 
RNA was quantified on a Nanodrop spectrophotometer and then stored at -80°C. 
 
2.3.2 Reverse Transcription 
 
Routinely, 1μg of RNA was transcribed in a 20μl reaction.  The reverse-transcription 
was carried out using random hexamer primers, dNTP mix, 0.1M DTT, 5x First Strand 
buffer, RNase out (Invitrogen-RNase inhibitor) and Reverse transcriptase Superscript II 
(Invitrogen).  The 1μg of RNA was made up to 9μl with RNase free water.  To this, 2μl 
of random hexamers was added and the mixture incubated at 70˚C for 10 minutes, and 
then placed on ice and spun briefly at 4˚C.  The remainder of components were added as 
shown in table 2.2. Particular care was taken to ensure thorough mixing as Superscript II 
and RNase out would sink to the bottom of the mix.  The reaction mixture was incubated 
at 42˚C for 60 minutes, the cDNA was then stored at -20˚C. 
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REAGENTS 20μl Reaction 
Random Primers 250ng 
RNA 1μg 
dNTP Mix 33mM 
5x First Strand Buffer 4μl 
0.1M DTT 2μl 
RNase Out (40U/μ)l 1μl 
 
Superscript II RT 1μl 
 
H20 up to a final volume of 20μl 
Table 2.2 Reverse Transcription components  
 
 
2.3.3 Semi Quantitative RT-PCR 
 
Semi-quantitative PCR was carried out to look at expression levels of Cbl genes using 
GAPDH as a normalisation control. The c-Cbl primers were run at 95˚C for 5 minutes, 
27 cycles of 95˚C for 30 seconds, 60˚C for 45 seconds, 72˚C for 60 seconds, one cycle 
of 72˚C for 10 minutes. 
Cbl b primers were run at 95˚C for 5 minutes, 27 cycles of 95˚C for 30 seconds, 59˚C 
for 30 seconds, 72˚C for 30 seconds, one cycle of 72˚C for 7 minutes. 
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GAPDH primers were run at 94˚C for 4 minutes, 27 cycles of 94˚C for 1 minute, 55˚C 
for 1 minute, 72˚C for 1 minute, one cycle of 72˚C for 10 minutes. 
Then 4 μl of 6x loading dye (0.25% bromophenol blue, 0.25%  xylene cyanol, 30% 
glycerol in water) was added  to samples before being run out on an agarose gel. 
 
PRIMER LOCATION SEQUENCE (5’-3’) 
C-Cbl Fwd 
C-Cbl Rev 
Exon 2 
Exon 9  
TCAGCCTAGGCGAAACCTAA 
TCCCTCTAGGATCAAACGGA 
Cbl-b Fwd 
Cbl-b Rev 
Exon 10 
Exon 13 
CCGGTTAAGTTGCACTCGAT 
CAAAGGGGTCCACGATTATG 
GAPDH Fwd 
GAPDH Rev 
Exon 4 
Exon 6 
ACCACAGTCCATGCCATCAC 
TCCACCACCCTGTTGCTGTA 
Table 2.3 RT-PCR primer sequences  
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REAGENTS 25μl Reaction 
10x PCR Buffer 2.5μl 
MgCl2 (mM) 1.5 
dNTP Mix (mM) 40 
Forward Primer (10μM) 0.5μl 
Reverse Primer (10μM) 0.5μl 
Taq Polymerase  0.2μl 
 
cDNA  1μl 
 
H20 up to a final volume of 25μl 
Table 2.4 Composition of RT-PCR reaction 
 
2.3.4 Agarose Gels 
 
To prepare 1% (w/v) and 2.5% (w/v), 1g or 2.5g of agarose were weighed out and added 
to a 100ml conical flask.  100ml of 1xTAE buffer (50x TAE: 242g Tris Base, 100ml 
0.5M EDTA, 57.1ml acetic glacial acid) was added and the agarose was dissolved in a 
microwave on half power.  After sufficient cooling, ethidium bromide was added at a 
1/50,000 dilution, and the gel poured into the mould. An 8-well comb was inserted into 
the gel and left to set.  After setting the comb was removed and the gel was placed into a 
running tank, 1xTAE solution was poured over the gel to cover.  Into the first well 5μl 
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of Hyperladder I (Bioline) was added.  Subsequent wells were loaded with 20μl of 
sample.  Gels were then run at 100V constant for 45 minutes. 
  
2.3.5 Real Time RT-PCR (Taqman)-18s 
 
As a control, levels of the housekeeping gene 18s were used to normalise the gene of 
interest. The cDNA was diluted to 1ng/μl and a total of 5ng used per reaction.  Each 
reaction was seeded in duplicate in a total reaction volume of 20μl.  The composition of 
the reaction mix is shown in table 3.4.  All reactions were carried out in a 96-well 
optical reaction plates (Applied Biosystems) and sealed with an adhesive strip.  The 
following cycling conditions were used; Stage 1: 50˚C for 2 minutes, Stage 2: 95˚C for 
10 minutes, and then 40 cycles of Step 4: 95˚C for 15 seconds and Step 5: 60˚C for 1 
minute.  Samples were run using an ABI 7500 thermocycler (Applied Biosystems). 
 
2.3.6 Real Time RT-PCR (Taqman)-c-Cbl 
 
The cDNA samples were diluted to 1ng/ μl and a total of 5ng was used in each reaction.  
Each reaction was carried out in duplicate in a 96-well plate using a final reaction 
volume of 20μl, reaction components are summarised in Table 2.5.  The c-Cbl 
primer/probes were obtained from Applied Biosytems (Hs00231981_m1) and contained 
a 5’ FAM reporter dye and a 3’ quencher TAMRA.  Reactions were carried out in 96-
well optical reaction plates using an ABI 7500 thermocycler (Applied Biosystems). 
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REAGENTS 20μl Reaction 
Primer/Probe 1μl 
2x Master Mix 10μl 
cDNA 5ng 
H20 5μl 
Table 2.5 Composition of RealTime RT-PCR reaction 
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2.4 Cell Culture Techniques 
 
2.4.1 General 
 
Cell lines were maintained in a 5% CO2 incubator at 37˚C.  A summary of cell lines 
used can be found in table 2.6. 
 
CELL 
LINE 
TYPE SOURCE MORPHOLOGY GROWTH 
MODE 
HEK-293 Human Embryonic 
Kidney 
ECACC Epithelial Adherent 
HEK293T Human Embryonic 
Kidney 
Dr P.Powell Epithelial Adherent 
COS-1 African Green Monkey 
Kidney 
ECACC Fibroblast Adherent 
MYL Human CML Blast 
Crisis 
Dr A.Kimura Myeloid Suspension 
MYL-R Human CML Blast 
Crisis 
Dr A.Kimura Myeloid Suspension 
K562 Human CML Blast 
Crisis 
Prof. J.Melo Myeloid Suspension 
Table 2.6 Cell lines 
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2.4.2 MYL/MYL-R Cells 
 
These cells lines were generated and kindly donated by Dr A. Kimura (Hiroshima 
University). Bone marrow mononuclear cells were obtained from a 24-year old female 
patient in blast crisis stage of CML.  Cells were initially cultured with or without a low 
dosage of Imatinib, cells were selected through single-cell cloning, and two populations 
with the greatest differential sensitivity were selected.  The most sensitive was named 
MYL and the most resistant MYL-R.  Both cell lines contained double Philadelphia 
chromosomes. 
 MYL and MYL-R cells were cultured in T75cm2 flasks at 37°C, 5% CO2 incubator in 
RPMI 1640 (Invitrogen 31870) media supplemented with 10% Foetal Bovine Serum 
(Autogen Bioclear), 1% penicillin streptomycin (Invitrogen), glutamine (200mM).  Cells 
were routinely sub-cultured by transferring to a falcon tube and spinning at 1200rpm for 
5 minutes.  The supernatant was aspirated and the cell pellet resuspended in 10mls fresh 
media.  The cells were then transferred into a 75cm2 culture flask at a dilution of 1/10. 
 
 
2.4.3 COS-1 / HEK 293/293T Cells 
 
COS-1 and HEK293 cells were grown in T75cm2 flasks at 37°C, 5% CO2 incubator in 
DMEM (Invitrogen 21885) supplemented with 10% FBS (Autogen Bioclear) and 1% 
p/s.  In order to subculture cells, once they had reached 80-90% confluency, the media 
was aspirated and cells were washed in 2ml PBS to remove residual media, then 1.5ml 
trypsin was added and cells incubated for 5 minutes at 37°C.  After the cells had 
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trypsinised, 8mls of fresh media was added.  The cells were then spun down at 1200rpm 
for 5 minutes in a 50ml falcon.  The supernatant was aspirated and the cell pellet 
resuspended in 10mls of media.  Cells were then added to a fresh 75cm2 culture flask at 
a dilution of 1/10. 
In addition to FBS and p/s, HEK293T media was supplemented with 1% Non-essential 
amino acids (Invitrogen) and 1% sodium pyruvate (Invitrogen). 
 
 
2.4.4 Cryopreservation of Cells 
 
Cells were prepared for long term storage to maintain sufficient cell  stocks.  Adherent 
cells were trypsinised with 2ml of trypsin for removal from the culture flask before 
being resuspended in 10ml of fresh media to neutralise the trypsin. Both adherent and 
suspension cells were spun down at 1200rcf for 5 minutes before removal of the 
supernatant.  The cell pellet would be washed in PBS and spun to pellet the cells again. 
Cell pellet was then re-suspended in 1ml of freezing media, containing FCS and 10% 
DMSO.  One ml of cell suspension was transferred to a cryopreservation vial and put on 
dry ice before being stored at -80°C or moved to liquid nitrogen for long term storage. 
 
 
2.4.5 Raising Cells from Frozen Stocks 
 
Vials of cryo-preserved cells were removed from either liquid nitrogen or the -80°C 
freezer and thawed in a water bath at 37°C. The cell suspension was added drop wise to 
10ml of fresh media.  Cells were spun down at 1200rcf and the supernatant aspirated. 
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The pellet was then re-suspended in 10mls of fresh media. The cells were transferred to 
a T25cm2 flask and incubated at 37°C, 5% CO2 incubator overnight.  The following day, 
the media of adhesion cells was aspirated, the cells were washed in 2mls of PBS to 
remove debris and fresh media was added. Suspension cells were counted and media 
added to maintain normal growing conditions. 
 
2.4.6 Sub-Culturing cells 
 
Both adherent and suspension cells were maintained in T75 flasks.  Fresh growth media 
would be added every 2-3 days.  Cells were routinely split 1/10 or 1/20 depending on 
confluence to maintain optimal growing conditions. 
 
 
2.4.7 Cell Viability and Number 
 
Viability and cell number were analysed by mixing cell suspension with Trypan blue at 
a ratio of 1:1 and assessed by cell counts under a light microscope on a haemocytometer. 
 
2.4.8 Transfection of Cells 
 
Adherent cells were transiently transfected using either FuGene 6 (Roche) or LipoD293 
(SignaGen).  Transfection reagent was mixed with a range of plasmid DNA 
concentrations at a ratio of 3:1 and added drop-wise to sub-confluent cells and left for 24 
hours at 37˚C.  Cell media was replaced with 2% FBS DMEM overnight.  Cells were 
then stimulated accordingly, and then lysed. 
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2.4.9 Luciferase Assays 
 
Cells were seeded in 6 well plates and grown overnight in normal media. After 24 hours 
cells were transfected (see 2.3.8) with luciferase reporter plasmids. Cells were 
stimulated accordingly and lysed in luciferase assay cell lysis buffer (Promega).  
Transcriptional activity was analysed by adding 50μl of luciferase reagent to10μl of 
lysate in a 96-well domino plate and reading luminescence using a Wallac Victor 
Luminometer at 595nm. 
 
2.4.10 MTS Assays 
 
Into 96 well plates, 5x103 cells were seeded in a volume of 100μl per well and grown 
overnight in 0.5% FCS-containing media. Cells were stimulated accordingly and 
incubated at 37°C for up to 72 hours. 10μl of the MTS solution (Promega) was added to 
each well.  Cells were further incubated for up to 3 hours before absorbance readings 
were taken at 490nm using a Wallac Victor Luminometer. 
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2.5 Protein Techniques  
 
2.5.1 Protein Markers 
 
Kaleidoscope pre-stained and All Blue (Biorad) markers were used to estimate protein 
size when separated by SDS PAGE gels.  Molecular standards ranged from 6 to 210kDa 
and were stained each with a separate colour for ease of identification. 
 
 
2.5.2 Preparation of Cell Lysates for Suspension Cells 
 
Cells were transferred to a fresh vial and spun down. The cell pellet was washed in ice-
cold PBS and re-spun.  The cell pellet was lysed for 10 minutes on ice in 50μl RIPA 
buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% 
SDS, and 50 mM Tris, pH 8.0) supplemented with protease and phosphatase inhibitors, 
sodium fluoride,  and sodium vanadate,  added at 1/200 and 1/100 dilutions respectively.  
Lysates were spun down at 13,000 rpm, at 4°C for 10 minutes. Supernatant was 
transferred to a fresh vial, where 2x lammelli (200mM Tris pH6.8, 10% glycerol, 6% 
SDS, 0.02% bromophenol blue) with 10% 0.1M DTT was added at a ratio of 1:1 with 
lysate. Samples were then heated to 100°C for 3 minutes, either run on SDS-PAGE gels 
or frozen at -20°C. 
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2.5.3 Co-immunoprecipitations 
 
Cells were washed in ice cold PBS before being lysed in 250μl 1% NP40 lysis buffer 
(Table 2.41) and were then placed on ice for 10 minutes.  Samples were spun at 13k for 
10minutes at 4°C.  Supernatants were transferred to new vials and 50μl would be 
removed and stored as whole cell lysates.  The remaining sample was incubated with 
primary antibodies for 1 hour at room temperature on a rocker.   
Next 20μl of protein A/G beads (Santa Cruz) were added to each sample before 
incubating at 4°C on a rocker overnight. Samples were spun down at 2000 rpm and the 
supernatant aspirated. Samples were washed six times in 0.1% NP40 wash buffer (Table 
2.7).  After the final wash approximately 5μl of wash buffer remained, to this 2x 
lammelli plus 10% 0.1M DTT was added to give 25μl.  Samples were then run on SDS-
PAGE gels. 
 
 
 
 Cell Lysis Buffer 
(50ml) 
Wash Buffer (50ml) 
Tris 50mM 50mM 
NP40 1% 0.1% 
Glycerol 10% 10% 
Sodium Chloride 0.4g 0.4g 
EDTA 1mM 1mM 
Sodium Vanadate 0.1M 500μl 500μl 
Sodium Fluoride 1M 50μl 50μl 
Table 2.7 Components of NP40 Lysis and wash buffers 
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2.5.4 Nickel Affinity Purification 
 
Cells were washed in ice cold PBS, then cell samples were lysed as above (see section 
2.5.3) but without the addition of EDTA in either lysis or wash buffers.  After whole cell 
lysate removal, 40μl of nickel coated beads (Invitrogen) were added to samples and 
incubated at 4˚C overnight on a shaker.  Samples were then washed and treated as 
section 2.5.3. 
 
 
2.5.5 SDS-PAGE 
 
BioRad apparatus was set up according to manufacturers guidelines using 1.5mm gel 
plates.  All samples were run out on 10% resolving gels.  The resolving gel was made 
up, and 8ml pipetted between the gel plates, and 70% ethanol was added on top to 
ensure a flat edge.  After polymerisation, the ethanol was poured off and ddH2O was 
added and poured off to remove residual ethanol. The stacking gel was made and added 
to the top of the resolving gel and a 10 well comb was inserted to form the wells.  
Resolving and stacking gel composition is shown in table 2.8. Once the stacking gel had 
polymerised, combs were removed and the gels were transferred from the casting 
brackets into the gel tank which was filled with 1x running buffer, the components of 
which can be found in table 2.9.  
To lane 1 of each gel, 5μl of protein marker (Biorad) was added.  In subsequent wells 
cell samples were added in equal volumes. Gels were run between 140V-170V for 
approximately 1.5hrs, varying depending on the size of the protein of interest.  Gels 
were then removed from the tank and proteins transferred via Western Blotting. 
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 10% Resolving Gel 6% Stacking Gel 
ddH2O 9.5ml 7.9ml 
30% Acrylamide 8ml 3ml 
1.5M Tris pH8.8/0.5M Tris pH6.8 6ml 3.75ml 
10% SDS 240μl 150μl 
10% APS 240μl 150μl 
TEMED 24μl 15μl 
Table 2.8 Components of stacking and resolving gels 
 
 
1 Litre  Running Buffer Transfer Buffer 
Tris 3g 3g 
Glycine 15g 15g 
10% SDS 12ml - 
Methanol - 200ml 
Table 2.9 Running and Transfer buffer components 
 
 
2.5.6 Western blotting 
 
Proteins were transferred to a nitrocellulose membrane using wet blotting apparatus 
(BioRad). Prior to transfer four pieces of Whatman filter paper were cut to the same size 
as the gel, along with sponges from the blotting kit which were maintained briefly in 
transfer buffer, the composition of which can be found in table 3.43.  The 0.45μM 
nitrocellulose transfer membrane (BioRad) was also cut to size and hydrated briefly in 
1x transfer buffer before transferring. The wet blotting apparatus was subsequently 
assembled according to manufacturer’s instructions, with particular care  taken to remove 
any air bubbles between layers.  Proteins were transferred at 110v for 75 mintutes at 
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4°C. Ponceau S staining was used to confirm even protein transfer among samples.  The 
stain was removed by several washes with ddH20. 
Membranes were blocked in 3% marvel or BSA (depending on primary antibody to be 
used) in 1xPBS for 60 minutes at room temperature on a shaker.  Antibodies were 
diluted in blocking solution (Table 2.10). Membranes were then incubated with the 
antibodies at 4°C overnight on a rocker.  Following the overnight incubation, 
membranes were washed for 4 x 15 minutes in washing buffer (0.1% Tween in PBS) on 
a shaker at room temperature.  A secondary antibody was added in a 3% blocking 
solution in a volume of 10mls and incubated for 90 minutes at room temperature.  The 
secondary antibodies used were horse-radish peroxidise conjugate antibodies, and were 
either anti-mouse (Sigma) at 1:10,000, anti-rat (Roche) 1:10,000 or anti-rabbit (Sigma) 
1:40,000.  Membranes were washed again in washing buffer for a further 4 x 15 
minutes. 
Proteins of interest were visualised using chemiluminescence (ECL reagents: 68mM p-
coumaric acid in 5ml DMSO, 1.25mM luminal in 50μl 0.1M Tris pH8.5, 1.5μl 30% 
hydrogen peroxide) with Amersham Hyperfilm (GE Healthcare), films were developed 
using standard solutions.   
Prior to re-probing membranes were stripped in 0.1M sodium hydroxide for 15 minutes, 
washed briefly in washing buffer before blocking in marvel/BSA and then incubated 
with the primary antibody as described previously. 
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Antibody Manufacturer Species Dilution 
Lyn Kinase Cell Signalling Rabbit 1:1000 
p-Lyn Kinase Cell Signalling Rabbit 1:1000 
Β-Actin Sigma Mouse 1:1000 
HA Roche Rat 1:500 
PARP Abcam Rabbit 1:400 
c-Cbl Cell Signalling Rabbit 1:1000 
Flag M2 Sigma Mouse 1:500 
HIS GE Healthcare Rabbit 1:1000 
Smad3 Zymed Laboratories Rabbit 1:500 
Table 2.10 Antibodies used on nitrocellulose membranes 
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2.6 Cell Sorting 
 
2.6.1 Cell Cycle Analysis 
 
Cell cycle analysis was carried out using flow cytometry (Accuri C6).  Cells were 
seeded at 5x105/ml in 0.5% FBS containing media and left overnight. For cells 
undergoing a double thymidine (0.2mM) block, it was added at this point for 16 hours 
before being washed out and cells returned to normal media for 9 hours, and finally 
thymidine added again for a further 16 hours.  After this point cells were returned to 
normal media in 1ml aliquots in a 24-well plate and treated accordingly.  
Cells were transferred to a 15ml falcon tube, spun at 1200rpm for 5 minutes, 
resuspended in ice-cold PBS and re-spun at 1200rpm for 5 minutes.  The supernatant 
was aspirated and cells were fixed by adding 5ml of 70% ice-cold ethanol drop-wise to 
the cell pellet whilst vortexing.  Cells were left for 60 minutes on ice.   Cells were then 
spun at 1000rpm for 5 minutes and the supernatant aspirated and the pellet resuspended 
in 1ml PBS to remove all traces of ethanol and transferred to a 1.5ml microcentrifuge 
tube.  This was spun at 1000rpm, the supernatant was aspirated and the cell pellet was 
resuspended in a final volume of 500μl of PBS. At this stage the samples were filtered, 
100μg of RNAse A was added and samples were incubated at 37˚C for 30 minutes.  
Propidium iodide (10μg) was then added to stain the cells followed by a 15 minute 
incubation at room temperature before analysis using FACS.  
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3. ANALYSIS OF TGFβ SIGNALLING IN CML  
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3.1 Introduction 
 
 
CML is characterized by the presence of the Philadelphia chromosome (Ph+) and the 
fusion protein Bcr-Abl. The evidence of the involvement and importance of the 
constitutively active Bcr-Abl tyrosine kinase in CML is extensive (Deininger et al., 
2000; Melo, 1996).  Research by Møller et al in 2007 looked at progenitor populations 
and the effects of TGFβ within CD34+ cells, following an early-disease stage focus. The 
reciprocal translocation is believed to occur in these early progenitor haematopoietic 
stem cells, and findings have indicated that these cells are resistant to Imatinib (Graham 
et al., 2002).  
The aim of this first chapter was to assess the role of TGFβ signalling in CML and 
haematopoietic cell growth.  Initially, experiments focused on signalling in an over-
expression system which allowed specific effects between TGFβ and Bcr-Abl to be 
studied.  During the project, a human CML model became available, which enabled 
experiments to be carried out in a more relevant cell system, allowing TGFβ analysis 
within haematopoietic CML cells.  It also allowed the development of a novel dual 
therapy approach to combat drug  resistance.  
The research presented here aimed to look at mature stage disease.  Drug resistance has 
become more of a recent research focus after the emergence of a reduction in Imatinib 
efficacy during late stage CML in addition to the reported inherent resistance of the 
leukemic stem cell (Jin et al., 2008).  In particular, my project aimed to define and 
characterise interconnections between Bcr-Abl and the TGFβ signalling pathway.  TGFβ 
is well known as a growth inhibitory cytokine in haematopoietic cells (Keller et al., 
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1990), but can have opposing  effects in different cells and surroundings, such as an 
involvement in integrin induction during T cell migration (Kang et al., 2011). It is this 
environmental specificity which makes the understanding of TGFβ signalling an 
important mechanism to uncover within all biological contexts.  TGFβ is believed to 
play a variety of roles within cancers, both inhibiting and in driving tumourigenesis. It is 
the deregulation of these finely balanced signals which often results in disease.  TGFβ is 
well known to signal through Smad intracellular messenger proteins, but recently TGFβ 
has been shown to signal independently of Smads, through MAPK activation via 
TRAF6 in Smad2/3 knockdown cells (Yamashita et al., 2008).  This highlights a further 
level of signalling complexity within the normal cell, and identifies additional potential 
for aberrant signalling to cause disease. 
Experimentally, TGFβ signalling activity is often monitored through the activation of its 
intracellular messengers the Smad proteins.  The activation of TGFβ responsive genes 
showed direct interactions between Smads 3 and 4 to CAGA sequences within the PAI-1 
promoter (Dennler et al., 1998).   These sequences are now used artificially within 
luciferase-based gene reporter plasmids to analyse TGFβ signalling activity. 
It is necessary to consider how different stages of CML disease can affect the treatment 
outcome. Research has shown in 32D cells that  levels of Bcr-Abl present in the cell 
during various disease stages can have a direct affect on treatment outcome (Barnes et 
al., 2005).  This suggests Bcr-Abl can continue to drive disease progression throughout 
the course of the disease, and that resistance to Imatinib may be a hallmark of all stages.  
In addition to the signalling aspect of the disease, Imatinib resistance has become a 
growing area of research, with the need for enhanced specificity and targeted drug 
development.  There are a number of known factors contributing to resistant phenotypes; 
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increased Bcr-Abl protein, increases in genomic instability and mutations in the Bcr-Abl 
gene itself, such as the T315I amino acid substitution.  Alongside this is the population 
of stem cells or leukemic initiating cells (LICs) which have also been shown to confer 
Imatinib resistance (Graham et al., 2002).  In addition, the discovery of cell niches allow 
populations of cells to respond differently to a similar signal depending on their 
differentiation status.  TGFβ has been found to play a critical role in the hibernation of 
HSCs in the bone marrow through Smad2/3 activation (Yamazaki et al., 2009).  Studies 
have shown that FOXO3a can play conflicting roles in CML.  In the Ph+ stem cell, 
FOXO3a mediates protection to stresses such as tyrosine kinase inhibition, whereas in 
the non-stem CML cell FOXO3a activation induces apoptosis (Naka et al., 2010b).  
Another recent development in the area of resistance was the findings of Ito et al in 
2007, showing over-expression of Lyn kinase to be involved in drug  resistance.  A 
recent review has highlighted the main factors involved in CML drug  resistance within 
stem cells and proposes a novel therapeutic approach (Naka et al., 2010a).   
To develop the understanding of the TGFβ involvement in this disease, a human, CML 
patient-derived cell line named MYL and the acquired Imatinib resistant MYL-R were 
used as a model to examine the role of TGFβ in blast phase CML.   
Results presented in this chapter establish the Bcr-Abl mediated up-regulation of TGFβ 
signalling through CAGA12-luc induction in HEK293 and COS-1 cell lines, both are 
known to be TGFβ-responsive.  To assess the role of Bcr-Abl on cellular growth with 
TGFβ stimulation in the haematopoietic system, mouse 32D and 32Dp210 cells were 
analysed.  Results suggest a Bcr-Abl driven increase in proliferation in response to 
TGFβ stimulation.  
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Experiments in human MYL and MYL-R cells indicated variation in sensitivity to the 
growth inhibitory effects of TGFβ, and it is speculated that this is due to the over-
expression of the Src family kinase Lyn.  In addition, cell cycle analysis was performed 
to address the effects of TGFβ on the cycling status of CML cells.  Results indicate that 
TGFβ induces MYL cell cycle arrest and that abrogation of TGFβ signalling using a 
specific TGFβ receptor kinase inhibitor reverses these effects.   
Based on these findings, combination therapy experiments were performed.  TGFβ 
signalling was inhibited through the SB431542 compound in combination with Imatinib, 
resulting in an increase in Imatinib-mediated cell death, analysed through MTS and 
PARP cleavage experiments.   
Overall it is observed that blast phase CML cells retain sensitivity to TGFβ, and the 
outcome of the combination therapy approach highlights the TGFβ signalling pathway 
as a potential therapeutic target for combating CML drug  resistance.    
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3.2 Results 
 
 
3.2.1 Bcr-Abl up-regulates transcriptional activity of the CAGA12-luc Smad-    
responsive reporter in a dose-dependent manner 
 
 
HEK293 cells were chosen to analyse the role of Bcr-Abl on the Smad3-dependent 
TGFβ signalling pathway.  These cells originate from human epithelial kidney and have 
been widely used to study the effects of TGFβ signalling activity (Bhowmick et al., 
2003; Shukla et al., 2009).  The Smad3 responsive reporter plasmid CAGA12-luc, 
together with a Bcr-Abl p210 plasmid were transiently co-transfected into cells.  The 
transcriptional effects of the plasmid were monitored through measurements of 
luciferase activity. Cells were stimulated 48 hours post-transfection with a range of 
TGFβ concentrations (0-2ng/ml) for 16 hours.  Results show that there is a clear TGFβ-
mediated, concentration-dependent increase in Bcr-Abl transfected cells at 
concentrations between 0.02 and 1ng/ml (Figure 3.1a).   This response appears to be 
reduced at 2ng/ml, possibly due to TGFβ saturation of the cells.  Additionally, Bcr-Abl 
has minimal effect on the reporter plasmid alone.  
To establish if this was a cell specific response, the experiment was repeated in the 
COS-1 cell line.  These cells are of fibroblast origin and are well studied with respect to 
TGFβ responsiveness (Kretzschmar et al., 1999; Zhang et al., 2010).  The same dose-
dependent up-regulation can be seen in these cells, which does not diminish at 2ng/ml as 
in the HEK293 cells (Figure 3.1b).   
The combined effect of Bcr-Abl and TGFβ on CAGA12 transcriptional activity appears 
to be the same in both cell lines.  It is apparent that there is a clear difference in 
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sensitivity to TGFβ between the two cell lines, with HEK293 cells giving a maximal 
response of 139-fold relative to the control, compared to the maximal 21-fold increase in 
COS-1. The variation in relative luciferase activity allows a greater degree of sensitivity 
to be used in future experiments.  Further HEK293 experiments used 1ng/ml while for 
COS-1 experiments 2ng/ml was used.  Data here indicate Bcr-Abl clearly up-regulating 
TGFβ-dependent transcriptional activity of the CAGA12-luc reporter.  
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(a) 
 
 
(b) 
 
 
 
 
 
 
 
Figure 3.1 Bcr-Abl up-regulates TGFβ-dependent transcriptional activity of CAGA12 in a dose 
dependent manner 
 
Cells were co-transfected with a TGFβ-dependent Smad-responsive CAGA12 luciferase reporter plasmid 
together with either the empty vector or the B3a2 Bcr-Abl variant expression plasmid.  (a) HEK293 cells 
were stimulated for 16 hours at varying concentrations of TGFβ (0-2ng/ml).  (b) COS-1 cells were 
stimulated for 16 hours at varying concentrations of TGFβ (0-2ng/ml).  Results are analysed at 490nm on 
a Wallac Victor luminometer normalized to the control and standard errors calculated, based on at least 
three independent experiments. 
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3.2.2 Bcr-Abl abrogates TGFβ-induced haematopoietic cell growth arrest and 
enhances proliferation  
 
 
The aim of this section was to assess the proliferative effect of Bcr-Abl on cells 
stimulated with TGFβ in more physiologically relevant mouse haematopoietic 32D and  
32Dp210 cell lines.  The 32Dp210 cells are stably transfected with the p210 form of 
Bcr-Abl (Laneuville et al., 1991).  Cell proliferation was assessed daily using an MTT 
assay, and this experiment was run in parallel alongside a cell count assessment of 
growth, using trypan blue staining.  The cell count method proved difficult, and 
culturing of cells under these conditions promoted cell clumping in the 32Dp210 cells, 
making accurate cell counts challenging.   
To look at the effect Bcr-Abl has on cellular growth, 32D cells and the Bcr-Abl 
transformed 32Dp210 were treated with two different concentrations of TGFβ which 
was added at day 0, and no further additions or changes of media were made during the 
experiment.  The change in TGFβ concentrations gave an insight into whether any 
effects seen were concentration dependent.   
Results show that 32D cells are growth inhibited 24 hours post treatment so remain 
sensitive to TGFβ-mediated growth arrest (Figure 3.2a). This inhibition is increased with 
a higher concentration of TGFβ (0.5ng/ml) after 24 hours.  32D cells remain inhibited 
by TGFβ at 48 hours compared to the control, but at 72 hours there is a moderate 
increase in cell number.  This is then followed by a decrease to basal levels at day 7, at 
which point other factors such as cell overcrowding and contact inhibition may be 
influencing the cellular response.  The increase in cell number after 72 hours may be due 
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to TGFβ breakdown, removing the growth inhibitory effect observed during the first 48 
hours of TGFβ stimulation.  The Bcr-Abl p210 containing cells showed no growth 
inhibitory response to TGFβ stimulation (Figure 3.2b).   After 24 hours there was no 
decrease in cell number compared to basal cell counts, unlike in the 32D cells.  
Increasing TGFβ concentration slightly enhanced proliferation after 48 hours.  This is 
also seen after 72 hours of stimulation, where TGFβ has a proliferative affect on cell 
growth, suggesting it can drive cell growth in combination with Bcr-Abl.  The 72 hour 
sample data again suggest a moderate rise in cell number, as seen in 32D cells.  This 
may be due to the breakdown of TGFβ, however it is more likely that cells at 72 hours 
have reached maximal numbers, and are unable to sustain the growth, which explains 
the decline in cell numbers seen at day 7.  The overall growth pattern in 32Dp210 cells 
is similar to that of 32D cells but the presence of Bcr-Abl appears to positively affect the 
growth responsiveness of these cells to TGFβ and prevent the TGFβ-mediated growth 
inhibition seen in 32D cells.  Further investigation with an inducible Bcr-Abl protein 
alongside Bcr-Abl knockdown studies would develop this theory and allow a firmer 
conclusion to be reached on the affect of Bcr-Abl on the growth of these cells. 
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Figure 3.2  Bcr-Abl expression desensitises 32D cells to TGFβ-mediated inhibition 
 
32D (a) and 32Dp210 (b) cells were seeded at an initial concentration of 2.5x10
5
/ml and maintained in 
that media throughout the experiment.  TGFβ was added at day 0, at either 0.5 or 5ng/ml.  Cell number 
was counted using a haemocytometer and cell viability assessed using trypan blue exclusion.  Data 
presented is normalised to an untreated sample. Cells were treated in triplicate repeats, averages and 
standard errors were calculated. 
 
107 
 
3.2.3 MYL cells are more sensitive to Imatinib,than MYL-R cells  
 
 
The emergence of Imatinib resistance with the inability to cure overall disease has led to 
intense research to discover the mechanisms contributing to this.  A human derived 
CML patient cell line was used to generate resistant and sensitive cell lines.  MYL cells 
were induced to develop resistance to Imatinib by means of cells maintained in media 
containing Imatinib. Successfully resistant cells were selected and cultured with 
increasing concentrations of the drug, leading to the generation of the Imatinib resistant 
MYL-R cell line.  Resistant cells were negative for Bcr-Abl mutations and shown to 
over-express Lyn kinase (Ito et al., 2007). 
Initial experiments were designed to characterise the cells and establish a system to 
study the effects of TGFβ in CML.  To test the differences in Imatinib sensitivity MTS 
assays were performed.  Cells were seeded in 0.5% serum overnight, before 48 hours of 
Imatinib treatment at concentrations ranging from 0μM to 10μM.  MTS solution was 
added and cell survival analysed through absorbance readings at 490nm.   
Up to 0.1μM Imatinib the survival of both cell lines remain largely unaffected.  At 
0.3μM a threshold is found and MYL cell survival dropped to just over 10% (Figure 
3.3).  The MYL-R cells are still able to show a survival rate of 80%.  MYL cells reach 
basal levels at 0.5μM while MYL-R cells are still at a 60% survival rate. The effect of 
Imatinib on MYL-R is dose dependent, with increases in concentration resulting in a fall 
in cell survival.  These results confirm that MYL-R cells do indeed display greater 
resistance to Imatinib than MYL cells. 
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Figure 3.3 MYL-R cells are more resistant to Imatinib than MYL 
 
MYL and MYL-R cells were seeded in 0.5% serum overnight.  Imatinib was added at a range of 
concentrations between 0μM and 10μM for 48 hours.  Cell survival was then analysed by adding  
MTS solution and measuring absorbance values at 490nm.  Treatments were carried out in triplicate 
repeats, averages and standard errors calculated.  Data shown is representative of at least three 
independent experiments.  
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3.2.4 MYL and MYL-R cells have increased sensitivity to TGFβ-mediated growth 
inhibition  in low serum media 
 
 
In order to investigate further the data obtained in adherent cell lines HEK293 and COS-
1, together with the murine haematopoietic 32D and 32Dp210 lineages, the more 
biologically relevant MYL and MYL-R cell lines were used in subsequent experiments. 
Assesment of response to treatments was analysed with two different serum levels, 
either 0.5% or 10%, to give an indication of whether intrinsic growth factors in the 
serum were masking the effects of treatment.  It would also establish a standard set of 
experimental conditions which would allow optimal and directly comparable data 
collection.  
Lowering serum levels enhanced the sensitivity to the inhibitory TGFβ response, 
significantly so in the MYL cells (Figure 3.4a)  These experiments also used  the 
TGFβRI inihbitor SB431542 which in the MYL cells can be seen to slightly inhibit the 
TGFβ-mediated inhibtion at 0.5% serum levels, and at 10% serum, SB431542  is able to 
slightly increase proliferation levels.  Furthermore, MYL-R cells appear to become 
sensitive to TGFβ in low serum levels which is not seen at 10%  levels, the inhibitory 
response is less pronounced than in MYL cells.  Also, the addition of SB431542 in 0.5% 
serum to MYL-R cells is  able to show an increase in proliferation compared to the 
control, and this is greater than that seen in 10% samples (Figure 3.4b).  Although the 
range seen here is not vast, and values are still in the range of those seen in  previous 
figures of TGFβ affecting cell growth and survival, the fact that a difference is apparent 
suggests residual cytokines found in the serum may be affecting response to stimulation.  
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In addition, MYL-R cells have an increased basal growth rate compared to MYL cells, 
therefore a reduction in serum levels would predicatably slow down this growth and 
potentially re-establish TGFβ sensitivity. 
 As mentioned previously, the difference in range especially for MYL-R cells is within 
10% so there is not a hugely significant point to draw from this other than experimental 
conditions are important to optimise and maintain throughout a set of experiments.  
From these data the conditions to be used for future experiments will be low serum at 
0.5% in cell media.  
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Figure 3.4 Lowering serum levels affects the sensitivity of MYL and MYL-R cells to TGFβ 
 
MYL (a) and MYL-R (b) cells were seeded in 96-well plates at 5x10
3
 cells/well with either 0.5 or 10% 
FCS-containing  media.   SB431542 (10μM) or TGFβ (0.1 or 1ng/ml) was added to cells for 48 hours.  
Treatments were performed in triplicate. Data was normalised to an untreated control and standard error 
calculated. 
112 
 
After establishing an optimal set of conditions for the serum level in the experiments, 
the MTS protocol was then optimised and the time points of TGFβ stimulation were 
varied to analyse effects on cell proliferation. 
MYL and MYL-R cell lines were grown overnight in 0.5% foetal calf serum containing 
media, and TGFβ was added at varying concentrations.  The cells were seeded in a 96-
well plate at 5x103 per well, and treatments were carried out in triplicate repeats. At this 
stage the MTS assay kit was untested with regards to the optimal time to obtain 
absorption values. Therefore, two different time points were chosen in consultation with 
the manufacturers guidelines, at two and four hours after addition of the MTS solution.  
Results show no significant differences between the two and four hour readings, so all 
future readings were analysed at two hours after the addition of the MTS solution 
(Figure 3.5). 
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Figure 3.5 MYL  and MYL-R cells show different sensitivities to TGFβ,  no significant difference 
observed between 2 and 4 hour readings post-MTS addition 
 
MYL and MYL-R cells were serum starved in 0.5% FCS containing media overnight.  TGFβ was added at 
a range of concentrations between 0-10ng/ml  for 16 hours to analyse the effects on cellular proliferation.  
MTS solution was added and cells were incubated for 2 or 4 hours and absorbance read at 490nm on a 
Wallac Victor luminometer.  Cells were treated in triplicate repeats, averages and standard errors 
calculated. 
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3.2.5 The effects of TGFβ stimulation peaks after 48 hours in CML cells 
 
To further characterise MYL and MYL-R cell lines, their response to TGFβ was 
analysed over a longer treatment period than the initial luciferase experiments. Despite 
the initial evidence of MYL-R unresponsiveness to TGFβ,  the effects had not been 
monitored over longer time points so these experiments were designed to assess if there 
were in fact time-dependent responses.   
Results show that TGFβ inhibits MYL cell survival but has minimal effect on MYL-R, 
which confirmed the previous findings.  To assess cell survival, TGFβ was added for 24, 
48 and 72 hour time points.  MTS assay solution was added to each well and absorbance 
read at 490nm.  After 24 hours the difference in response to treatment between the cell 
lines is seen at the lowest concentration of 0.1ng/ml (Figure 3.6 a).  At this time point, 
increasing TGFβ concentration does not have any enhanced effects on inhibiting growth 
in the MYL cells, while no effect is seen throughout the treatment course in the MYL-R 
cells.  These observed effects are more clearly demonstrated at 48 hours  where at a 
concentration of 1ng/ml the difference in survival is over 30% between the two cell 
lines, showing MYL cells are growth inhibited by TGFβ and the MYL-R cells remain 
unaffected.  The inhibition in MYL cells remains at 72 hours  but is less well defined, no 
inhibition is seen at 0.1ng/ml and it is not until a concentration of 0.3ng/ml TGFβ that 
any inhibition can be seen. For this reason, future readings will be taken after 48 hours. 
The MYL-R cells show no significant changes in response to TGFβ throughtout the 72 
hour treatment period.  The largest difference is observed after 72 hours at 0.3ng/ml 
where TGFβ enhances proliferation. 
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Figure 3.6 TGFβ-mediated effect is seen to be greatest between the MYL and MYL-R cells after 48 
hours of treatment  
 
MYL and MYL-R cells were seeded at 2.5x10
5
/ml and serum starved in 0.5% serum containing media 
overnight.  TGFβ was added at a range of concentrations between 0-10ng/ml  for 24 hours (a) 48 hours (b) 
and 72 hours (c) to analyse the effects on cell proliferation.  MTS solution was added for 2 hours and 
absorbance read at 490nm.  Cells were treated in triplicate repeats, averages and standard errors 
calculated. 
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3.2.6 Abrogation of the TGFβ signalling pathway reverses CML growth 
inhibition  
 
 
After establishing a TGFβ effect in MYL cells the type I TGFβ receptor kinase inhibitor 
was added to analyse if the observed effects could be reversed or inhibited.  Again, time 
points of 24, 48 and 72 hours were chosen to keep in line with previous results. TGFβ 
inhibited growth in MYL cells as previously observed, but actually increased 
proliferation in MYL-R cells (Figure 3.7a).  Treatment of SB431542 was able to 
increase survival in MYL cells, reversing the effects of TGFβ.  Interestingly, SB431542 
also enhanced survival in MYL-R cells to a greater extent than TGFβ addition alone. 
This would suggest the TGFβ pathway is still responsive in these cells.  SB431542 was 
able to cause the same effect in MYL-R cells in combination with TGFβ but with a 
slightly diminished response.  This could suggest that TGFβ may in part be by-passing 
the type I receptor to mediate effects seen here, or that additional TGFβ has no effect on 
MYL-R cells. It is possible that the MYL-R cells have adapted themselves to use TGFβ 
as a growth stimulus, yet in the absence of  stimulation the default mechanism results 
and cells again are able to proliferate. 
To compare these effects to another human-derived CML cell line, K562 cells were 
analysed alongside MYL and MYL-R cells (Fgure 3.7b)  TGFβ is able to inhibit MYL 
and K562 cells which is reversed by SB431542 addition.  K562 cells were more 
sensitive to TGFβ-mediated growth arrest with  a 30% reduction in survival compared 
with 15% in MYL cells.   Combining TGFβ and SB431542 is able to prevent inhibition 
in K562 cells but shows little effect in MYL which supports the previous data.  MYL-R 
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cells show a TGFβ-mediated increase in proliferation which is not altered by SB431542 
or with the combination  treatments.  K562 cells have a similar TGFβ response to MYL 
cells, which correlates with a mutual sensitivity to Imatinib.  
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Figure 3.7 SB431542 potentiates growth in the absence of TGFβ, this is not observed in combination 
with TGFβ 
 
(a) MYL and MYL-R cells were serum starved overnight in 0.5% serum-containing media before being 
treated in 96-well plates with either 1ng/ml TGFβ, 10μM SB431542 or a combination of the two . 
(b) K562 cells were treated the same in an independent experiment. 
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3.2.7 MYL-R cells have enhanced SMAD3 Activation in response to TGFβ 
stimulation 
 
 
In order to dissect the signalling pathway within these cells further, a CAGA12  
luciferase reporter construct was made which would allow TGFβ/Smad-dependent 
signalling to be monitored through establishing a stably transfected population of cells. 
The pGL3b CAGA12-luc plasmid was modified to contain the neomycin resistance gene 
to allow for antibiotic selection of successfully transfected clones. 
The cloned plasmid was tested by transfecting into COS-1 cells and being treated +/- 
TGFβ to check the Smad reporter region was still functional (Figure 3.8).  MYL and 
MYL-R cells were transfected using Amaxa Nucleofecter protocol T016.  The aim was 
to create stable cell lines expressing the plasmid and positive selection would be made 
by adding G418 to the media.   
Unfortunately, cell clones were not able to be selected.  It was thought this may be due 
to a lack of viable cells after electroporation and antibiotic selection, so an additional 
media was prepared which had been previously optimised to promote cell growth and 
viability among limited cell populations. Again this proved unsuccessful. 
Instead of monitoring Smad3 activity using a luciferase reporter in these cells, 
endogenous Smad3 activation was looked at to establish if there were differences 
between sensitive and resistant cell lines, which may be underlying the variation in 
response to TGFβ and Imatinib treatments.  
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Figure 3.8 Characterisation of TGFβ luciferase reporter containing the Neomycin resistance gene  
 
COS-1 cells were transiently transfected with the cloned vector containing CAGA12 luciferase reporter 
with the neomycin resistance gene, pRK5 or un-transfected.  Cells were then stimulated for 16 hours with 
TGFβ or an unstimulated control.  Cells were lysed and analysed through luciferase activity.  Treatments 
were carried out in triplicate repeats and averages and standard errors calculated Data presented is 
representative of at least three independent experiments 
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Cells were seeded in 0.5% FCS containing media and left overnight.  A TGFβ time 
course was set up to look at activation of Smad3.  Cells were stimulated for time points 
between 0-6 hours with 1ng/ml TGFβ. SB431542 treatment was added to establish if it 
effectively blocked the signalling pathway.  Imatinib (0.5µM) and Dasatinib (0.5µM) 
were used to look at their effects on Smad3 activation after 60 mintutes of stimulation. 
Results show that TGFβ is able to induce Smad3 phosphorylation within 10 minutes of 
treatment in both MYL and MYL-R cells (Figure 3.9a).  Smad3 phosphorylation 
appears to be greater in MYL-R cells and is sustained throughtout the TGFβ treatment 
periods and, although MYL cells have phosphorylated Smad3 after 60 mintues, it is very 
much diminshed and is only just apparent above unstimulated levels.  SB431542 is able 
to inhibit TGFβ-mediated Smad3 phosphorylation in both cell lines, and this supports 
the MTS data which suggests both cell lines can respond to inhibition of TGFβ 
signalling.  Total Smad3 levels were assessed under the same experimental conditions, 
and no change in levels were observed in either cell line therefore increases in activated 
Smad3 is not due to increases in overall Smad protein.  To quantify the Western blot 
analysis, densitometry software was used to assess changes in Smad3 activation, taking 
into account variation in β-actin levels (Figure 3.9b). As the blots indicated, MYL-R 
cells have a more sustained and intense TGFβ response, but both cell lines show the 
same pattern of activation over the time course, peaking at 60 minutes of stimulation.   
Interestingly, Dasatinib is also able to block Smad3 activation in both cell lines. 
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Figure 3.9 TGFβ induces Smad3 phosphorylation and is inhibited by SB431542 
 
MYL and MYL-R cells were serum starved overnight in 0.5% serum containing media.  Cells were 
seeded into 24-well plates at 5.0x10
5
/ml.  (a)Cells were treated with 1ng/ml TGFβ for a range of time 
points 0-360 mins, SB431542 and Dasatinib treatments were also looked at,  a Smad3 expression plasmid 
was transfected into HEK293 as a positive control. (b) Densitometry analysis of MYL and MYL-R 
western blots using ImageJ analysis 
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In addition to a TGFβ time course, Smad3 phosphorylation was investigated in 
combination with Bcr-Abl inhibitors with endogenous and exogenous addition of TGFβ.  
Cells were treated for 60 minutes with TGFβ  in combination with SB431542, Imatinib 
or Dasatinib.  This time point was chosen as the previous data highlighted it to be 
sufficient to induce maximal Smad3 phosphorylation.   
Results show that Imatinib has no effect on TGFβ-mediated Smad3 phosphorylation in 
MYL cells,  and Dasatinib reduces Smad3 activation 2-fold.  This is observed in the  
MYL-R cells where Imatinib does not inhibit TGFβ-induced Smad3 activation but 
Dasatinib is able to cause inhibition (Figure 3.10b). Densitometry software was used on 
the Western blots to analyse the observed differences in response to these treatments 
more accurately, by comparing each treatment to its untreated control.  Results are 
shown as relative fold increase using the unstimulated sample from each treatment pair.  
In the MYL cells,  control samples show a nearly 5-fold increase in smad3 activation, 
SB431542 is able to completely inhibit this activation in these cells.  Interstingly 
Imatinib is shown here to increase Smad3 activation and Dasatinib is able to reduce the 
activation by around 40% (Figure 3.10b).   
MYL-R cells here show a much lower activation than previously observed, with TGFβ 
only inducing a 2-fold increase in active Smad3.  SB431542 is not able to fully inhibit 
TGFβ activation in these cells, unlike the MYL cells.  Imatinib has no affect on Smad3 
activation, while Dasatinib is able to reduce activation slightly compared to the 
stimulated control (Figure 3.10c). 
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Figure 3.10 TGFβ induces Smad3 phosphorylation and is inhibited by SB431542 
 
MYL and MYL-R cells were serum starved overnight in 0.5% serum containing media.  Cells were 
seeded into 24-well plates at 5.0x10
5
/ml.  (a)Cells were treated with or without 1ng/ml TGFβ for 60 
minutes, in combination with SB431542, Imatinib or Dasatinib treatments. Lysates were separated 
through SDS-PAGE,  subsequent Western blots were probed with anti-phosphorylated Smad3 antibodies, 
anti- β-Actin antibodies were used to check for equal protein loading. (b) Densitometery analysis of MYL 
phosphorylated Smad3 Western blot using ImageJ software (c) Densitometry analysis of MYL-R 
phosphorylated Smad3 Western blot using ImageJ software 
125 
 
Atfi et al (2005) suggest that Bcr-Abl activates Akt and suppresses TGFβ-mediated 
growth-inhibitory signals.  A recent report suggests that the Bcr-Abl-mediated up-
regulation of TGFβ signalling has been implicated in the mobilsation of CML cells into 
the blood through Akt/MMP-9-associated release of membrane-bound cytokines m-KitL 
and m-ICAM-1 (Zhu et al., 2011).  Also, Akt has been shown to sequester Smad3 from 
the nucleus (Conery et al., 2004).  Interestingly, Akt has been shown to regulate TGFβ 
signalling, via destabilsation of Ski, a negative regulator of TGFβ signalling through 
Smad7 (Band et al., 2009).   
Therefore it was decided to investigate Akt levels in MYL and MYL-R cells and analyse 
the effect of TGFβ on Akt over a time course.   
Results show increased Akt levels in MYL-R cells compared to MYL (Figure 3.11a).  
After 60 minutes of treatment, Akt levels have increased in the MYL-R cells, MYL Akt 
levels remain constant, but have a slight increase after 180 minutes of TGFβ treatment, 
by which stage MYL-R levels have peaked and are in decline.  The Akt increase in 
MYL-R cells mirrors that of Smad3 activation., which suggests the two may be linked, 
especially with the evidence of Akt/Smad3 associations. Densitometry analysis of the 
relative Akt levels from the Western blot confirms MYL-R cells to have over a 2-fold 
increase compared to MYL cells (Figure 3.11b). 
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Figure 3.11 Different Akt levels in MYL and MYL-R cells 
 
MYL and MYL-R cells were serum starved overnight in 0.5% serum containing media.  Cells were 
seeded into 24-well plates at 5.0x10
5
/ml. (a) Cells were TGFβ treated for time points between 0-180 
minutes. Lysates were separated through SDS-PAGE,  subsequent Western blots were probed with anti-
Akt antibodies.  Anti-β-actin antibodies were used  to ensure equal protein loading.  (b) A comparison of 
Akt protein levels between MYL and MYL-R cell lines treated for 60 minutes, corrected for loading 
variability, analysed using Image J software.  
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3.2.8 Inhibiting TGFβ Signalling in Combination with Imatinib Enhances Cell 
Death in MYL cells 
 
 
One of the theories of CML persistence is the survival of a residual population of 
quiescent cells which remain insensitive to the Imatinib target cell population (Copland 
et al., 2006; Graham et al., 2002).  Data presented earlier in this chapter show TGFβ to 
have an anti-proliferative response in MYL cells, and no affect on MYL-R cells.   
Experiments undertaken here aim to look at whether TGFβ may be playing a roll in 
Imatinib resistance.  MYL and MYL-R cells were seeded in 96-well plates and treated 
with Imatinib at a range of concentrations between 0-0.5μM, and in combination with 
the TGFβ receptor I inhibitor SB431542 (10μM) to see if inhibiting this signalling 
pathway would have any effect on Imatinib-mediated cell death. 
Results suggest that MYL-R cells are unresponsive to the control treatments of TGFβ 
and SB431542, and go on to show no difference in survival rates between Imatinib and 
Imatinib with SB431542 treatments over the entire range of Imatinib concentrations 
(Figure 3.12a).  MYL cells show an enhanced response to inhibition of the TGFβ 
signalling pathway compared to the control.  The combination treatments show an 
enhanced Imatinib-mediated cell death response at 0.03μM, where there is over a 10% 
reduction in cell survival.  An increase in Imatinib efficiency is seen in concentrations of 
0.01μM up to 0.1μM, and thereafter there appears to be no difference in cell survival 
compared to Imatinib treatment alone (Figure 3.12b). 
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Figure 3.12 Combination treatment of Imatinib and SB431542enhance Imatinib-mediated cell death 
in MYL but not MYL-R cells 
 
Cells were serum starved in 0.5% serum containing media overnight.  Cells were seeded into 96-well 
plates and treated with either a range of Imatinib concentrations between 0-0.5μM or in combination with 
a TGFβ receptor inhibitor SB431542.  TGFβ and SB431542 controls were also carried out. Cells were 
treated for 48 hours before addition of MTS solution and incubated for a further 2 hours before analysing 
absorbance at 490nm.  (a) MYL-R cells (b) MYL cells. Cells were seeded in triplicate repeats, averages 
and standard error were calculated. 
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3.2.9 TGFβ signalling increases CML cell quiescence   
 
 
A number of studies have suggested TGFβ as having an anti-proliferative effect on cell 
cycle, and one of the underlying theories of residual drug  resistance in CML is the 
quiescent population of cells, potentially mediated by TGFβ (Jonuleit et al., 2000; 
Møller et al., 2007 ; Naka et al., 2010b). 
Experiments were undertaken to establish the affects of TGFβ on the cell cycle in late-
stage disease, using MYL cells as a model system. 
MYL cells were seeded in 0.5% FCS containing media overnight and then aliquoted at 
5.0x105 cells/ml into 24-well plates. Cells were synchronised in G1/S phase through a 
double thymidine block, briefly 19 hour thymidine incubation, replace with basal media 
for 9 hours, then add thymidine again for an additional 16 hour incubation, TGFβ and 
SB431542 were then added for a period of 12 hours.  Cells were fixed in 70% ethanol 
before staining with propidium iodide and analysed using flow cytometry. 
Cell cycle histogram profiles show addition of TGFβ increases the population in G0/G1 
phase by 5%. This difference is supported by the 5% reduction in S phase in TGFβ 
treated cells, with no difference observed in G2/M phase cells (Figure 3.13a).  The 
TGFβ-mediated increase in G0/G1 cells can be reversed by the addition of SB431542 to 
inhibit endogenous TGFβ signalling. This causes a decrease in the G0/G1 cell 
population and an increase in those cells in the mitotic stage of the cell cycle, an 
increase of almost 6% compared to TGFβ treated cells.  The histogram profiles have 
also been represented in bar chart form to show results more clearly (Figure 3.13b) 
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Figure 3.13 TGFβ causes cell cycle arrest in CML cells which can be reversed by SB431542 
treatment 
 
MYL cells were synchronised with a double thymidine block, then treated with either TGF β or SB431542 
for 12 hours.  Cells were fixed in 70% ethanol before propidium iodide was used and cell cycle status 
analysed on a flow cytometer. Data was then analysed using CFlow Plus software. 
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3.2.10 SB431542 Combined with Imatinb Increases PARP cleavage in MYL cells 
 
 
To support the findings that SB431542 enhanced Imatinib-mediated cell death, PARP 
cleavage was examined.  Poly (ADP-ribose) polymerase (PARP) is routinely used to 
assess cells undergoing apoptosis, and cleavage of PARP by caspase-3 activity is 
recognised to occur at the onset of apoptosis (Chang et al., 2010; Dean et al., 2010). 
Initially, a preliminary experiment was set up to test the conditions to obtain a read-out 
of apoptotic cells using this system.  MYL cells were seeded in a 24-well plate and 
exposed to a range of treatments to study the effect.  The high molecular weight band at 
113kDa can be seen strongly in the untreated lane and the 0.3μM Imatinib lane, with no 
bands corresponding to cleaved PARP at 29kDa.  As cell treatment concentrations 
increase, a subsequent increase in the strength of the 29kDa band, indicating PARP 
cleavage, is seen. Concomitantly, a reduction in the un-cleaved band is apparent at 
113kDa (Figure 3.14a).   
As it was unknown how these cells would respond to treatments in terms of their PARP 
cleavage profile, hydrogen peroxide and Tamoxifen were also added to cells as positive 
controls to induce apoptosis.  The absence of bands for hydrogen peroxide and 
Tamoxifen treatments suggest the doses were too concentrated for any response to be 
analysed. 
To look at the combination effect of TGFβ signalling inhibition and Imatinib treatment, 
MYL cells were seeded in 24-well plates in 0.5% FCS containing media.  SB431542 
was added to cells 60 minutes before Imatinib.  Two separate time courses were set up 
for 6 and 12 hour treatment.  
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After 6 hours of treatment there appeared to be no significant changes in either the un-
cleaved or cleaved PARP bands compared to the control. Samples treated for 12 hours 
show a reduction in un-cleaved PARP which can be seen in all three lanes in comparison 
to the control, but only in the SB431542 and Imatinib lane is there a clear increase in 
cleaved PARP at 29kDa, indicating a combination treatment is able to enhance PARP 
cleavage in these cells, more so than Imatinib alone (Figure 3.14b). 
Densitometry analysis of Western blots shows that there is an increase in PARP 
cleavage after 6 hours of treatment, and that the combination of TGFβ signalling 
inhibition and Imatinib treatment is more efficient at inducing cleavage than the two 
treatments alone. The 12 hour samples reflect more strongly what is seen after 6 hours.  
The graph shows a clear increase in PARP cleavage correlating with a decrease in un-
cleaved PARP (Figure 3.14c). 
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Figure 3.14 Imatinib and SB431542 combination treatments enhances PARP cleavage in chronic 
myeloid leukaemia cells     
 
MYL cells were serum starved overnight in 0.5% serum containing media before treatment with (a) 
Imatinib, Dasatinib, hydrogen peroxide or Tamoxifen (b) either 0.3μM Imatinib, 10μM SB431542 or a 
combination of the two for 6 or 12 hours. Lysates were separated through SDS-PAGE,  subsequent 
Western blots were probed with anti-PARP antibodies Expression of PARP cleavage was determined 
through anti-PARP western blots.  Anti-β-Actin blots were probed to ensure equal protein loading (c) 
Densitometry analysis of PARP Western blot comparing relative fold compared to untreated controls, 
analysed with ImageJ software. 
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3.2.11 TGFβ inhibition combined with Imatinib increases the sub-G0 cell 
population 
 
 
To establish if the results seen in the MTS and PARP cleavage experiments would be 
supported by cell cycle data, analysis to assess the sub-G0 apoptotic cell populations 
was carried out.  MYL cells were again seeded in 0.5% FCS containing media overnight 
before being treated in 24-well plates at 5.0x105cells/ml.   
Samples were treated for 12 hours. SB431542 (10μM) was added 60 minutes before 
Imatinib (0.3μM) in the combination treatment.  Imatinib treated samples have a G0/G1 
population of 55.2% this, as previous data would suggest is reduced in the Imatinib and 
SB431542 treated cells by just under 14%. (Figure 3.15a) This decrease seen with 
combined treatment also causes an increase in Sub-G0 cells, which increases nearly 8% 
from 54.8% to 62.7%.  The S and G2/M cell populations in the dual treated samples 
have a total increase of almost 8% compared to Imatinib treatment alone.  Cell cycle 
histogram profiles are also presented in bar chart form for an easier comparison of cell 
populations between treatments (Figure 3.15b). 
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Figure 3.15 TGFβ inhibition enhances Imatinib-mediated cell death through induction of the cell 
cycle  
 
MYL cells were seeded in 0.5% FCS containing media. Cells were treated with SB431542 60 minutes 
before Imatinib addition.  After 12 hours cells were fixed in 70% ethanol before addition of propidium 
iodide and analysis on a cytometer.  
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3.3 DISCUSSION 
 
 
The aim of this chapter was to analyse the effect of Bcr-Abl on TGFβ signalling, in 
addition to studying its effect on haematopoietic cell proliferation.   
Analysing the Bcr-Abl effect on TGFβ Smad-dependent signalling showed a dose-
dependent up-regulation in two independent TGFβ responsive cell lines HEK293 and 
COS-1.  Establishing the effect of combining this cytokine and Bcr-Abl oncogene has in 
the 32D haematopoietic system suggested that Bcr-Abl might prevent the growth 
inhibitory effects of TGFβ, observed in the absence of the p210 protein, and may 
enhance cell proliferation in response to TGFβ, suggesting that Bcr-Abl can de-regulate 
the normal cytostatic effect of TGFβ (Figure 3.2). These results support the findings of 
Atfi et al (2005) who report that Bcr-Abl prevents TGFβ-mediated growth arrest in 
Ba/F3 cells stability transfected with a Bcr-Abl plasmid. Unfortunately, the coagulation 
or clumping of the mouse haematopoietic cells especially those expressing p210, made it 
increasingly difficult to analyse results.  The use of an anti-clumping agent such as 
citrate dextrose may have been necessary to enable further studies in this system. 
Results presented in this chapter also support the findings of Møller et al (2007) who 
show Bcr-Abl up-regulating TGFβ signalling.  Interestingly, Atfi et al (2005) go on to 
suggest TGFβ signalling is not altered by the presence of Bcr-Abl in K562 cells, which 
is in contrast to the findings presented in this chapter. 
To study and characterise the TGFβ effect in human CML-derived cell lines, MYL and 
MYL-R myeloid leukaemia cells were analysed to elucidate how the response might be 
altered within these cells. These cells are derived from a CML patient and had 
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previously been characterised by Ito et al (2007) in terms of their mutation status and 
Imatinib resistance, but not in terms of their responsiveness to TGFβ.  Their data had 
highlighted an alternative mechanism of drug  resistance to that proposed previously. 
This suggested an increase in Bcl-2 levels (Dai et al., 2004), yet MYL-R cells did not 
have elevated levels compared to K562 or MYL cells (Ito et al., 2007). 
Results through MTS assays showed that MYL cells had maintained a response to 
TGFβ, and were growth inhibited.  In contrast, the MYL-R cells did not show a 
significant reponse to TGFβ stimulation.  Interestingly Jonuleit et al (2000) showed that 
Bcr-Abl completely blocks TGFβ-induced p27 induction, preventing normal cell cycle 
regulation.  These observed differences in TGFβ sensitivity may be due to changes in 
Bcr-Abl signallling and regualtion but are independent of Bcr-Abl mutations as 
characterised by Ito et al (2007).  Secretion of TGFβ has also been studied in Bcr-Abl 
expressing dendritic cells (DCs) and suggested this as being responsible for the reduced 
maturation in these cells (Mumprecht et al., 2009).  Further upregulation of TGFβ by c-
Abl is reported in scleroderma (SSc) sufferers , and fibrotic effects can be successfully 
reduced with Imatininb (Bujor et al., 2009).  When compared to K562 cells, which have 
been shown to contain similar levels of Lyn to MYL cells (Ito et al., 2007), a similar 
proliferation pattern is observed, which is not followed by MYL-R cells.  The K562 cell 
line is a good comparison as like the MYL/MYL-R cells they also contain double 
philadelphia postive chromosomes.  In addition, MYL-R cells have previously been 
shown to have enhanced activated STAT5, as a result of increased Lyn activation (Ito et 
al., 2007).  TGFβ has been reported to directly inhibit STAT5 activation (Cocolakis et 
al., 2008).  It therefore probable that TGFβ addition to MYL-R cells would antagonize 
the Lyn mediated activation of STAT5, but no effect on proliferation was observed. 
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The phosphorylation of endogenous Smad3 levels in CML cells indicate that TGFβ 
signalling is not inhibited in the MYL or MYL-R cell lines, as both see a TGFβ-
mediated induction of Smad3 phosphorylation and an abrogation with SB431542.  
Interestingly both cell lines have no detectable phosphorylated Smad3 in unstimulated 
samples.  If Bcr-Abl is up-regulating TGFβ signalling then Smad3 activation is more 
likely, although up-regulation could be a transient mechanism in the endogenous CML 
environment.  Results presented here suggest that MYL-R may undergo hyperactivation 
in response to TGFβ compared to MYL cells, and certainly appear to have a more 
sustained Smad3 response, and this may explain the desensitisation of MYL-R to the 
TGFβ signal if Smad signalling is over-active. The activation of Smad proteins however 
does not guarantee they are entering the nucleus and activating transcription, and further 
downstream signalling pathways could be inhibiting TGFβ effects within MYL-R cells.  
For example, Akt has been shown to sequester activated Smad3 from the nucleus, and 
indeed increased Akt levels are shown to protect liver cells from TGFβ-induced 
apoptosis (Conery et al., 2004).  Within CML, the observed results could be explained 
by Bcr-Abl causing an up-regulation of TGFβ signalling, but the absence of Smad3 
activation in untreated cells suggests if up-regulation is occurring, it is a transient 
process.  There are studies showing that TGFβ-Smad target genes are themselves Smad 
interacting factors, enabling TGFβ transcriptional responses such as ATF3 (Kang et al., 
2003).  These responses have been shown to cause sustained Smad signalling over 
extended periods suggesting genes such as ATF3 themselves are able to influence Smad 
signalling through specific binding. Research has shown that alternative pathways are 
able to influence Smad signalling such as the Erk/MAPK pathway which inhibits 
nuclear translocation of activated Smads (Derynck and Zhang, 2003).   It is apparent that 
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signalling pathways are not exclusive in their mediators or interaction partners, and 
therefore it is interesting to speculate that additional proteins may be involved directly 
with Smad3 signalling in MYL and MYL-R cells, which may be the cause of the 
observed responses.  
It is possible that a delay in TGFβ receptor de-activation in MYL-R cells is responsible 
for the potential increased levels in phosphorylated Smad3 levels.  Interestingly, SNIP1 
has been found to interact with Smads 1 and 2 and inhibit signalling, while a Smad3 
interaction was not found.  SNIP1 did inhibit the Cbp/p300 protein which is a co-
activator of many genes including TGFβ-regulated genes. Furthermore, the p300 gene is 
located on chromosome 22 which is involved in the translocation in CML.   Akt 
activation sequesters FoxO3 in the cytoplasm, preventing its apoptotic mechanism and 
leading to oncogenic transformation by Bcr-Abl (Kharas et al., 2004).  Akt has also been 
shown to sequester Smad3 outside the nucleus, preventing Smad3 regulated 
transcription and apoptosis (Conery et al., 2004) It was therefore decided to look at the 
effect TGFβ had on Akt in MYL and MYL-R cells.   
Results showed an increased level of Akt in MYL-R cells, this could explain the 
increased oncogenic capacity, through sequestering of FoxO3, leading to inhibted 
apoptosis.  It could also be suggested that this elevated Akt level could be sequestering 
Smad3 levels from the nucleus in MYL-R cells which may explain why no cytostatic 
effect is seen despite enhanced Smad3 activation upon TGFβ stimulation.  Akt is known 
to be constitutively active in blast crisis CML, and treatment with Imatinib has been 
shown to inhibit its kinase activity (Kawauchi et al., 2003).  Interestingly Akt has 
recently been shown to be involved in the relocation of p27 to the cytoplasm, resulting 
in an increase in CML cell proliferation (Chu et al., 2010).  The differences observed 
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here could go some way to explain the divergence in response to stimulation, and 
potentially highlight cross-talk between TGFβ/Akt signalling pathways which may have 
become more prominent in MYL-R cells and influence their enhanced growth potential 
in response to TGFβ, while at the same time a reduction in nuclear p27 levels would 
support enhanced cellular growth observed in MYL-R populations.   Other studies have 
looked at inhibiting Akt phosphorylation in CML, and have found that Resveratrol can 
efficiently reduce activation, but has no effect on Bcr-Abl activation (Banerjee et al., 
2010). 
Studies have shown that TGFβ plays an inhibitory role in early stage haematopoiesis 
(Park et al., 2004), the point at which the initial chromosomal translocation occurs.  
Previous findings suggest that Bcr-Abl can reverse these inhibitory effects on cell cycle 
(Jonuleit et al., 2000).  One study suggests the effect of Bcr-Abl on CD34+ cells to be 
more limited than previously thought, and by comparing CML and normal CD34+ cells 
it reveals more differences between quiescent and dividing normal cells than their CML 
counterparts (Graham et al., 2007). 
In this chapter, cell cycle data shows a marked response between TGFβ stimulation and 
its inhibition with the SB431542 compound, suggesting MYL blast phase cells remain 
sensitive to TGFβ signalling (Figure 3.13). This is contrary to the findings of Atfi et al 
(2005) who suggest Bcr-Abl inhibits the TGFβ mediated cell cycle arrest, and also 
PARP cleavage. Their results were obtained in transfected mouse cells, while results 
presented in this chapter were carried out in human CML cells so the differences may be 
due to cell specificity.  One study looking at the CML cell cycle concluded there was a 
defective Bcr-Abl-dependent  response to growth factor deprivation (Jonuleit et al., 
1998).  Results in this thesis support this evidence but go on to uncover specific 
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treatment effects.  Evidence also implicates Imatinib in increasing the number of G0/G1 
cells and thus increasing the quiescent population. (Jin et al., 2008).  My results support 
an Imatinib-mediated increase in G0/G1 cells, but when combined with SB431542 this 
population decreases significantly.  Interestingly, a study has shown that CML can 
generate leukaemic stem cells through missplicing causing aberrant β-catenin activation 
(Abrahamsson et al., 2009), which would contain Imatinib resistant cell populations. 
During advanced and blast crisis stages there is conflicting evidence regarding the 
involvement of Bcr-Abl, while some evidence suggests disease progression is met with 
an increased need for Bcr-Abl up-regulation (Barnes et al., 2005), known as Bcr-Abl 
addiction, whereas other reports suggest that as CML evolves it can begin to rely less 
heavily on oncogenic addiction in favour of other key proteins to sustain and drive the 
disease.  So, while Bcr-Abl may still be active within cells it may not be as heavily 
relied on, as newly acquired oncogenic pathways emerge to drive disease progression, 
such as constitutively active PI3K/AKT signalling in Imatinib resistant cells 
(Quentmeier et al., 2011).  
Research has shown that a K562 Imatinib-resistant cell line exhibiting a decrease in Bcr-
Abl levels is more susceptible to DNA damaging agents (Ju et al., 2007).   To overcome 
resistance there has been a vast range of experimental approaches with the advent of 
second generation tyrosine kinase inhibitors such as Dasatinib and Nilotinib.  
The next experiments in this chapter focused on the theory of a sub-population of 
quiescent cells, being maintained in this non-dividing state through an up-regulation of 
TGFβ signalling, which are subsequently resistant to Imatinib.  Interestingly, MYL-R 
cells were found to contain higher levels of CD34 than MYL cells (Ito et al., 2007), 
which is a marker for haematopoietic progenitor cells, and is known to confer inherent 
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drug  resistance (Roeder et al., 2006).  By inhibiting TGFβ signalling, these cells are 
forced back into the cell cycle, begin to divide and become sensitive to Imatinib-
mediated cell death.  Cell cycle analysis of combined SB431542 and Imatinib treatment 
gives a significant increase in SubG0 cells which are considered to be apoptotic 
populations, compared to Imatinib treatment alone. The cell cycle data showing cells to 
be growth inhibited by TGFβ is not a dramatic effect, yet this may be explained by the 
fact that CML exists as mixed population of cells within the samples which respond 
differently to TGFβ.  MYL-R cells which have induced-Imatinib resistance show no 
response to TGFβ, suggesting this de-sensitization is further along in the disease 
evolution process, as the MYL cells still retain TGFβ sensitivity.  
The combination therapy approach showed that by inhibiting the TGFβ signalling 
pathway, cells were induced to undergo Imatinib-mediated cell death slightly more so 
than Imatinib treatment alone. This was confirmed by PARP cleavage analysis, which 
are supported by the survival assays which show an increase in CML cell death with the 
combined treatment.  These results suggest that TGFβ does play a role in the blast phase 
of CML.  The necessity for TGFβ signalling inhibition is supported by results indicating 
that Imatinib treatment has no effect on TGFβ in vitro (Larmonier N, 2008).  Another 
study has shown the use of a TGFβ inhibitor together with Imatinib treatment is able to 
impair the colony forming ability of leukaemia initiating cells (LICs) (Naka et al., 
2010b).   Bcr-Abl siRNA together with Imatinib has yielded promising results showing 
an increase in apoptosis (Koldehoff et al., 2010), although this was in 32Dp210 cells, so 
may not be representative of blast phase disease.  It is also of note that these cells carried 
mutations in the Bcr-Abl gene so siRNA treatment would have had more of a targeted 
impact than Imatinib in cells containing Bcr-Abl mutations.    
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CML is a slowly evolving disease which increases the likelihood for a range of 
mutations which could change a cell response. It is important to realise that the effects 
seen in these cells may be transient in terms of disease progression.  So it is suggested to 
take these results as a snapshot of what is occurring within CML cells at their current 
disease stage, and that it will not necessarily apply to other types of analyses. 
As the emergence of further research into drug resistance progresses, it is found that 
mutations in the Bcr-Abl gene are often not responsible for resistance. For this reason 
attention has focused on other modes of resistance development in CML.  The CML cell 
lines being used in this research, one of which has Imatinib resistance but no Bcr-Abl 
mutations, suggests a Bcr-Abl independent resistance mechanism, that could be linked 
to elevated levels of Lyn kinase (Ito et al., 2007). This leads onto the next chapter which 
looks at the involvement of Lyn kinase and TGFβ within the context of CML and drug  
resistance. 
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4. A ROLE FOR LYN KINASE IN TGFβ-
MEDIATED DRUG  RESISTANCE 
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4.1 Introduction 
 
 
The advent of Imatinib was a huge breakthrough in the treatment of CML and saw vast 
improvements in survival rates.  The drug is extremely effective when used during early 
stages of disease development where Bcr-Abl alone is driving disease progression.  Over 
the years it has become apparent that Imatinib is not as effective on later disease stage 
patients (Druker et al., 2001; Rousselot et al., 2007).  This can be due to increasing 
mutations, either Bcr-Abl dependent such as point mutations in the Abl kinase domain 
or Bcr-Abl independent mechanisms (Quintás-Cardama et al., 2009).  Recently there has 
been a much more focused drive towards understanding Bcr-Abl independent 
mechanisms contributing to drug  resistance.  Imatinib has been shown to be ineffective 
at curing CML completely, with persistent residual drug reported, and removal of 
treatment often resulting in CML re-emergence (Hughes et al., 2006).  It is important to 
consider that resistance is a multi-factorial process, often the result of many genetic 
alterations occurring throughout disease evolution. Clinically, Imatinib is given orally, 
which gives rise to a range of environmental influences such as intestinal absorption, 
drug efflux and influx for example, before target cells are reached, and all of these 
factors can play a role in affecting drug efficacy. 
The advent of second generation tyrosine kinase inhibitors such as Nilotinib and 
Dasatinib was aimed at patients who had failed on Imatinib therapy. These new 
inhibitors have shown respectively a 20-30 fold and 325-fold increase in potency over 
Imatinib against Bcr-Abl in vitro (Deininger et al., 2009).  They have shown to be active 
against the majority of Bcr-Abl mutants, but the T315I mutant confers resistance to 
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Imatinib, Dasatinib and Nilotinib, (Copland et al., 2006; Redaelli et al., 2009), and thus 
highlights the need for further developments. 
The previous chapter touched on dual therapy approaches to overcome drug  resistance, 
in this next chapter experiments will aim to look at the impact of TGFβ in CML through 
the protein Lyn kinase which is up-regulated in an Imatinib-resistant, Bcr-Abl mutation- 
negative form of CML (Ito et al., 2007). 
Lyn kinase itself is present in myeloid cells where it is known to act as both a positive 
and negative modulator of cellular responses, Lyn deficient mice show hyper-
proliferation of myeloid cells due to an enhanced sensitivity to colony stimulating 
factors (Xu et al., 2005).  Conversely, Lyn has been shown to act in a positive role for 
stem cell factor-induced proliferation and chemotaxis in primary haematopoietic cells 
(O'Laughlin-Bunner et al., 2001).   
The involvement of Lyn kinase in CML was highlighted by (Donato et al., 2003; Ito et 
al., 2007; Wu et al., 2008a) who show it to be over-expressed in an Imatinib-resistant 
cell line.  This evidence combined with research suggesting TGFβ is able to down-
regulate members of the Src kinase family (Atfi et al., 1994) made TGFβ and Lyn 
interesting subjects to look at, with a view to understanding further how they may be 
linked in CML. 
Lyn kinase has previously been shown to be modified through ubiquitination (Kyo et al., 
2003; Shao et al., 2004).  Interestingly, Src family kinase ubiquitination and subsequent 
proteasomal degradation has been associated with the activity levels of these kinases. 
Constitutively active Lyn mutants showed increased Lyn activity, yet a decrease in 
protein levels (Harder et al., 2001).  It will therefore be important to understand what the 
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impact the different levels of Lyn has between resistant and sensitive cells and how this 
may affect its subsequent degradation.   
Whilst my research was being carried out there were a number of studies that looked at 
Lyn and its interactions with the E3 ligase c-Cbl (Kyo et al., 2003; Wu et al., 2008b).  
Previous reports have suggested c-Cbl phosphorylation might be regulated by Bcr-Abl 
(Andoniou et al., 1994), and silencing of Bcr-Abl has shown a reduction in c-Cbl 
phosphorylation (Wu et al., 2008b).  In addition, Lyn silencing was able to increase c-
Cbl phosphorylation and protein levels (Wu et al., 2008b). Research has identified c-Cbl 
to have negative regulatory roles in tyrosine kinase signalling.  Knockout mice have 
been shown to develop an enlarged thymus, expanded haematopoietic progenitor pools 
and increased bone marrow re-population (Naramura et al., 1998).  It is the loss of 
function mutations which have given the c-Cbl protein the branding as a tumour 
suppressor protein.  A c-Cbl knockout has been shown to accelerate blast phase CML 
(Sanada et al., 2009).  In addition, Lyn has been implicated in the substrate list of c-Cbl 
where it is shown to be ubiquitinated and down-regulated (Kyo et al., 2003). 
Here results are presented which demonstrate TGFβ to be playing a role in Lyn kinase 
activation and degradation through ubiquitination and it is suggested to be mediated 
through the E3 ubiquitin ligase c-Cbl. 
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The aims of this chapter are therefore to the following: 
 
1. Investigate TGFβ-mediated effects on Lyn kinase through post-translational 
modification 
 
2. Analyse these interconnections in an endogenous CML system 
 
3. Identify the E3 ligase responsible for the modification 
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4.2 Results 
 
4.2.1 TGFβ Causes Ubiquitination of Lyn kinase and Bursts of Activation 
 
 
The first aim of this chapter was to analyse the effect TGFβ had on the protein Lyn 
kinase through Western blotting.   MYL cells were seeded at 5.0x105 cells/ml in 0.5% 
FCS-containing media.  TGFβ was added for various time points between 0-3 hours, and 
SB431542 treatment (60 mintues) was used to look at the effect of inhibiting TGFβ 
signalling.  The experiment was carried out in the absence and presence of the 
proteasomal inhibitor MG132.   
Results indicate that TGFβ causes Lyn levels to fluctuate during treatment, a significant 
decrease in levels can be seen between 0 and 30 minutes of stimulation in the absence of 
the proteasomal inhibitor, and the levels then show an increase for the future time points 
(Figure 4.1).  In contrast, the initial drop at 30 minutes in Lyn levels is not seen in the 
presence of MG132.  Also, after 60 and 180 minute time-points, high molecular weight 
bands can be seen with increased intensity compared to the MG132 negative cells when 
probed with anti-Lyn antibodies, and bands appear at much larger molecular weights 
than in those without the proteasomal inhibitor.  The high molecular weight band is not 
seen in SB431542 treated cells suggesting that the band is TGFβ dependent and can be 
prevented by inhibiting the signalling pathway.  The absence of a drop in protein levels 
after 30 minutes in MG132 treated cells suggests TGFβ is involved in Lyn protein 
turnover. 
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Since these high molecular weight bands can be seen with increased intensity and 
abundance in the presence of proteasomal inhibitors, it is possible that these bands 
represent polyubiquitinated protein species. 
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Figure 4.1 TGFβ induces Lyn ubiquitination in the prescence of the proteasomal inhibitor MG132   
 
MYL cells were serum starved overnight in 0.5% serum-containing media before treatment with 1ng/ml 
TGFβ for a range of time points bewteen 0-180 minutes or 10μM SB431542 with and without the 
proteasomal inhibitor MG132.  Cells were lysed in RIPA buffer and subsequent Western blots were 
probed with anti-Lyn and anti-β-Actin antibodies. 
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4.2.2 TGFβ mediates Lyn ubiquitination  
 
 
Ubiquitination is an important post-translational modification involved in numerous 
biological functions such as cell growth, apoptosis, proliferation and the DNA damage 
response. Whilst these processes are generally considered to be carried out via 
proteasomal degradation  (Hoeller and Dikic, 2009; Pickart, 2001), recent evidence has 
suggested protein trafficking and localisation as further roles for ubiquitination (Chen 
and Sun, 2009).  
Currently, there are only a few papers suggesting links between TGFβ and Lyn (Atfi et 
al., 1994; Pazdrak et al., 1995).  Evidence of Lyn ubiquitination is not published in 
human CML, but has been researched in rat basophilic leukaemia (Bhattacharyya, 2001; 
Kyo et al., 2003).  To look further at the effect of TGFβ on Lyn, and investigate TGFβ-
mediated Lyn ubiquitination, HEK293 cells were transiently transfected with a Lyn-Flag 
plasmid.  Cells were seeded in 2% FCS-containing media, and a range of 0-1μg of a 
Lyn-Flag expression plasmid was transiently transfected into cells.  Using this over-
expression system would potentially clarify the pattern seen in the endogenous 
experiment using MYL cells. 
Results indicate a TGFβ mediated response.  It is apparent from this experiment that 
HEK293 cells contain endogenous Lyn and this has been detected in the first two lanes 
(Figure 4.2a).  TGFβ is able to cause an increase in the high molecular weight band seen 
previously in MYL cells.  At 0.25μg of Lyn the response is less clear, possibly due to 
transfection efficiency, however at 0.5μg there is a high molecular weight band present 
in the TGFβ treated cells which is not seen in the absence of stimulation.  This response 
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appears to be lost at the 1μg level suggesting that the induction may be Lyn 
concentration dependent.    
In addition to this, a co-immunoprecipitation experiment was undertaken to look at the 
outcome of combining Lyn with an HA-Ub plasmid in the presence of TGFβ. This 
would look to support the evidence of high molecular weight species found in MYL 
cells (Figure 4.1).  After lysis, anti-HA antibodies were used to precipitate out the HA-
tagged Ub and any covalently bound Lyn.  Western blot analysis alongside whole cell 
lysates shows that in this over expression system, Lyn appears to be ubiquitinated even 
at time 0 (Figure 4.2b). The top panel suggests that TGFβ is able to increase 
ubiquitination of Lyn, seen through increased smearing at 30 and 60 minute time points, 
SB431542 and Dasatinib treatments appear to reduce ubiquitination.  These observations 
support evidence seen endogenously albeit not at the same time points, but these results 
are seen in an over expression system which differ kinetically compared to the effects 
seen endogenously. Also of note, this latter experiment was not carried out in the 
presence of any proteasomal inhibitors, yet the over-expressed proteins appear abundant 
enough to highlight the effect. 
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Figure 4.2 TGFβ is able to induce high molecular weight Lyn bands in HEK293 cells  
 
(a) HEK293 cells were  transfected with a range of concentrations between 0-1μg of the expression 
plasmid Lyn-Flag.  Cells were then put into low serum 2% before being treated with 1ng/ml TGFβ for 60 
minutes.  Cells were then lysed in RIPA buffer and subsequent Western blots were probed with anti-Flag 
antibody (b) HEK293 cells were stimulated with TGFβ, SB431542(60min) or Dasatinib (60min), lysates 
were treated with anti-HA antibody before being analysed with Western blotting, probed with anti-Lyn, 
HA or β-actin. 
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To develop further the effect of TGFβ on Lyn ubiquitination, and clarify if this 
modification showed changes in Lyn protein levels, nickel affinity analysis was used.   
HEK293T cells were transiently co-transfected with a Lyn plasmid and a His-tagged 
ubiquitin plasmid.  This experiment utilised the ability of Histidine to bind nickel beads 
after cell lysis, and therefore separate ubiquitin with any associated proteins from non-
ubiquitinated proteins.  The high affinity of the nickel nitrilotriacetic acid (NTA) should 
provide high specificity for the HIS-tagged Ub whilst reducing non-specific binding 
from other proteins. These proteins are then probed with specific Lyn antibodies to 
analyse ubiquitination levels of Lyn throughout the time course.  
After 21 hours of transfection, cells were treated for a range of time points between 0-
360 minutes with TGFβ or SB431542, together with the appropriate controls (Figure 
4.3). 
Results show a  pattern of ubiquitinated Lyn seen in panel (b) which peaks at 60 minutes 
before declining at 180 and 360 minutes points.  Whole cell Lyn levels appear to 
fluctuate during the treatment which may correspond to changes in ubiquitination levels.  
To look at ubiquitinated proteins, the whole cell extract was probed with anti-His 
antibody to highlight all ubiquitinated proteins.  While this is not specific for Lyn 
protein ubiquitination, it is observed that ubiquitinated proteins are only seen in cells 
containing Lyn and the ubiquitin plasmid, and neither of the controls independently, 
suggesting that the ubiquitination seen in these lanes is indeed ubiquitinated Lyn.  
Additionally, the ubiquitinated species in the His-probed blot in panel (a) follows a 
similar pattern to that of the nickel affinity blot panel (b), and also that of the active 
phosphorylated Lyn blot (Figure 4.3a). This result also supports the results seen in the 
endogenous system with the high molecular weight band seen in the presence of MG132 
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after 60 minutes of TGFβ treatment (Figure 4.1).  Densitometry analysis of the western 
blots using Image J software also support the observed changes (Figure 4.3c), panel (a) 
is represented as Ub, while panel (b) of the Western blot is represented as Lyn Ub. It 
also clarifies that SB431542 is inhibiting TGFβ ubiquitination after 60 minutes, as 
relative to 60 minute TGFβ stimulation, the SB431542 treated cells show lower 
ubiquitination levels. 
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Figure 4.3 TGFβ causes  ubiquitination of Lyn 
 
HEK293T cells were co-transfected with expression plasmids for Lyn (0.5µg) and Ubiquitin-HIS 
(0.25µg). Cells were put into 2% FCS-containing media overnight before TGFβ treatment for a range of 
time between 0-360 minutes, or 10μM SB431532. Cells were then lysed in 1% NP40 lysis buffer and 
incubated overnight with nikel beads.  Lysates were washed with 0.1%NP40 buffer, subsequent Western 
blots were probed with (a) anti-Ha and (b) anti-Lyn antibodies and the whole cell extracts with anti-Lyn 
and anti-β-Actin antibodies, (c) blot analysis showing fold changes in nickel affinity Lyn ub levels and 
His-ub relative to the untreated controls, images analysed using Image J software. 
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4.2.3 Lyn kinase is modified via Sumoylation 
 
 
While looking for potential E3 ligases involved in Lyn ubiquitination, a ubiquitin like 
modifier was investigated to establish if TGFβ could have an effect on this type of 
modification. 
Small ubiquitin-like modifier (SUMO) is another post-translational modification which 
is known to be involved in a range of cellular processes such as gene transcription, cell 
cycle regulation and cellular localisation.  Sumoylation counteracts ubiquitination via 
directly competing for the same lysine residue (Bergink and Jentsch, 2009).  SUMO is 
known to be involved in subcellular localisation, DNA binding and activation of 
transcription factors (Geiss-Friedlander and Melchior, 2007; Hilgarth et al., 2004).  
Interestingly SUMO2 has the ability to form polymeric chains, whereas SUMO1 cannot 
(Tatham et al., 2001).  There has been a number of papers linking SUMO with TGFβ 
signalling.  The TGFβ type I receptor is sumoylated which promotes activation (Kang et 
al., 2008; Miyazono et al., 2008). Smad3 has been shown to undergo sumoylation, 
resulting in its nuclear export (Imoto et al., 2008).   
Experiments again utilise HEK293T cells which are co-transfected with Lyn and 
SUMO2 plasmids.  Cells were put into 2% FCS media post-transfection and left 
overnight before being treated with TGFβ (1ng/ml) or SB431542 (10μM).  
Results suggest SUMO2 to have an effect on Lyn, as dark, high molecular weight bands 
and smearing can be seen in lanes 4 and 5 of the top anti-His panel (Figure 4.4a).  There 
does not appear to be a significant difference between TGFβ negative and positive 
samples, however the SB431542 sample in lane 6 does have a marked reduction in the 
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smearing pattern in comparison with the previous two lanes. Also of note is the increase 
in Lyn protein levels in the presence of SUMO2 in the anti-Lyn panel, suggesting 
SUMO2 may increase Lyn protein stabilisation. 
The second experiment aimed to provide evidence of Lyn sumoylation alongside that of 
Lyn ubiquitination, in order to provide a relative comparison of abundance.  This was 
achieved by running samples alongside each other on the same gel (Figure 4.4b).  Nickel 
affinity was used to pull out His-tagged SUMO2 and Ub proteins, plus any bound Lyn.  
Western blot analysis shows both SUMO2 and Ub are immunopreciptated with Lyn 
(Figure 4.7b middle panel).  Ub appears to be the more prominent modification, a much 
larger amount of Lyn bound Ub is seen on the western compared to the SUMO2 bound 
Lyn.  This would suggest Lyn has a greater amount of  Ub modification rather than 
SUMO2.  To compare levels of Lyn in the absence and presence of SUMO2 
modification, densitometry analysis was used, and shows a 2.5-fold increase in relative 
protein amount (Figure 4.4c), this may implicate SUMO2 in Lyn protein stabilisation.  
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Figure 4.4 Lyn is modified by Sumoylation 
(a)HEK293T cells were co-transfected with Lyn and Sumo2 plasmids. 2% FCS media was added 
overnight. TGFβ (1ng/ml) or SB431542 (10μM) was added to cells for 60 minutes.  Blots were probed 
with anti-Lyn and anti-His antibodies,   β-Actin was probed for to check equal loading (b) In addition to 
panel (a) Ub was transfected with Lyn and Nickel beads were added to lysates overnight. Anti-Lyn and 
Anti-His antibodies were used to detect protein levels. (c) uses ImageJ software to compare Lyn protein 
levels with and without SUMO2 
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4.2.4 TGFβ activates Lyn through turnover and enhanced  activation 
 
 
Protein activation is largely phosphorylation dependent, and may be linked to 
ubiquitination (Levkowitz et al., 1999).  Protein kinases can modify substrates by adding 
phosphate groups to them.  Phosphorylation will often result in functional changes of the 
substrate protein.  The addition of phosphate often results in changes in cellular location, 
enzymatic activity, and association with other proteins.  Evidence exists to suggest that 
phosphorylation can serve as a marker for ubiquitination of kinase substrates, this has 
been shown for TAK1 (Bottero et al., 2011). Indeed Smad proteins themselves are 
known to be ubiquitinated after activation through phosphorylation, Smads 2 and 3 are 
ubiquitinated by Smurf 2 (Lin et al., 2000) and casein kinase 1 gamma 2  (Guo et al., 
2008), respectively.  Lyn is known to be regulated through two distinct phosphorylation 
sites at 397 and 508 (Koch et al., 1991).  Recently Lyn phosphorylation and subsequent 
signalling has been shown to be involved in Nilotinib resistance (Gioia et al., 2011).  
Dephosphorylation at residue 508 is necessary to induce Lyn activation, and protein 
tyrosine phosphatase Shp2 is known to carry out this task after granulocyte colony-
stimulating factor stimulation (Futami et al., 2011).     
After looking at TGFβ inducing Lyn ubiquitination, the phosphorylation status of Lyn 
was examined to determine if there was a link between ubiquitination and 
phosphorylation. MYL cells were serum starved overnight in 0.5% FCS-containing 
media before TGFβ treatment was undertaken for a range of time-points between 0-360 
minutes.  SB431542 treatment was used to inhibit TGFβ signalling, and Dasatinib to 
prevent Lyn activation. 
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Results show a  burst of Lyn activation with phosphorylation levels peaking at 180 
minutes before diminishing at 360 minutes (Figure 4.5a).   Interestingly, Lyn 
phosphorylation is found in untreated cells showing that active Lyn is present, possibly 
due to endogenous TGFβ signalling in these cells.  SB431542 was added for 60 minutes 
and shows lower active Lyn levels compared to the 60 minute TGFβ treated cells.  
Dasatinib is seen to effectively prevent Lyn phosphorylation, identified by the slightly 
lower migrating band. 
After studying Lyn activation over a time course, the difference in Lyn and 
phosphorylated Lyn levels were compared between MYL and MYL-R cell lines.  A 
subsequent experiment to analyse if resistant cells responded differently to CML 
treatment, which may also affect their response to TGFβ, was performed.   Figure 4.5b 
shows that there is no significant change in Lyn levels over the course of the different 
treatments in either MYL or MYL-R cells, although a slight reduction can be seen in 
MYL-R cells treated with TGFβ. The phosphorylated Lyn levels appear in much lower 
amounts in the MYL cells compared to MYL-R (Figure 4.5c).  There is slightly elevated 
phosphorylated p-Lyn in TGFβ treated MYL cells compared to control cells.  Imatinib 
has no effect on Lyn levels in either state.  In both cell lines, Dasatinib is able to 
markedly reduce phosphorylated Lyn levels.   Compared to the control, TGFβ slightly 
decreases phosphorylated Lyn in MYL-R cells.  
Figure 4.5d-f uses Image  J software to look at the differences in protein levels of Lyn, 
and phosphorylated Lyn through densitometry analysis of the Western blots, and also 
provides quantifiable data.  Both MYL and MYL-R cells show very similar patterns in 
response to the different treatments.  Dasatinib had the largest effect on phosphorylated 
Lyn levels, and was more effective in the MYL-R cells at reducing relative levels, 
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showing a 10-fold decrease, compared to 3-fold for MYL cells.  TGFβ shows a greater 
effect in the non-resistant cell line and does appear to increase phosphorylated Lyn 
levels. The final figure looks at phosphorylated Lyn levels between the two cell lines 
and confirms that MYL-R cells have just under a 3-fold increase in levels compared to 
the MYL cells.   
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Figure 4.5 TGFβ induces f Lyn kinase activity 
 
MYL cells were serum starved overnight in 0.5% serum containing media before treatment with (a) 
1ng/ml TGFβ for a range of time points between 0-360 minutes, or with either 10μM SB431542 or 0.5μM 
dual Bcr-Abl/Lyn kinase inhibitor Dasatinib.  Cells were treated for 60 minutes, lysed in RIPA buffer, and 
subsequent Western blots were probed with (a) anti-P-Lyn (b) anti-Lyn or (c) phospho-Lyn and anti- β-
actin antibodies. (d-f) analysis of blot densitometery using ImageJ software.  
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4.3 A Candidate E3 Ligase  
 
  
4.3.1 TRAF6 does not associate with Lyn kinase in the absence or presence          
of TGFβ 
 
 
The addition of Ub to target proteins is mediated through an enzymatic cascade, 
resulting in an E3 ligase transferring Ub to a lysine residue of a specific target substrate.  
After analysing the ubiquitination of Lyn through TGFβ, the search for the E3 ligase 
responsible for its transfer was investigated.  The E3 ligase TRAF6 was identified as a 
possible candidate, as it was known to associate with the activated TGFβ receptors I and 
II (Yamashita et al., 2008).  The TRAF family consist of seven members and are 
characterised by a C-terminal TRAF domain and a less well conserved N-terminal 
RING (Really Interesting New Gene) domain which is responsible for the E3 ligase 
activities (Twomey et al., 2009).  Initially TRAF6 was reported to facilitate poly lysine-
63 ubiquitination, rather than lysine-48 linked chains, targeting substrates for 
degradation (Inoue et al., 2007)   TRAF6 has recently been found to be involved in the 
TGFβ intracellular domain-induced activation of invasive cancer promoting genes (Mu 
et al., 2011). Therefore it was speculated it could provide the link between TGFβ and 
the ubiquitination of Lyn.  
Four TRAF6 constructs were obtained, wild type (WT), a mutant defective in ubiquitin 
ligase activity (C70A), and is therefore unable to ubiquitinate its usual substrates, a 
mutant with a defective ubiquitin acceptor site responsible for auto-ubiquitination 
(K124R), auto-ubiquitination often serves as a marker of activation, and a dominant 
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negative mutant lacking the N-terminal RING finger and six zinc finger motifs (DN), so 
has no E3 ligase activity (Twomey et al., 2009).   
Each of the four constructs were transiently transfected into HEK293 cells and treated 
with or without TGFβ to look for any TGFβ-mediated effects on the protein.  Analysis 
suggests that addition of TGFβ did not have an effect on levels of TRAF6 expression 
(Figure 4.6a).  Whole cell extracts were also probed with β-Actin to check protein 
loading levels. 
To establish if TRAF6 had any direct involvement with Lyn through a TGFβ-mediated 
interaction, HEK293 cells were transfected with WT TRAF6 and co-transfected with 
Lyn-Flag.  Samples were co-immunoprecipitated using anti-Lyn antibodies and then 
probed for anti-Flag. It is important to highlight that both plasmids used were Flag-
tagged.   Results suggest that there is no interaction between TRAF6 and Lyn as no 
bands can be seen which correspond to the TRAF6 protein (Figure 4.6b) 
Despite no direct interaction between Lyn and TRAF6, there was still potential for 
TRAF6 to be the E3 ligase responsible for Lyn ubiquitination via an intermediary 
protein.  Therefore TRAF6 was analysed in combination with Lyn and ubiquitin. WT 
TRAF6, Lyn and Ub constructs were transiently transfected into HEK293 cells. Co-
immunoprecipitation experiments were carried out to pull out the Flag-tagged TRAF6 
and Lyn proteins and then probe with anti-HA antibodies to pick up the ubiquitinated 
proteins.  
Unfortunately, these experiments did not yield any results at the time and are possibly 
something to develop again in the future. It is of note that the two proteins used for the 
immunoprecipitation experiments as well as both being Flag tagged are also of a similar 
molecular weight so would potentially be difficult to resolve through Western blotting.  
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I acknowledge that immunoprecipitating with Flag antibody and then probing with Lyn 
antibody would have been more informative in these experiments. 
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Figure 4.6 TRAF6 could be involved in Lyn activation 
 
HEK293 cells were transfected with TRAF6 constructs, Wild Type (WT), ubiquitin ligase deficient 
mutant (C70A) ubiquitin acceptor site mutant (K124R). (a) Shows whole cell lysates of the WT, C70A. 
K124R and DN mutant constructs with and without TGFβ treatment (b) shows a co-IP of WT TRAF6 
with Lyn and appropriate controls.  
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4.3.2 C-Cbl interacts with Lyn kinase 
 
 
Alongside the TRAF6 experiments, another candidate E3 ligase was assessed to reveal if 
it played a role in the TGFβ mediated Lyn ubiquitination, namely the cbl E3 ligases.  It 
was decided to investigate the involvement of these E3 ligases focusing on c-Cbl and 
Cbl-b.  Cbl-c also exists but is mainly expressed in epithelial cells so was not considered 
for this analysis.  C-cbl has been identified as a negative regulator of haematopoietic 
stem cells (Rathinam et al., 2008),  and therefore may play a role in the regulation of 
cell expansion in CML.  
To look for any potential involvement, HEK293T cells were transfected with Cbl-b or c-
Cbl together with Lyn to look for an association.  Cells were maintained in 2% FCS 
media post-transfection before stimulation with TGFβ.  
The HA-tag on c-Cbl plasmid was not well expressed initially, but later lysates 
confirmed its presence.  No interaction between Lyn and cbl-b was seen in this 
experiment (Figure 4.7a). However, initial analysis suggested that TGFβ plays a 
negative role in the interaction of Lyn with c-Cbl, as addition of TGFβ appears to 
remove the presence of Lyn in the sample co-transfected with c-Cbl, supported by the 
absence of the anti-Lyn band in the TGFβ treated c-Cbl sample (Figure 4.7a). 
Interestingly, after repeating the experiment and still observing no cbl-b/Lyn interaction 
it was decided to investigate the potential c-Cbl interaction with Lyn. In a co-
immunoprecipitation experiment it appears that TGFβ increases the association between 
Lyn and c-Cbl, and this is seen with cells immunoprecipitated with anti-Lyn antibodies 
and then probed with anti-HA antibodies to pick up the associated proteins.  There is a 
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band in the Lyn/c-Cbl TGFβ treated lane which corresponds to Lyn associated with c-
Cbl (Figure 4.7b). 
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Figure 4.7 TGFβ induces Lyn/c-Cbl interaction 
 
HEK293T cells were co-transfected with expression plasmids for Lyn and c-Cbl-HA or singly as a 
control.  Cells were put into 2% FCS media overnight before 1ng/ml TGFβ treatment for 60 minutes.  (a) 
Cells were lysed, and lysates mixed with anti-HA antibodies, proteins separated with SDS-PAGE, 
Western blot was then probed with anti-HA or Anti-Lyn antibodies (b)Cells were then lysed in 1% NP40 
lysis buffer and Lyn protein immunoprecipitated overnight with anti-Lyn antibody using  protein A/G 
agarose beads.  Lysates were washed with 0.1%NP40 buffer, subsequent Western blots were probed with 
anti-HA, anti-Lyn and the whole cell extracts with anti-Lyn and anti-β-Actin antibodies.  
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Lyn is reported to be ubiquitinated by c-Cbl (Kaabeche et al., 2004; Kyo et al., 2003).  
The tyrosine kinase binding domain of c-Cbl allows it to interact with a wide range of 
substrates (Meng et al., 1999).  To assess if TGFβ was involved in c-Cbl mediated Lyn 
ubiquitination, different amounts of c-Cbl together with a Ub-His construct, were 
transfected into HEK293T cells to see if protein ubiquitination could be altered.  
Cells were transfected and maintained in 2% FCS media before being stimulated with 
TGFβ for 60 minutes.  Nickel affinity was used to pull out the Ub through its ability to 
bind the tagged histidine, and any bound proteins. 
In control samples there is no sign of any ubiquitination occurring endogenously. After 
0.25μg of c-Cbl in combination with Lyn and Ub were transfected into the cells, there is 
an immediate effect seen on Lyn with increased smearing, which is in the presence of 
TGFβ.  In the 0.5μg c-Cbl sample there is further smearing seen and this is increased in 
the 1μg c-Cbl transfected cells in the presence of TGFβ. Interestingly, the smearing at 
1μg c-Cbl can be reduced in both nickel affinity anti-Lyn and whole cell anti-Lyn panels 
by blocking TGFβ signalling with the SB431542 compound suggesting that TGFβ is 
enhancing c-Cbl mediated Lyn ubiquitination (Figure 4.8).  Bcr-Abl is known to 
phosphorylate c-Cbl (Gotoh and Broxmeyer, 1997), which may further enhance Lyn 
ubiquitination in CML, but this was not looked at during this experiment. 
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Figure 4.8 Increasing c-Cbl levels enhances Lyn ubiquitination 
 
HEK293T cells were transfected with Lyn, c-Cbl and Ub plasmids. Cells were maintained in 2% FCS 
media post-transfection before TGFβ (1ng/ml) or SB431542 (10μM) stimulation for 60 minutes.  Nickel 
beads were added to lysates overnight before blots were probed with anti-Lyn, anti-His and anti-β-Actin 
antibodies to analyse protein levels. 
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4.3.3 Lyn and c-Cbl are able to affect reciprocal protein levels  
 
 
After identifying c-Cbl as a candidate E3 ligase involved in the ubiquitination of Lyn 
kinase, experiments were carried out in an over-expression system to see if any direct 
effects on protein levels were occurring. Studies have suggested that Lyn is negatively 
regulated by c-Cbl (Kyo et al., 2003).  Lyn itself has been implicated in the regulation of 
c-Cbl in CML cells (Wu et al., 2008a). 
Lyn was co-transfected with a range of c-Cbl concentrations (0.25μg-1μg). Treatments 
were run in duplicate with MG132 (20μM).  Results show that increasing levels of c-Cbl 
protein cause a reduction in Lyn levels (Figure 4.9a).  Over this time-point it appears 
that inhibition of proteasomal degradation with MG132 is not able to prevent Lyn 
breakdown.  
Alongside this, Lyn plasmid was dosed in (0.25μg-1μg) with 0.25μg of c-Cbl.  
Increasing levels of Lyn are able to reduce protein levels of c-cbl (Figure 4.9b).  This 
was done in the absence of TGFβ, inhibiting TGFβ signalling with SB431542 treatment 
showed no significant difference to c-Cbl levels. 
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Figure 4.9 Lyn kinase and c-Cbl regulate reciprocal protein levels 
 
HEK293T cells were transiently transfected with Lyn and c-Cbl plasmids and left for 21 hours. (a) C-Cbl 
was dosed in at concentrations between 0.25μg-1μg while Lyn was at 0.25μg throughout, samples were 
treated with and without MG132. (b) Lyn was dosed in at concentrations between 0.25μg-1μg while c-Cbl 
was at 0.25μg throughout. 
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4.4 Endogenous c-Cbl levels in MYL and MYL-R cells 
 
 
c-Cbl has recently been shown to ubiquitinate Bcr-Abl, leading to its proteasomal 
degradation (Mao et al., 2010),  and  c-Cbl overexpression in CML cells led to an 
increase in Bcr-Abl degradation (Dinulescu et al., 2003).  The emergence of c-Cbl 
mutations in a range of cancers (Caligiuri et al., 2007; Klapper et al., 2000; Tan et al., 
2010) has led to speculation of it becoming an oncogene after mutational events. 
Earlier experiments have concentrated on c-Cbl in an overexpression system, next MYL 
and MYL-R cell lines were used to look at endogenous levels.  Cells were seeded in 
0.5% serum overnight, and then treated with either TGFβ (1ng/ml), SB431542 (10μM) 
or Imatinib (0.3μM) for 60 minutes.  Cells were lysed and RNA extracted (SV total 
RNA isolation, Promega).  RNA was then reverse transcribed to cDNA in a 20μl 
reaction.  The cDNA from each sample was then added to a PCR mastermix before run 
on a thermocycler. Figure 4.10a shows the results from this experiment, in MYL cells, 
TGFβ causes an increase in c-Cbl levels of 30% (Figure 4.10b).  SB431542 and Imatinib 
do not have any significant affect on c-Cbl RNA levels.  MYL-R cells appear to have no 
changes in response to treatment, although there may be a slight increase with 
SB431542 treatment, but this may be explained by a slightly higher GAPDH level.  To 
investigate the apparent TGFβ-induced increase in c-Cbl mRNA levels Taqman analysis 
was used to give a more sensitive and quantative readout.  Existing cDNA samples of 
TGFβ stimulated (1ng/ml) for 60 minutes or unstimulated samples were used with Cbl 
Taqman primers (Applied Biosystems).  The cDNA levels were normalised using 18S.  
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The data indicates a 8-fold increase in c-Cbl mRNA when TGFβ stimulated (Figure 
4.10c). 
MYL and MYL-R cells are known to have different levels of Lyn kinase (Ito et al., 
2007).  It is proposed that these different levels are affected through TGFβ which may 
activate/recruit the E3 ligase c-Cbl to ubiquitinate Lyn.  The following experiments were 
therefore designed to look at the endogenous levels of c-Cbl in the two CML cell lines.   
Both cells lines were seeded at 5.0x105 cells/ml and incubated overnight in 0.5% serum 
containing media.  Cells were then stimulated with 1ng/ml TGFβ for a range of time 
points between 0-24 hours to look for any effects it may be having on the protein levels 
of the E3 ligase. 
Results suggest that TGFβ does have an effect on protein levels.  Initially c-Cbl was 
found at very low levels in the cell so an increased amount of protein was loaded onto 
the gel to enhance the ECL signal, consequently the β-actin signal was extremely strong. 
MYL cells appeared to have increased c-Cbl levels after 30 minutes of TGFβ 
stimulation and this appeared to follow a  pattern where a reduction in levels was 
apparent after 60 minutes, with a subsequent rise after 180 minutes, a further reduction 
in levels after 360 minutes is followed by an increase after 24 hours of stimulation.   
TGFβ appears to have less of an effect on MYL-R cells, although a decrease in protein 
levels can be seen after 30 and 60 minutes and this is increased up to the final time point 
of 24 hours (Figure 4.11a). 
Despite the protein samples being on different blots it appeared that c-Cbl protein levels 
differed considerably between the cell lines, so samples from the two cell lines were run 
alongside each other to enable a direct comparison of protein levels.  Results indicate 
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higher levels of c-Cbl protein in MYL cells compared to the MYL-R.  Again the  effects 
on protein levels can be seen (Figure 4.11b).  
Densitometry analysis of the Western blot with Image J software confirms the increase 
in c-Cbl levels, after 30 minutes MYL cells have a 20% increase in levels (Figure 
4.11c).  This increase does not occur after 30 minutes in MYL-R cells (Figure 4.11d).  
Interestingly the later time points show conflicting patterns between MYL and MYL-R 
cells. In MYL cells c-Cbl levels appear to fluctuate, possibly representing normal 
protein activity and turnover.  However in MYL-R cells there is an increase in c-Cbl 
levels from 30 minutes up to 24 hours. This may be due to the lower levels of c-Cbl in 
these cells, causing an increase in the time taken to see any TGFβ effect.  The apparent 
difference in c-Cbl levels is confirmed with Image J analysis, MYL-R has 50% less c-
Cbl compared to MYL cells (Figure 4.11e). 
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Figure 4.10 TGFβ upregulates c-Cbl mRNA levels 
(a)MYL and MYL-R cells were treated with either TGFβ (1ng/ml), SB431542 (10μM), or Imatinib 
(0.3μM) for 60 minutes.  RNA was extracted, and cDNA synthesised.  Samples were then run on a 
thermocycler with c-Cbl primers (b) Relative levels of c-Cbl were analysed in MYL -/+ TGFβ using 
Image J software (c) Quantitative real time PCR data of MYL cDNA after  60minute TGFβ (1ng/ml) 
treatment with 5ng cDNA run with c-Cbl Taqman primers, data was normalised to an 18s control. 
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Figure 4.11 TGFβ affects c-Cbl levels in MYL and MYL-R cells 
 
MYL and MYL-R cells were seeded in 0.5% serum-containing media overnight before being treated with 
TGFβ for time points ranging from 0-24 hours. (a) TGFβ time course showing C-Cbl levels in MYL and 
MYL-R with β-actin loading control, (b) Comparison of c-Cbl levels between MYL and MYL-R cells 
with β-actin loading control. (c,d) Densitometry looking at TGFβ effect on MYL and MYL-R cells (e) 
Densitometry analysis comparing c-Cbl levels in both cell lines, analysed using ImageJ software. 
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4.5 Discussion 
 
 
The aim of this chapter was to analyse the effect TGFβ had on the regulation of Lyn 
kinase and to understand how this was mediated, and in particular assess whether the 
process of protein turnover mediated through Lyn ubiquitination was affected by TGFβ 
stimulation. 
Lyn kinase has previously been shown to be up-regulated in a number of instances of 
Imatinib resistance in CML (Ito et al., 2007; Wu et al., 2008a), and TGFβ has been 
implicated in the regulation of Lyn (Atfi et al., 1994). However, these two research 
areas had not previously been linked in any way.  Therefore, a study to look at the effect 
of TGFβ on Lyn levels was undertaken.  Previous research investigating Lyn 
ubiquitination has shown it to be mediated through a proteasome specific pathway 
(Bhattacharyya, 2001). Interestingly, Lyn has been shown to phosphorylate csk binding 
protein (Cbp) leading to the recruitment of SOCS1 which ubiquitinates Lyn (Ingley et 
al., 2006). Lyn has also been shown to be ubiquitinated by c-Cbl in mast cells, leading 
to its degradation (Kyo et al., 2003).  
Analysing the effect of TGFβ on Lyn kinase has shown that levels of Lyn play a role in 
the sensitivity to TGFβ-mediated growth arrest.  TGFβ is able to cause a burst of Lyn 
activation, measured through activating phosphorylation-specific antibody detection.  
Moreover, TGFβ causes Lyn ubiquitination which has been shown experimentally 
through endogenous and transient over-expression analyses.  This ubiquitination leads to 
proteasomal Lyn degradation, the active Lyn levels are then replenished.  This model 
has been shown previously in the TGFβ/BMP/Smad signalling pathway where Smad 
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linker region phosphorylation is necessary to cause maximal activity, yet also leads to 
Smad degradation through recruitment of E3 ligases (Alarcón et al., 2009; Gao et al., 
2009).   In addition, the E3 ligase c-Cbl has been identified and analysed in both 
endogenous and over-expression systems and is shown to be involved in the 
ubiquitination of Lyn. 
Initial experiments highlighted TGFβ to have an effect on Lyn kinase levels in the 
presence of MG132 which inhibits proteasomal degradation, implicating TGFβ in 
protein regulation through ubiquitination (Figure 4.1). To further investigate this 
hypothesis, co-immunoprecipitation experiments were used to look at ubiquitination 
levels of Lyn over a TGFβ-stimulated time course.  Whilst results were often difficult to 
replicate in terms of precise timings, it can be concluded that Lyn does undergo 
ubiquitination, seen by increased high molecular weight smearing (Figures 4.2 and 4.3). 
Often closely linked with protein turnover and ubiquitination is protein activation 
through phosphorylation (Gao and Karin, 2005; Gao et al., 2009).  The EGFR requires 
phosphorylation before ubiquitination, with the E3 ligase binding through a 
phosphotyrosine binding domain (Levkowitz et al., 1999), and it is possible that Lyn 
ubiquitination works in this way too as many parallels have been drawn between the two 
processes, with activated proteins often targeted for proteasomal degradation.  Protein 
phosphorylation is also a common and well documented way of creating an E3 ligase 
binding site (Zhou and Snyder, 2005).   CML cells were looked at in terms of their 
activation through activating phosphorylation-specific anti-Lyn antibodies. TGFβ 
appears to play a role in activation of Lyn kinase seen through bursts of activity.  The 
increase in activated Lyn in the resistant cell line supports evidence of Lyn-mediated 
resistance (Ito et al., 2007). 
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Ubiquitination analysis through nickel affinity experiments highlighted Lyn 
ubiquitination, which supports the activation via phosphorylation data, and shows Lyn is 
replenished after degradation (Figure 4.3). 
In addition to ubiquitination it became apparent that this may not be the only 
modification occurring, with the SUMO2 protein having also been implicated in protein 
modification.  The TGFβ receptor has been shown to be sumoylated leading to enhanced 
activation of the pathway (Kang et al., 2008; Miyazono et al., 2008).  Results here 
suggest that Lyn is modified via sumoylation, addition of TGFβ did not appear to alter 
any effects of SUMO2. However, blocking the pathway with SB431542 did appear to 
reduce sumoylation (Figure 4.4b).  Sumoylation has been highlighted to promote the 
stabilisation of HIF-1alpha (Carbia-Nagashima et al., 2007), and SUMO3 is involved in 
PML nuclear stabilisation (Fu et al., 2005), it is therefore likely that this modification is 
also involved in protein stabilisation of Lyn in CML. During experiments it was 
observed that Lyn protein levels were increased in the prescence of SUMO2 (Figure 
4.4a and b). While the precise effects are not understood it may promote stabilisation of 
Lyn as it becomes more influential during the progression to a resistant phenotype and 
may also be involved in protein translocation, serving as a molecular chaperone, 
allowing Lyn to interact with downstream substrates.  It would be interesting to look for 
direct competition for Lyn between the both Ub and sumoylation modifications, which 
may further contribute to the understanding of the mechanism of Lyn signalling in CML 
resistance. 
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In order to provide a link between TGFβ and Lyn ubiquitination, potential E3 ligases 
were investigated.  A number of candidates were considered. The E3 ligase TRAF6 
posed as a potential Ub donor, but co-immunoprecipitation experiments were unable to 
confirm a role, possibly due to the unfortunate nature of similar molecular weight and 
protein tags further complicating the analysis.  The next candidates were the members of 
the Cbl family, and co-immunoprecipitation experiments show a direct interaction 
between Lyn and the E3 ligase c-Cbl (Figure 4.7b).  Results also demonstrated direct 
effects of Lyn down-regulating c-Cbl and c-Cbl down-regulating Lyn protein levels 
(Figures 4.8 and 4.9).  This down regulation of Lyn via c-Cbl has been shown 
previously in the rat leukaemia cell line RBL-2H3 (Kyo et al., 2003), although there was 
no suggestion there however of Lyn negatively regulating c-Cbl.  This result is 
supported endogenously in the two CML cell lines where c-Cbl is seen at higher levels 
than the MYL-R cells which are known to be over-expressing Lyn, suggesting that the 
higher levels of Lyn in MYL-R cells might be due to the reduction in c-Cbl levels. 
However, it is also possible that the higher Lyn levels in these cells may be due to a 
reduction in c-Cbl levels. Preliminary results of the effect of TGFβ on c-Cbl 
transcription through RT-PCR suggested it was able to induce c-Cbl transcription in 
MYL cells, although only slightly above basal levels.  The more sensitive Taqman 
analysis of this effect showed TGFβ to have a marked effect on inducing c-Cbl 
transcription. 
There have been many other studies which have looked at the impact of Lyn kinase in 
drug  resistance.  One study suggests Lyn activation plays a role in Imatinib resistance, 
but suggests no mechanism for the activation (Wu et al., 2008a).  Another study by the 
same group suggest Lyn is responsible for Bcr-Abl phosphorylation, which has been 
185 
 
found by numerous groups and is combined with reports of Lyn being a down-stream 
substrate of  the Bcr-Abl signalling pathway. Bcr-Abl silencing has also been shown to 
reduce c-Cbl tyrosine phosphorylation (Wu et al., 2008b), which may promote drug  
resistance.  The recent introduction of Nilotinib treatment for newly diagnosed CML 
sufferers has increased research into the drug.  Experiments to generate a Nilotinib 
resistant cell population have found Lyn activation to be involved in cell survival 
(Okabe et al., 2011).    Together, these results suggest a signalling network existing 
between Bcr-Abl and Lyn which is mediated through a range of adaptor molecules such 
as Gab2, c-Cbl and CrkL. 
Jak2 inhibition has been shown to increase the serine/threonine phosphatase PP2A and 
in turn reduce levels of activated Lyn (Samanta et al., 2009).  Interestingly, inhibition of 
the Jak/Stat signalling pathway shows reduction in TGFβR (Lakner et al., 2010), 
suggesting levels of the receptor could be playing a role in CML. 
In conclusion, the data presented in this and the previous chapter suggests that TGFβ 
plays a role in regulating Lyn kinase protein levels with  bursts of activation, mediated 
through its phosphorylation.  This phosphorylation then targets Lyn for proteasomal 
degradation via c-Cbl-mediated ubiquitination. 
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5. FINAL DISCUSSION 
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5.1 Introduction 
 
 
The TGFβ signalling pathway has been well studied in haematopoietic cell function and 
development (Blank and Karlsson, 2011; Larsson and Karlsson, 2005).  Under normal 
conditions the TGFβ influence on these cells is to induce growth arrest through increases 
in p21 and p27 (Cheng et al., 2001).  The study into haematological diseases such as 
leukaemia unveiled abnormalities in this signalling pathway (Imai et al., 2001; Rooke et 
al., 1999). 
In the case of CML, a disease driven by the presence of Bcr-Abl, TGFβ signalling has 
been found to be up-regulated (Møller et al., 2007 ).  If detected and treated early, CML 
can be controlled.  In many cases however, the disease cannot be completely eradicated, 
and relapse can often occur in apparently disease free patients (La Rosée and Deininger, 
2010).  It is this unresolved issue which renders further research into refractory disease 
necessary. 
In this thesis I have looked at the mechanistic role of TGFβ in late disease stage CML 
cells alongside over-expression cell systems in order to uncover the TGFβ involvement 
in drug  resistance to Imatinib, paying particular attention to Lyn kinase and how this 
protein may be regulated in CML resistance. 
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5.2 Bcr-Abl up-regulates TGFβ signalling and may overcome TGFβ-mediated 
growth arrest 
 
 
Initially, this project set out to analyse TGFβ signalling in CML.  This was carried out 
through the utilisation of two TGFβ responsive cell lines HEK293 and COS-1.  These 
cells were transfected with a luciferase reporter plasmid containing 12 CAGA repeat 
elements, which is the transcriptional binding site for Smad signalling.  In addition, a 
Bcr-Abl plasmid was transfected into these cells along with TGFβ stimulation. 
Analysis of the effect of Bcr-Abl, showed it could up-regulate TGFβ transcriptional 
activity in a TGFβ concentration dependent manner in both of these independent cell 
lines Figures 3.1a and b. 
To further investigate the effect of Bcr-Abl on TGFβ signalling it was decided to see if 
the increase in signalling could be seen to be having an effect on cell growth.  For this , a 
more relevant cell system was used: the mouse haematopoietic 32D and the stably 
expressing Bcr-Abl variant 32Dp210.  These experiments highlighted Bcr-Abl in 
preventing the cytostatic effects of TGFβ, seen in the non-expressing cells.  Although 
this was analysed through cell counts, which was quite a crude approach, it clearly 
demonstrates the selective growth advantage that Bcr-Abl presents to these 
haematopoietic cells, and supports the previous results of Bcr-Abl up-regulating TGFβ 
signalling.  Evidence presented here supports that of another study which concluded that 
Bcr-Abl suppresses the cytostatic effects of TGFβ in CML (Atfi et al., 2005). 
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5.3 MYL and MYL-R cells differ in their TGFβ responsiveness  
 
 
TGFβ is known to have cytostatic effects on normal haematopoietic cells (Larsson and 
Karlsson, 2005).   Human CML cell lines were obtained in the form of MYL and MYL-
R cells, with MYL-R cells having increased resistance to Imatinib.  
The first aim with these cells was to characterise them and establish their sensitivity to 
TGFβ.  This was carried out using MTS assays and showed the MYL-R cells to be 
significantly more resistant to Imatinib than MYL cells, despite these cells themselves 
showing a degree of tolerance.  It was found that the two cell lines exhibit different 
sensitivities to TGFβ. The MYL cells showed slight growth inhibition whereas MYL-R 
cells showed no TGFβ-mediated inhibition.  Once an optimal set of conditions had been 
defined, the experiments were repeated with TGFβRI inhibition using SB431542 to see 
if this could reverse the effects seen by TGFβ stimulation.  The TGFβ response 
remained the same, but interestingly MYL-R cells responded to the SB431542 
treatment, showing a marginal increase in cell proliferation. This suggested that the 
MYL-R cells may have retained a degree of TGFβ sensitivity, but that this response may 
be masked under normal conditions in these cells.  This could be due to an over-active 
TGFβ signalling pathway, and by inhibiting this, cell proliferation is enhanced.  
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5.4 Resistant CML cells have enhanced TGFβ signalling  
 
 
As previously discussed, Bcr-Abl up-regulates TGFβ signalling in HEK293 and COS-1 
cell lines.  The aim of the next section was to study the effects of TGFβ signalling 
endogenously in a human CML system.  The neomycin resistance gene was cloned into 
the previously used pGL3b-CAGA12-luc vector, enabling successfully transfected cells 
to be selected through antibiotic resistance.  Both MYL and MYL-R cells were 
electroporated to insert the plasmid, but stable cells were unable to be sustained. 
Alternatively, endogenous Smad3 levels were analysed in the two cells lines.  Both cell 
lines showed no changes of overall Smad levels for the duration of the experiment. 
Interestingly, MYL-R cells showed agreater activation response of Smad3 than MYL 
cells.  This evidence correlated with the hypothesis that MYL-R cells have increased 
endogenous levels of TGFβ, despite the un-stimulated sample having no active Smad3, 
and this may be explained by transient activation of the pathway in these cells.  When 
phosphorylated Smad3 was analysed in response to treatments in the absence and 
presence of TGFβ, it was interesting to find that Dasatinib was more effective in 
reducing phosphorylated Smad3 in the MYL-R cells than in MYL cells (Figure 3.9). 
Since this is specific for targeting Lyn kinase in addition to Bcr-Abl, it suggests Lyn is 
more actively involved in the signalling pathway in the resistant cells, while MYL cells 
are less dependent on Lyn activation. 
TGFβ is known to activate the PI3K/Akt pathway (Horowitz et al., 2004), and Akt is a 
known substrate of Bcr-Abl (Atfi et al., 2005).  Analysis of Akt levels in the two cell 
lines over a shorter time course indicated increased levels within MYL-R cells.  
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Interestingly, Akt has been implicated in the sequestering of Smad3 from the nucleus 
through direct physical interaction, while other reports suggest an Akt dependent 
suppression of Smad3 via mTOR (Song et al., 2006).  Therefore, this increase in Akt 
levels in the MYL-R cells may be responsible for attenuating the TGFβ response seen in 
these cells.  
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5.5 Does combination therapy enhance Imatinib-mediated cell death? 
 
 
One of the theories of CML disease persistence is that there exists a subset of quiescent 
CML stem cells which is resistant to Imatinib.  This is believed to occur because of 
signals preventing cells from entering the cell cycle. As already mentioned, TGFβ is a 
potent cell cycle inhibitor of normal haematopoietic cells (Batard et al., 2000).  It is 
understood that the cytostatic effects of these quiescent cells is due to the over-
expression of TGFβ which is known to be driven by Bcr-Abl. Therefore in theory, if 
these arrested cells are able to start dividing again, they should become sensitive to the 
effects of Imatinib.  In addition to targeting this known population of stem cells, 
research has found that there are a group of granulocyte macrophage progenitor cells 
which have the ability to require self-renewal properties during advanced stage disease 
(Jamieson et al., 2004).  This suggests that in addition to a clonal population of stem 
cells, disease evolution can also generate these more Imatinib resistant cell types. 
In order to overcome this resistance, a combined treatment approach of TGFβ inhibition 
and Imatinib treatment was compared to Imatinib treatment alone.  MTS results showed 
MYL cells to have a slight decrease in cell survival with the combined treatments, 
compared to Imatinib alone. No difference was seen in the MYL-R cells.  This was 
interesting because previous SB431542 treated MYL-R cells had shown an increase in 
cell proliferation assays, suggesting the combination treatment would have successfully 
increased Imatinib-mediated apoptosis.  However, the threshold at which Imatinib is 
able to induce cell death may be a critical difference between the two cell lines. 
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The unresponsiveness of MYL-R cells to this particular treatment regime meant MYL 
cells were used for the next analysis.  To confirm the findings of increased Imatinib 
induced cell death, a PARP-cleavage assay was developed.  Analysis confirms that after 
12 hours of combination treatment there is an increase in PARP cleavage indicating 
apoptosis. 
Finally, to support the previous data from combination treatments, cell cycle analysis 
was undertaken to show the effects of the treatments on the cells.  Both TGFβ and 
SB431542 exhibited results in accordance with the previous findings of growth 
inhibition and increased proliferation respectively.  When SB431542 treatment was 
combined with Imatinib a large increase in the Sub-G0 cell population was apparent 
which has previously been referred to in published data as apoptotic cells (Lu et al., 
2010).  Overall, this data suggests that by inhibiting TGFβ signalling in combination 
with Imatinib, there is enhanced apoptosis within the CML cell population. 
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5.6 TGFβ causes Lyn ubiquitination  
 
 
TGFβ was initially found to down-regulate Src kinases in the prostate carcinoma cell 
line PC3 (Atfi et al., 1994).  This data only analysed the effect during time-points up to 
30 minutes, and indeed results presented in this thesis agree with an initial down-
regulation of Lyn, mediated by TGFβ.  Lyn kinase is implicated in Imatinib resistance in 
CML (Ito et al., 2007; O'Hare et al., 2008).  Therefore, the potential TGFβ effect on Lyn 
in the CML context was investigated.   
Initial experiments aimed to analyse the effects over a TGFβ time course.  Interestingly, 
results immediately indicated a role for TGFβ in Lyn regulation within CML.   Lyn co-
transfected with Ub suggested an increase in Lyn ubiquitination.  Alongside this, Lyn 
activation through phosphorylation was identified and implicated in the cascade of 
ubiquitination, together with evidence showing increased Lyn activation in MYL-R 
cells.  Analysis of ubiquitination using a Ub-His tagged plasmid with its nickel affinity 
properties went on to further confirm a  role for TGFβ-induced ubiquitination of Lyn. 
Lyn was also found to undergo sumoylation via SUMO2. This may affect protein 
stability as well as localisation, as Lyn levels appeared to increase in the presence of 
SUMO2. This type of modification has been implicated in cancer, where Ubc9, the 
SUMO E2 enzyme has been found to be up-regulated leading to increased cancer cell 
growth (Moschos et al., 2010).  Currently there is no published work on Lyn 
sumoylation, so these initial findings could pave the way for a more in-depth analysis of 
the effects of this modification in CML resistance.  The effect of SUMO2 in CML 
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requires much further research but could potentially pose as a therapeutic target if like 
other cancers it is found to be deregulated. 
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5.7 The E3 ligase c-Cbl is involved in Lyn ubiquitination 
 
 
After implicating TGFβ in the ubiquitination of Lyn kinase, the next set of experiments 
aimed to determine the E3 ligase responsible. 
Due to the TRAF6 involvement and known association with the TGFβRI (Sorrentino et 
al., 2008), it  was looked at as the first potential candidate.  No association between Lyn 
and TRAF6 was found, nor did there appear to be any enhanced ubiquitination 
occurring. 
The E3 ligase c-Cbl has now been intensively investigated (Ogawa et al., 2010), yet at 
the time of this research was less well defined with respect to Lyn kinase in CML.  
Initial experiments showed a direct interaction between the two proteins which appeared 
to be TGFβ dependent.  When increasing amounts of the E3 ligase were dosed in with 
Lyn and Ub plasmids, an increase in high molecular weight bands was seen. 
c-Cbl had previously been implicated in Lyn regulation through ubiquitination in rat 
basophil leukaemia (Kyo et al., 2003).  Experiments in this thesis show that not only is 
c-Cbl able to negatively regulate Lyn, in contrast, Lyn is able to negatively regulate c-
Cbl, suggesting a negative feedback loop as an additional mode of control. 
Through analysing endogenous c-Cbl, it is apparent that MYL-R cells have a lower level 
of the E3 ligase, supporting evidence of the negative regulation by Lyn.  There are many 
papers detailing c-Cbl as an anti-oncogenic protein, largely due to its role in targeting 
proteins for proteasomal degradation (Miyake et al., 1998).  It is believed that mutations 
in this protein lead it to acquire oncogenic functions (Dunbar et al., 2008; Loh et al., 
2009). 
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5.8 Conclusion 
 
 
In conclusion, TGFβ is shown to play a varied role within the context of CML, initially 
having a strong inhibitory role during normal haematopoiesis and TGFβ sensitive CML 
cells.  It is the later stage disease, where Imatinib resistance occurs, that was the main 
focus of this research.  A combination approach, enabling the quiescent sub-population 
of cells to enter back into the cell cycle and become sensitive to the Imatinib-induced 
cell death, shows enhanced cell death compared to Imatinib alone, paving the way for 
dual therapy approaches to be investigated further.  
Results presented here also show TGFβ to be involved in the activation and 
ubiquitination of Lyn kinase which is known to be involved in drug  resistance (Donato 
et al., 2003; Ito et al., 2007).  The activation of Lyn is followed by its ubiquitination and 
subsequent degradation, and Lyn is then replenished with active forms of the protein. 
The ubiquitination is mediated through the E3 ligase c-Cbl, which is potentially TGFβ 
regulated. 
Therefore, I believe that this thesis has demonstrated an important and diverse role for 
TGFβ in CML, highlighting a dual therapy approach to overcome drug  resistance 
combined with an analysis of the role of TGFβ in regulating Lyn kinase ubiquitination.   
At this stage I feel it is important to relate the findings of this thesis to CML disease as a 
whole and to try to rationalise the results.  The effect of Lyn kinase is evidently involved 
in drug  resistance in the case of MYL/MYL-R cell lines, and this is known to not 
exclusively be the only route of resistance.  However, uncovering the network involved 
in Lyn-mediated resistance will develop a further understanding of the complexity 
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within CML.  The discovery of the TGFβ involvement in Lyn-mediated resistance is a 
novel one and presents a further role for TGFβ in CML.  The ability of TGFβ to cause 
activation of Lyn, and also induce the E3 ligase responsible for its degradation, suggests 
an extremely well regulated and balanced signalling network. Resistant cell populations 
have been able to reduce levels of the E3 ligase preventing degradation of Lyn, leading 
to persistent activation.   
Overall, within this diverse signalling network it is extremely difficult to address aspects 
of the disease as isolated factors.  TGFβ can promote cell quiescence, leading to residual 
disease, with suggestions of inhibiting TGFβ signalling to combat this.  Yet, here it is 
shown that TGFβ can promote c-Cbl induction, leading to Lyn ubiquitination which 
could potentially reduce resistance if over-expressed.  Therefore, what is needed is a 
tailored balance to address factors as they become apparent within CML development. 
From these results I present a diagram of this signalling network detailing the 
interconnections between TGFβ, Bcr-Abl, Lyn kinase and c-Cbl (Figure 5). 
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5.9 Future Work 
 
 
The research into CML drug  resistance has intensified significantly within the last few 
years.  The involvement of TGFβ up until now has focused primarily on its effect on cell 
growth.  Results presented in this thesis highlight its involvement in the activation and 
ubiquitination of Lyn kinase which has been directly linked to drug  resistance. 
There are always new ideas and further studies required to progress with current 
theories, unfortunately due to time constraints not all of these were achievable.  
Therefore I have proposed a number of future studies which would go on to develop the 
research presented here; 
 Analyse further the TGFβ effect on c-Cbl.  Using a haematopoetic stem cell 
model to look at relative levels of c-Cbl and how they are affected by the 
presence of TGFβ.  Analysing the interconnections between Bcr-Abl, c-Cbl and 
Lyn with TGFβ in early CML cells would allow for a greater understanding of 
disease development and the signalling occurring during later disease stages.  In 
addition, analyse the c-Cbl promoter for potential TGFβ regulatory sites.  This 
thesis only looked at the effect on Smad3 levels, it would be informative to 
analyse the Smad2 signalling both endogenously and in overexpression studies 
using the DE4 Smad2-specific reporter plasmid. 
 Using c-Cbl siRNA to assess the effect on Lyn levels and drug resistance within 
CML cells.  A c-Cbl knockdown will allow a study into whether it develops a 
more resistant and aggressive phenotype. 
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 Obtaining primary CML cells and undertaking these experiments will provide a 
much clearer picture as to the significance and relevance of previous data 
obtained through over-expression and cell line systems. 
 Developing further the dual therapy approach again using primary CML cell 
lines in order to ascertain the clinical significance of previous PARP and cell 
cycle data.  Analysis using Annexin V staining of cells will give a more accurate 
and sensitive readout of apoptotic cells.  In addition, analysing the relative levels 
of TGFβ sensitive regulators of the cell cycle such as p21.  This may provide 
informative results as to the precise mechanisms involved in the cycling of MYL 
and MYL-R cells and indicate an explanation to the observed differences in their 
TGFβ response. 
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